# EDGAR Filing Document

**Accession Number:** 0001106861
**File Stem:** 0001214659-25-010712
**Filing Date:** 2025-7
**Character Count:** 389850
**Document Hash:** d5711c6caec67d5990c65f8882ee687a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-25-010712.hdr.sgml**: 20250722

**ACCESSION NUMBER**: 0001214659-25-010712

**CONFORMED SUBMISSION TYPE**: 10-12G

**PUBLIC DOCUMENT COUNT**: 207

**FILED AS OF DATE**: 20250722

**DATE AS OF CHANGE**: 20250722

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CS DIAGNOSTICS CORP.
- **CENTRAL INDEX KEY:** 0001106861
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-PREPACKAGED SOFTWARE [7372]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 201290331
- **STATE OF INCORPORATION:** WY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-29611
- **FILM NUMBER:** 251138779

**BUSINESS ADDRESS:**
- **STREET 1:** STRESEMANNALLEE 4B
- **CITY:** NEUSS
- **STATE:** 2M
- **ZIP:** 41460
- **BUSINESS PHONE:** 49 21311510871

**MAIL ADDRESS:**
- **STREET 1:** STRESEMANNALLEE 4B
- **CITY:** NEUSS
- **STATE:** 2M
- **ZIP:** 41460

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLASHZERO CORP.
- **DATE OF NAME CHANGE:** 20221108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHILDRENS INTERNET INC
- **DATE OF NAME CHANGE:** 20030205

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DWC INSTALLATIONS
- **DATE OF NAME CHANGE:** 20000214

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10**

**GENERAL FORM FOR REGISTRATION OF SECURITIES**

**Pursuant to Section 12(g) of The Securities Exchange Act of 1934**

![](cscorp_logo.jpg)

**CS DIAGNOSTICS CORP.**

(Exact name of registrant as specified in its charter)

Wyoming 20-1290331 <br> (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

Stresemannallee 4b Neuss, Germany 41460

(Address of principal executive offices)

+49 (0)2131 151 08 71

(Issuer's telephone number)

Securities registered pursuant to Section 12(b) of the Act: Not Applicable

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value $0.001 per share

Indicate by check mark whether the registrant is a large accelerated ﬁler, an accelerated ﬁler, a non-accelerated ﬁler, a smaller reporting company, or an emerging growth company. See the deﬁnitions of "large accelerated ﬁler," "accelerated ﬁler," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer □ Accelerated filer □ <br> Non–Accelerated filer □ Small reporting company ⌧ <br> Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised ﬁnancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

**INFORMATION REQUIRED IN REGISTRATION STATEMENT**

**CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10**

Certain information required to be included herein is incorporated by reference to specifically-identified portions of the body of the information statement filed herewith as Exhibit 99.1. None of the information contained in the information statement shall be incorporated by reference herein or deemed to be a part hereof unless such information is specifically incorporated herein by reference.

**Item 1. Business.**

The information required under this item is contained under the sections of the information statement entitled "Business," "Risk Factors," "Security Ownership," and "Capitalization." Those sections are incorporated herein by reference.

**Item 1A. Risk Factors.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors" and "MD&A." Those sections are incorporated herein by reference.

**Item 2. Financial Information.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Security Ownership," "Description of Capital Stock," and "Capitalization—Management's Discussion and Analysis of Financial Condition and Results of Operation" and the financial statements referenced therein, of the Information Statement which sections are incorporated herein by reference.

**Item 3. Properties.**

The information required under this item is contained under the section of the information statement entitled "Business—Leased Offices." Those sections are incorporated herein by reference.

**Item 4. Security Ownership of Certain Beneficial Owners and Management.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Security Ownership," "Directors, Executive Officers, and Corporate Governance," "Description of Capital Stock," and "Capitalization." Those sections are incorporated herein by reference.

**Item 5. Directors, Executive Officers and Corporate Governance.**

The information required under this item is contained under the section of the information statement entitled "Security Ownership," "Directors, Executive Officers, and Corporate Governance," "Description of Capital Stock," and "MD&A" Those sections are incorporated herein by reference.

**Item 6. Executive Compensation.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Directors, Executive Officers, and Corporate Governance—Executive Compensation," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 7. Certain Relationships and Related Transactions, and Director Independence**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Security Ownership," "Directors, Executive Officers, and Corporate Governance—Stock and Stock Option Issuances in 2023 and 2024 and Related Party Transactions," "Description of Capital Stock," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 8. Legal Proceedings.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors" and "Legal Proceedings." Those sections are incorporated herein by reference.

**Item 9. Market Price of and Dividends on the Registrant's Common Equity and Related Stockholder Matters.**

The information required under this item is contained under the section of the information statement entitled "Business," "Risk Factors," "Security Ownership," "Directors, Executive Officers, and Corporate Governance," "Description of Capital Stock," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 10. Recent Sales of Unregistered Securities.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Directors, Executive Officers, and Corporate Governance—Related Party Transactions," "Description of Capital Stock—Recent Issuances of Securities," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 11. Description of Registrant's Securities to be Registered.**

The information required under this item is contained under the section of the information statement entitled "Business—Overview," "Risk Factors," "Security Ownership," "Directors, Executive Officers, and Corporate Governance," "Description of Capital Stock," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 12. Indemnification of Directors and Officers.**

The information required under this item is contained under the section of the information statement entitled "Business," "Risk Factors," "Directors, Executive Officers, and Corporate Governance—Limitation of Liability and Indemnification," and "MD&A." Those sections are incorporated herein by reference.

**Item 13. Financial Statements and Supplementary Data.**

The information required under this item is contained under the indexed unaudited financial statements of the Information Statement which are incorporated herein by reference.

**Item 14. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.**

None.

**Item 15. Financial Statements and Exhibits.**

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.0 | [Bylaws](ex10_0.htm) |
| 10.1 | [Series C Designation (Amended)](ex10_1.htm) |
| 10.2 | [Financial Statement period ending March 31, 2025](ex10_2.htm) |
| 10.3 | [Financial Statement period ending December 31, 2024](ex10_3.htm) |
| 10.4 | [Financial Statement period ending December 31, 2023](ex10_4.htm) |
| 10.5 | [PatientTrac Limited Securities Purchase Agreement, April 4, 2022](ex10_5.htm) |
| 10.6 | [CS Interpharm Asset Purchase Agreement, September 4, 2023](ex10_6.htm) |
| 10.7 | [Lachman Consulting Agreement, March 5, 2025](ex10_7.htm) |
| 99.1 | [Information Statement](ex99_1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: July 21, 2025 | **CS Diagnostics Corp.** | **CS Diagnostics Corp.** |
|  | By: | /s/Mohammad EsSayed |
|  |  | Mohammad EsSayed |
|  |  | Group CFO, VP |

---

## Exhibit 10.0

**Exhibit 10.0**

![](ex100-001.jpg)

For Office Use Only Wyoming Secretary of State Herschler Building East, Suite 101122 W 25th Street Cheyenne, WY 82002-0020 Ph. 307.777.7311 Email: Business@wyo.gov P-Amendment ? Revised June 2021Profit Corporation Articles of Amendment 1. Corporation name:(Name must match exactly to the Secretary of State's records.)is amended as follows: 3.If the amendment provides for an exchange, reclassification, or cancellation of issued shares, provisions forimplementing the amendment if not contained in the amendment itself which may be made upon facts objectivelyascertainable outside the articles of amendment.4.The amendment was adopted on . (Date ? mm/dd/yyyy) 2.Article number(s)\*See checklist below for article number information.

![](ex100-002.jpg)

P-Amendment ? Revised June 20215.Approval of the amendment: (Please check only one appropriate field to indicate the party approving the amendment.)Shares were not issued and the board of directors or incorporators have adopted the amendment. OR Shares were issued and the board of directors have adopted the amendment without shareholder approval, in compliance with W.S. 17-16-1005. OR Shares were issued and the board of directors have adopted the amendment with shareholder approval, in compliance with W.S. 17-16-1003. Signature: ___________________________________________ Date: (May be executed by Chairman of Board, President or another of its officers.) (mm/dd/yyyy) Print Name: Title: Contact Person: Daytime Phone Number: Email: (An email address is required. Email(s) provided will receive important reminders, notices and filing evidence.)Checklist Filing Fee: $60.00 Make check or money order payable to Wyoming Secretary of State.Processing time is up to 15 business days following the date of receipt in our office.\*Refer to original articles of incorporation to determine the specific article number being amended or use the next number in sequence if you are adding an article. Article number(s) is not the same as the filing ID number.Please mail with payment to the address at the top of this form. This form cannot be accepted via email.Please review the form prior to submission. The Secretary of State's Office is unable to process incomplete forms.

![](ex100-003.jpg)

SPECIAL MEETING OF THE BOARD OF DIRECTORS OF CS DIAGNOSTICS CORP. f/k/a FlashZero Corp. A SPECIAL MEETING OF THE BOARD OF DIRECTORS OF CS DIAGNOSTICS CORP., was held on March 24, 2023. A quorum was called and the Directors, Thomas Fahrhoefer, Thomas Migotsch, and Thomas Graus were present and a quorum was present. The meeting was held telephonically due to the location of the Directors. The Corporate Secretary, Thomas Graus, reported to the Board of Directors the status of the Corporate Action pending with FINRA for the Corporations name change, symbol change, the reverse and forward slit of its Common Stock. Mr. Graus reported that the approval process had been delayed to the staff of FINRA reporting a deficiency in the documentation for the Corporation's Preferred Stock. Mr. Graus reported to the Board of Directors that its representative Coral Capital had refiled a new application to FINRA on 24 March, 2023 and had recommended the Board of Directors file an Amendment to the Articles of Incorporation whereas the Board of Directors and the Majority Shareholder approval of Amendment and Restatement for Certificate of Designation for the Corporation's Preferred Series A, Amendment and Restatement for Certificate of Designation for the Corporation's Preferred Series B and Amendment and Restatement for its By-Laws. WHEREAS, the President recommended that is in the best interest of the shareholders of the Company, Pursuant to Wyoming Revised Statues Title 17, Chapter 10, Article 10, Sections 17-16-602 and section-17-19-1006, that it amends the Articles of Incorporation with an Amendment and Restatement of its By-Laws to include its new name, new address, its digitation of its Stock Certificates, and utilization of digital technology for communication. WHEREAS, the President recommended that it is in the best interest of the shareholders of the Company that it mends the Articles of Incorporation with an Amendment and Restatement Certificate of Designation of Preferred Series A. WHEREAS, the President recommended that it is in the best interest of the shareholders of the Company that it mends the Articles of Incorporation with an Amendment and Restatement Certificate of Designation of Preferred Series B. RESOLVED, the 1 for 100,000 reverse-split, with all fractional shares rounded up to the nearest whole share; and immediately after the completion of the rounding upwards to the nearest whole share, a 200 for 1 forward stock split is hereby approved. RESOLVED, Pursuant to Wyoming Revised Statues Title 17, Chapter 10, Article 10, Sections 17-16-602 and section-17-19-1006, that it amends the Articles of

![](ex100-004.jpg)

SPECIAL MEETING OF THE BOARD OF DIRECTORS OF CS DIAGNOSTICS CORP. f/k/a FlashZero Corp. Incorporation with an Amendment and Restatement of its By-Laws, as attached hereto as Exhibit A, is approved. RESOLVED, Pursuant to Wyoming Revised Statues Title 17, Chapter 10, Article 10, Sections 17-16-602 and section-17-19-1006, that it amends the Articles of Incorporation with an Amendment and Restatement Certificate of Designation of Preferred Series A, as attached hereto as Exhibit B, is approved. RESOLVED, Pursuant to Wyoming Revised Statues Title 17, Chapter 10, Article 10, Sections 17-16-602 and section-17-19-1006, that it amends the Articles of Incorporation with an Amendment and Restatement Certificate of Designation of Preferred Series B, as attached hereto as Exhibit C, is approved. RESOLVED, the Corporate Secretary, Thomas Graus, is approved to make all requisite filings with the Wyoming Secretary of State and a Supplemental Disclosure of these actions with OTC Markets, the Company Transfer Agent, TransferOnline, Inc., FINRA and any other requirements it deems necessary. I Thomas Graus the Corporate Secretary of the Company do hereby and herein attest the foregoing is a true and correct copy of the Special Meeting of the Board of Directors of FlashZero Corp held on 24th March 2023. ATTTEST Dated: 24th March 2023 Thomas Graus Corporate Secretary

![](ex100-005.jpg)

![](ex100-006.jpg)

![](ex100-007.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation ARTICLE I OFFICES Principal Office . The principal office for the transaction of business of the Corporation is hereby fixed and located at Stresemannallee 4c, Neuss, Germany 41460. The location may be changed by approval of a majority of the authorized directors, and additional offices may be established and maintained at such other place or places, either within or outside of Wyoming, as the Board of Directors may from time to time designate. Other Offices. Branch or subordinate offices may at any time be established by the Board of Directors at any place or places where the Corporation is qualified to do business. ARTICLE II DIRECTORS ? MANAGEMENT Powers : Subject to the provisions of the Wyoming Revised Statutes (hereinafter the "Code"), and subject to any limitations in the Articles of Incorporation of the Corporation relating to action required to be approved by the Shareholders, as that term is defined in the Code, or by the outstanding shares, as that term is defined in the Code, the business and affairs of the Corporation shall be managed and all corporate powers shall be exercised by or under the direction of the Board of Directors. The Board of Directors may delegate the management of the day-to-day operation of the business of the Corporation to a management company or other persons, provided that the business and affairs of the Corporation shall be managed, and all corporate powers shall be exercised, under the ultimate direction of the Board.

![](ex100-008.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation Standard of Care; Liability: Each Director shall exercise such powers and otherwise perform such duties, in good faith, in the matters such Director believes to be in the best interests of the Corporation, and with such care, including reasonable inquiry, using ordinary prudence, as a person in a like position would use under similar circumstances. In performing the duties of a Director, a Director shall be entitled to rely on information, opinions, reports, or statements, including financial statements and other financial data, in which case prepared or presented by: () One or more officers or employees of the Corporation whom the Director believes to be reliable and competent in the matters presented, () Counsel, independent accountants or other persons as to which the Director believes to be within such person's professional or expert competence, or () A Committee of the Board upon which the Director does not serve, as to matters within its designated authority, which committee the Director believes to merit confidence, so long as in any such case the Director acts in good faith, after reasonable inquiry when the need therefore is indicated by the circumstances and without knowledge that would cause such reliance to be unwarranted. Number and Qualification of Directors . The authorized number of Directors of the Corporation shall be not less than one (1) nor more than five (5) until changed by a duly adopted amendment to the Articles of Incorporation or by an amendment to this Section 2 of Article II of these Bylaws or, without amendment of these Bylaws, the number of directors may be fixed or changed by resolution adopted by the vote of the majority of directors in office or by the vote of holders of

![](ex100-009.jpg)

![](ex100-010.jpg)

![](ex100-011.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation the provisions of the Articles of Incorporation the holders of the shares of any class or series voting as a class or series are entitled to elect one or more Directors, any Director so elected may be removed only by the applicable vote of the holders of the shares of that class or series. Place of Meetings . Regular meetings of the Board of Directors shall be held at any place within or outside the state that has been designated from time to time by resolution of the Board. In the absence of such resolution, regular meetings shall be held at the principal executive office of the Corporation. Special meetings of the Board shall be held at any place within or outside the state that has been designated in the notice of the meeting, or, if not stated in the notice or there is no notice, at the principal executive office of the Corporation. Any meeting, regular or special, may be held by conference telephone or other digital communication equipment, so long as all Directors participating in such meetings can hear one another, and all such Directors shall be deemed to have been present in person at such meeting. Annual Meetings. Immediately following each annual meeting of Shareholders, the Board of Directors shall hold a regular meeting for the purpose of organization, the election of officers and the transaction of other business. Notice of this meeting shall not be required. Minutes of any meeting of the Board, or any committee thereof, shall be maintained as required by the Code by the Secretary or other officer designated for that purpose. Other Regular Meetings. Other regular meetings of the Board of Directors shall be held without call at such time as shall from time to time be fixed by the Board of Directors. Such regular meetings may be held without notice, provided the time and place of such meetings has been fixed by the Board of Directors, and further provided the notice of any change in the time of such meeting shall be given to all the Directors. Notice of a change in the determination of the time shall be given to each Director in

![](ex100-012.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation the same manner as notice for such special meetings of the Board of Directors. If said day falls upon a holiday, such meetings shall be held on the next succeeding day thereafter. Special Meetings/Notices. Special meetings of the Board of Directors for any purpose or purposes may be called at any time by the Chairman of the Board or the President or any Vice President or the Secretary or any two Directors. Notice of the time and place for special meetings shall be delivered personally or by telephone to each Director or sent by first class mail or telegram, charges prepaid, addressed to each Director at his or her address as it is shown in the records of the Corporation. In case such notice is mailed, it shall be deposited in the United States mail at least four days prior to the time of holding the meeting. In case such notice is delivered personally, or by telephone or telegram, it shall be delivered personally or be telephone or to the telegram company at least 48 hours prior to the time of the holding of the meeting. Any oral notice given personally or by telephone may be communicated to either the Director or to a person at the office of the Director who the person giving the notice has reason to believe will promptly communicate same to the Director. The notice need not specify the purpose of the meeting, nor the place, if the meeting is to be held at the principal executive office of the Corporation. Waiver of Notice . The transactions of any meeting of the Board of Directors, however called, noticed, or wherever held, shall be as valid as though had at a meeting duly held after the regular call and notice if a quorum is present and if, either before or after the meeting, each of the Directors not present signs a written waiver of notice, a consent to holding the meeting or an approval of the minutes thereof. Waivers of notice or consent need not specify the purposes of the meeting. All such waivers, consents and approvals shall be filed with the corporate records or made part of the minutes of the meeting. Notice of a meeting shall also be deemed given to any Director who attends the meeting without protesting, prior thereto or at its commencement, the lack of notice to such Director.

![](ex100-013.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation Quorums. Presence of a majority of the authorized number of Directors shall constitute a quorum for the transaction of business, except to adjourn as provided in Section 12 of this Article II. Members of the Board may participate in a meeting through use of conference telephone or similar communications equipment, so long as all members participating in such meeting can hear one another. Participation in a meeting as permitted by the preceding sentence constitutes presence in person at such meeting. Every act or decision done or made by a majority of the Directors present at a meeting duly held at which a quorum was present shall be regarded as the act of the Board of Directors, unless a greater number is required by law or the Articles of Incorporation. A meeting at which a quorum is initially present may continue to transact business notwithstanding the withdrawal of Directors, if any action taken is approved by at least a majority of the required quorum for that meeting. Adjournment. A majority of the directors present, whether or not constituting a quorum, may adjourn any meeting to another time and place. Notice of Adjournment. Notice of the time and place of the holding of an adjourned meeting need not be given, unless the meeting is adjourned for more than 24 hours, in which case notice of such time and place shall be given prior to the time of the adjourned meeting to the Directors who were not present at the time of the adjournment. Sole Director Provided by Articles or Bylaws. In the event only one Director is required by the Bylaws or the Articles of Incorporation, then any reference herein to notices, waivers, consents, meetings or other actions by a majority or quorum of the Board of Directors shall be deemed or referred as such notice, waiver, etc., by the sole Director, who shall have all rights and duties and shall be entitled to exercise all of the powers and shall assume all the responsibilities otherwise herein described, as given to the Board of Directors.

![](ex100-014.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation Directors Action by Unanimous Written Consent. Any action required or permitted to be taken by the Board of Directors may be taken without a meeting and with the same force and effect as if taken by a unanimous vote of Directors, if authorized by a writing signed individually or collectively by all members of the Board of Directors. Such consent shall be filed with the regular minutes of the Board of Directors. Compensation of Directors. Directors, and members as such, shall not receive any stated salary for their services, but by resolution of the Board of Directors, a fixed sum and/or expenses, if any, may be allowed for their attendance at each regular and special meeting of the Board of Directors or for their services contributed to the Board of Directors; provided, however, that nothing contained herein shall be construed to preclude any Director from serving the Corporation in any other capacity as an officer, employee or otherwise receiving compensation for such services. Committees. Committees of the Board of Directors may be appointed by resolution passed by a majority of the whole Board. Committees shall be composed of two or more members of the Board of Directors. The Board may designate one or more Directors as alternate members of any committee, who may replace any absent member at any meeting of the committee. Committees shall have such powers as those held by the Board of Directors as may be expressly delegated to it by resolution of the Board of Directors, except those powers expressly made non-delegable by the Code. Meetings and Action of Committees. Meetings and action of committees shall be governed by, and held and taken in accordance with, the provisions contained herein, with such changes as are necessary to substitute the committee and its members for the Board of Directors and its members, except that the time of the regular meetings of the committees may be determined by resolution of the Board of Directors as well as the committee, and special meetings of committees may also be

![](ex100-015.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation given to all alternate members, who shall have the right to attend all meetings of the committee. The Board of Directors may adopt rules for the government of any committee not inconsistent with the provisions of these Bylaws. Advisors. The Board of Directors from time to time may request and/or hire for a fee one or more persons to be Advisors to the Board of Directors, but such persons shall not by such appointment be members of the Board of Directors. Advisors shall be available from time to time to perform special assignments specified by the President, to attend meetings of the Board of Directors upon invitation, and to furnish consultation to the Board of Directors. The period during which the title shall be held may be prescribed by the Board of Directors. If no period is prescribed, the title shall be held at the pleasure of the Board of Directors. ARTICLE III OFFICERS Officers. The principal officers of the Corporation shall be a President, a Chief Operations Officer, a Secretary, and a Treasurer who may also be called Chief Financial Officer. The Corporation may also have, at the discretion of the Board of Directors, a Chairman of the Board, one or more Vice Presidents, one or more Assistant Secretaries, one or more Assistant Treasurers, and such other officers as may be appointed in accordance with the provisions of Section 3 of this Article III. Any number of offices may be held by the same person. Election of Officers. The principal officers of the Corporation, except such officers as may be appointed in accordance with the provisions of this Article, shall be chosen by the Board of Directors, and each shall serve at the pleasure of the Board of Directors, subject to the rights, if any, of an officer under any contract of employment. Each officer shall hold office until his successor shall be duly elected and qualified, or until his death, resignation, or removal in the manner hereinafter provided.

![](ex100-016.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation Subordinate Officers, Etc. The Board of Directors may appoint such other officers as the business of the Corporation may require, each of whom shall hold office for such period, have such authority and perform such duties as are provided in the Bylaws or as the Board of Directors may from time to time determine. Removal and Resignation of Officers. Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by a majority of the Directors at that time in office, at any regular or special meeting of the Board of Directors, or, except in the case of an officer chosen by the Board of Directors, by any officer upon whom such power of removal may be conferred by the Board of Directors. Any officer may resign at any time by giving written notice to the Board of Directors. Any resignation shall take effect on the date of the receipt of that notice or at any later time specified in that notice; and, unless otherwise specified in that notice, the acceptance of the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party. Vacancies. A vacancy in any office because of death, resignation, removal, disqualification or any other cause shall be filled in the manner prescribed in the Bylaws for regular appointments to that office. Chairman of the Board. The Chairman of the Board, if such an officer be elected, shall, if present, preside at the meetings of the Board of Directors and exercise and perform such other powers and duties as may, from time to time, be assigned by the Board of Directors or prescribed by the Bylaws. If there is no President, the Chairman of the Board shall, in addition, be the Chief Executive Officer of the Corporation and shall have the powers and duties prescribed in Section 7 of this Article III.

![](ex100-017.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation President. Subject to such supervisory powers, if any, as may be given by the Board of Directors to the Chairman of the Board, if there is such an officer, the President shall be the Chief Executive Officer of the Corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the Corporation. The President shall preside at all meetings of the Shareholders and, in the absence of the Chairman of the Board, or if there be none, at all meetings of the Board of Directors. The President shall have the general powers and duties of management usually vested in the office of President of a corporation, shall be ex officio a member of all the standing committees, including the Executive Committee, if any, and shall have such other powers and duties as may be prescribed by the Board of Directors or the Bylaws. Vice President. In the absence or disability of the President, the Vice Presidents, if any, in order of their rank as fixed by the Board of Directors, or if not ranked, the Vice President designated by the Board of Directors, shall perform all the duties of the President, and when so acting, shall have all the powers of, and be subject to all the restrictions upon, the President. The Vice Presidents shall have such other powers and perform such other duties as from time to time may be prescribed for them, respectively, by the Board of Directors or the Bylaws, the President, or the Chairman of the Board. Secretary. The Secretary shall keep, or cause to be kept, a book of minutes of all meetings of the Board of Directors and Shareholders at the principal office of the Corporation or such other place as the Board of Directors may order. The minutes shall include the time and place of holding the meeting, whether regular or special, and if a special meeting, how authorized, the notice thereof given, and the names of those present at Directors' and committee meetings, the number of shares present or represented at Shareholders' meetings and the proceedings thereof. The Secretary shall keep, or cause to be kept, at the principal office of the Corporation or at the office of the

![](ex100-018.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation Corporation's transfer agent, a share register, or duplicate share register, showing the names of the Shareholders and their addresses; the number and classes or shares held by each; the number and date of certificates issued for the same; and the number and date of cancellation of every certificate surrendered for cancellation. The Secretary shall give, or cause to be given, notice of all the meetings of the Shareholders and of the Board of Directors required by the Bylaws or by law to be given. The Secretary shall keep the seal of the Corporation in safe custody, and shall have such other powers and perform such other duties as may be prescribed by the Board of Directors or by the Bylaws. Treasurer. The Treasurer shall keep and maintain, or cause to be kept and maintained, in accordance with generally accepted accounting principles, adequate and correct accounts of the properties and business transactions of the Corporation, including accounts of its assets, liabilities, receipts, disbursements, gains, losses, capital, earnings (or surplus) and shares issued. The books of account shall, at all reasonable times, be open to inspection by any Director. The Treasurer shall deposit all monies and other valuables in the name and to the credit of the Corporation with such depositaries as may be designated by the Board of Directors. The Treasurer shall disburse the funds of the Corporation as may be ordered by the Board of Directors, shall render to the President and Directors, whenever they request it, an account of all of the transactions of the Treasurer and of the financial condition of the Corporation, and shall have such other powers and perform such other duties as may be prescribed by the Board of Directors or the Bylaws.

![](ex100-019.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation ARTICLE IV SHAREHOLDERS' MEETINGS Place of Meetings. Meetings of the Shareholders shall be held at any place within or outside the state of Wyoming designated by the Board of Directors. In the absence of any such designation, Shareholders' meetings shall be held at the principal executive office of the Corporation. Annual Meeting. The annual meeting of the Shareholders shall be held, each year, as follows: Time of Meeting: 10:00 A.M. Date of Meeting: September 15 If this day shall be a legal holiday, then the meeting shall be held on the next succeeding business day, at the same time. At the annual meeting, the Shareholders shall elect a Board of Directors, consider reports of the affairs of the Corporation and transact such other business as may be properly brought before the meeting. If the above date is inconvenient, the annual meeting of Shareholders shall be held each year on a date and at a time designated by the Board of Directors within a reasonable date of the above date upon proper notice to all Shareholders. Special Meetings. Special meetings of the Shareholders for any purpose or purposes whatsoever, may be called at any time by the Board of Directors, the Chairman of the Board, the President, or by one or more Shareholders holding shares in the aggregate entitled to cast not less than 50% of the votes at any such meeting. If a special meeting is called by any person or persons other than the Board of Directors, the request shall be in writing, specifying the time of such meeting and the general nature of the business proposed to be transacted, and shall be delivered personally or sent by registered mail or by electronic digital mail or other digital transmission to the Chairman of the Board, the President, any Vice President or the Secretary of the Corporation. The officer receiving

![](ex100-020.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation such request shall forthwith cause notice to be given to the Shareholders entitled to vote, in accordance with the provisions of Sections 4 and 5 of this Article, that a meeting will be held at the time requested by the person or persons calling the meeting, not less than 35 nor more than 60 days after the receipt of the request. If the notice is not given within 20 days after receipt of the request, the person or persons requesting the meeting may give the notice in the manner provided in these Bylaws or upon application to the Superior Court. Nothing contained in this paragraph of this Section shall be construed as limiting, fixing or affecting the time when a meeting of Shareholders called by action of the Board of Directors may be held. Notice of Meetings ? Reports. Notice of any Shareholders meetings, annual or special, shall be given in writing not less than 10 days nor more than 60 days before the date of the meeting to Shareholders entitled to vote thereat by the Secretary or the Assistant Secretary, or if there be no such officer, or in the case of said Secretary or Assistant Secretary's neglect or refusal, by any Director or Stockholder. Such notices or any reports shall be given personally or by mail or other means of written communication as provided in the Code and shall be sent to the Stockholder's address appearing on the books of the Corporation, or supplied by the Stockholder to the Corporation for the purpose of notice, and in the absence thereof, as provided in the Code by posting notice at a place where the principal executive office of the Corporation is located or by publication at least once in a newspaper of general circulation in the county in which the principal executive office is located. Notice of any meeting of Shareholders shall specify the place, the day and the hour of meeting, and (i) in case of a special meeting, the general nature of the business to be transacted and that no other business may be transacted, or (ii) in the case of an annual meeting, those matters which the Board of Directors, at the date of mailing of notice, intends to present for action by the Shareholders. At any meetings where Directors are elected, notice shall include the names of the nominees, if any, intended at the date of notice to be presented for election.

![](ex100-021.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation Notice shall be deemed given at the time it is delivered personally or deposited in the mail or via electronic digital mail or posted on OTC Markets website, https://www.otcmarkets.com, a Form 8K, or sent by other means of verifiable communication. The officer giving such notice or report shall prepare and file in the minute book of the Corporation an affidavit or declaration thereof. If action is proposed to be taken at any meeting for approval of (i) contracts or transactions in which a Director has a direct or indirect financial interest, pursuant to Section 310 of the Code, (ii) an amendment to the Articles of Incorporation, pursuant to Section 902 of the Code, (iii) a reorganization of the Corporation, pursuant to Section 1201 of the Code, (iv) dissolution of the Corporation, pursuant to the Code, or (v) a distribution to preferred Shareholders, pursuant to the Code, the notice shall also state the general nature of such proposal. Quorum. The holders of a majority of the shares entitled to vote at a Shareholders' meeting, present in person, or represented by proxy, shall constitute a quorum at all meetings of the Shareholders for the transaction of business except as otherwise provided by the Code or by these Bylaws. The Shareholders present at a duly called or held meeting at which a quorum is present may continue to transact business until adjournment, notwithstanding the withdrawal of enough Shareholders to leave less than a quorum, if any action taken (other than adjournment) is approved by a majority of the shares required to constitute a quorum. Adjourned Meeting and Notice Thereof. Any Shareholders' meeting, annual or special, whether or not a quorum is present, may be adjourned from time to time by the vote of the majority of the shares represented at such meeting, either in person or by proxy, but in the absence of a quorum, no other business may be transacted at such meeting. When any meeting of Shareholders, either annual or special, is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place thereof are announced at a meeting at which the adjournment is taken, unless a new record date for the adjourned meeting is fixed, or unless the adjournment is for more than 45 days from the date set for the original meeting, in which case the Board of

![](ex100-022.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation Directors shall set a new record date. Notice of any adjourned meeting shall be given to each Stockholder of record entitled to vote at the adjourned meeting in accordance with the provisions of Section 4 of this Article. At any adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. Waiver or Consent by Absent Shareholders The transactions of any meeting of Shareholders, either annual or special, however called and noticed, shall be valid as though had at a meeting duly held after regular call and notice, if a quorum be present either in person or by proxy, and if, either before or after the meeting, each of the Shareholders entitled to vote, not present in person or by proxy, sign a written waiver of notice, or a consent to the holding of such meeting or an approval of the minutes thereof. The waiver of notice or consent need not specify either the business to be transacted or the purpose of any regular or special meeting of Shareholders, except that if action is taken or proposed to be taken for approval of any of those matters specified in this Article, the waiver of notice or consent shall state the general nature of such proposal. All such waivers, consents or approvals shall be filed with the corporate records or made a part of the minutes of the meeting. Attendance of a person at a meeting shall also constitute a waiver of notice of such meeting, except when the person objects, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened, and except that attendance at a meeting is not a waiver of any right to object to the consideration of matters not included in the notice. A Shareholder or Shareholders of the Corporation holding at least 5% in the aggregate of the outstanding voting shares of the Corporation may (i) inspect, and copy the records of Shareholders' names and addresses and shareholdings during usual business hours upon five days prior written demand upon the Corporation, and/or (ii) obtain from the transfer agent by paying such transfer agent's usual charges for such a list, a list of the Shareholders' names and addresses who are entitled to vote for the election of Directors, and their shareholdings, as of the most recent record date for which such list has been compiled or as of a date specified by the Shareholders subsequent to the

![](ex100-023.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation day of demand. Such list shall be made available by the transfer agent on or before the later of five days after the demand is received or the date specified therein as the date as of which the list is to be compiled. The record of Shareholders shall also be open to inspection upon the written demand of any Shareholder or holder of a voting trust certificate, at any time during usual business hours, for a purpose reasonably related to such holder's interest as a Shareholder or as a holder of a voting trust certificate. Any inspection and copying under this Section may be made in person or by an agent or attorney of such Shareholder or holder of a voting trust certificate making such demand. Section .Maintenance and Inspection of Bylaws . The Corporation shall keep at its principal executive office, or if not in this state, at its principal business office in this state, the original or a copy of the Bylaws amended to date, which shall be open to inspection by the Shareholders at all reasonable times during office hours. If the principal executive office of the Corporation is outside the state and the Corporation has no principal business office in this state, the Secretary shall, upon written request of any Shareholder, furnish to such Shareholder a copy of the Bylaws as amended to date. Annual Report to Shareholders The Corporation shall post its Annual Reports to its portal on OTC Markets, https://www.otcmarkets.com . The posting of the Annual Report on OTC Markets Public Portal is sufficient notice. The Annual Report to Shareholders shall contain a Balance Sheet as of the end of the fiscal year and an Income Statement and Statement of Changes in Financial Position for the fiscal year, accompanied by any report of independent accountants or, if there is no such report, the certificate of an authorized officer of the Corporation that the statements were prepared without audit from the books and records of the Corporation. Financial Statements. A copy of any annual financial statement and any Income Statement of the Corporation for each quarterly period of each fiscal year, and any accompanying Balance Sheet of the Corporation as of the end of each such period, that has been prepared by the Corporation

![](ex100-024.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation shall be kept on file at the principal executive office of the Corporation for 12 months from the date of its execution, and each such statement shall be exhibited at all reasonable times to any Shareholder demanding an examination of such statement or a copy shall be made for any such Shareholder. The Corporation shall post its Financial Statements and Quarterly Financial Repots on the OTC Markets Portal, https://www.otcmarkets.com, which is adequate notice. Annual Statement of General Information. The Corporation shall, in a timely manner, in each year, file with the Secretary of State of Wyoming , on the prescribed form, the statement setting forth the authorized number of Directors, the names and complete business address of all incumbent Directors, the names and complete business address of the Chief Executive Officer, Secretary and Chief Financial Officer, the street address of its principal executive office or principal business office in this state and the general type of business constituting the principal business activity of the Corporation, together with a designation of the agent of the Corporation for the purpose of the service of process, all in compliance with the Code. ARTICLE V AMENDMENTS TO BYLAWS Amendment by Shareholders. All Bylaws of the Corporation shall be subject to alteration or repeal, and new Bylaws may be made by the affirmative vote of shareholders holding of record in the aggregate at least a majority of the outstanding shares of stock entitled to vote in the election of directors at any annual or special meeting of shareholders, provided that the notice or waiver of notice of such meeting shall have summarized or set forth in full therein, the proposed amendment. Amendment by Directors. The Board of Directors shall have power to make, adopt, alter, amend and repeal, from time to time, Bylaws of the Corporation, provided, however, that the shareholders entitled to vote with respect thereto as in this Article V above-provided may alter, amend or repeal

![](ex100-025.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation Bylaws made by the Board of Directors, except that the Board of Directors shall have no power to change the quorum for meetings of shareholders or of the Board of Directors or to change any provisions of the Bylaws with respect to the removal of directors or the filling of vacancies in the Board resulting from the removal by the shareholders. If any bylaw regulating an impending election of directors is adopted, amended or repealed by the Board of Directors, there shall be set forth in the notice of the next meeting of shareholders for the election of directors, the Bylaws so adopted, amended or repealed, together with a concise statement of the changes made. Record of Amendments. Whenever an amendment or new Bylaw is adopted, it shall be copied in the corporate book of Bylaws with the original Bylaws, in the appropriate place. If any Bylaw is repealed, the fact of repeal with the date of the meeting at which the repeal was enacted or written assent was filed shall be stated in the corporate book of Bylaws. ARTICLE VI SHARES OF STOCK Certificate of Stock. Shares of the capital stock of the Corporation may be certificated or uncertificated. Owners of shares of the capital stock of the Corporation shall be recorded in the share transfer records of the Corporation and ownership of such shares shall be evidenced by a certificate or book entry notation in the share transfer records of the Corporation. Any certificates shall be signed by the President or a Vice President and either the Secretary or any Assistant Secretary or such other officer or officers as the Board of Directors shall designate, and shall bear the seal of the Corporation or a facsimile thereof. The signatures of such officers upon a certificate may be facsimiles. In case any officer who has signed or whose facsimile signature has been placed upon such certificate shall have ceased to be such officer before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer at the date of its issuance. Shareholders of Record. The Board of Directors of the Corporation may appoint one or

![](ex100-026.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation more transfer agents or registrars of any class of stock of the Corporation. The Corporation may be its own transfer agent if so appointed by the Board of Directors. The names and addresses of shareholders as they appear on the stock transfer book shall be the official list of shareholders of record of the Corporation for all purposes. The Corporation shall be entitled to treat the holder of record of any shares of the Corporation as the owner thereof for all purposes and shall not be bound to recognize any equitable or other claim to, or interest in, such shares or any rights deriving from such shares, on the part of any other person, including (but without limitation) a purchaser, assignee or transferee, unless and until such other person becomes the holder of record of such shares, whether or not the Corporation shall have either actual or constructive notice of the interest of such other person. Lost or Destroyed Certificates. The holder of any certificate representing shares of stock of the Corporation shall immediately notify the Corporation of any loss or destruction of the certificate representing the same. The Corporation may issue a new certificate in the place of any certificate theretofore issued by it, alleged to have been lost or destroyed. On production of such evidence of loss or destruction as the Board of Directors in its discretion may require, the Board of Directors may, in its discretion, require the owner of the lost or destroyed certificate, or his legal representatives, to give the Corporation a bond in such sum as the Board may direct, and with such surety or sureties as may be satisfactory to the Board, to indemnify the Corporation against any claims, loss, liability or damage it may suffer on account of the issuance of the new certificate. A new certificate may be issued without requiring any such evidence or bond when, in the judgment of the Board of directors, it is proper to do so. Transfer of Shares. The shares of the Corporation shall be transferable on the stock transfer books of the Corporation by the holder of record thereof, or his duly authorized attorney or legal representative, upon endorsement and surrender for cancellation of the certificates for such shares if such shares are represented by certificates. All certificates surrendered for transfer shall be

![](ex100-027.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation canceled, and no new certificate shall be issued until a former certificate or certificates for a like number of shares shall have been surrendered and canceled, except that in the case of a lost, destroyed or mutilated certificate, a new certificate may be issued therefor upon such conditions for the protection of the Corporation and any transfer agent or registrar as the Board of Directors or the Secretary or any other officer may prescribe. Uncertificated shares shall be transferred in the share transfer records of the Corporation upon the written instruction originated by the appropriate person to transfer the shares. Record Date. In lieu of closing the stock ledger of the Corporation, the Board of Directors may fix, in advance, a date not exceeding sixty (60) days, nor less than ten (10) days, as the record date for the determination of shareholders entitled to receive notice of, or to vote at, any meeting of shareholders, or to consent to any proposal without a meeting, or for the purpose of determining shareholders entitled to receive payment of any dividends or allotment of any rights, or for the purpose of any other action. If no record date is fixed, the record date for the determination of shareholders entitled to notice of, or to vote at, a meeting of shareholders shall be at the close of business on the day next preceding the day on which the notice is given, or, if no notice is given, the day preceding the day on which the meeting is held. The record date for determining shareholders for any other purpose shall be at the close of business on the day on which the resolution of the directors relating thereto is adopted. When a determination of shareholders of record entitled to notice of, or to vote at, any meeting of shareholders has been made, as provided for herein, such determination shall apply to any adjournment thereof, unless the directors fix a new record date for the adjourned meeting. ARTICLE VII DIVIDENDS

![](ex100-028.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation Subject to applicable law, dividends may be declared and paid out of any funds available therefore, as often, in such amount, and at such time or times as the Board of Directors may determine. ARTICLE VIII FISCAL YEAR The fiscal year of the Corporation shall be December 31, and may be changed by the Board of Directors from time to time subject to applicable law. ARTICLE IX CORPORATE SEAL The corporate seal shall be circular in form, and shall have inscribed thereon the name of the Corporation, the date of its incorporation, and the word "Wyoming " to indicate the Corporation was incorporated pursuant to the laws of the State of Wyoming . The Corporate is not required to maintain a physical Corporate Seal and instead may utilize a digital Corporate Seal. ARTICLE X INDEMNITY Every person who was or is a party or is threatened to be made a party to or is involved in any action, suit, or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or a person of whom he is the legal representative is or was a director or officer of the corporation or is or was serving at the request of the corporation or for its benefit as a director or officer of another corporation, or as its representative in a partnership, joint venture, trust, or other enterprise, shall be indemnified and held harmless to the fullest extent legally permissible under the general corporation law of the State of Wyoming from time to time against all expenses,

![](ex100-029.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation liability and loss (including attorneys' fees, judgments, fines, and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection therewith. The Board of Directors may, in its discretion, cause the expense of officers and directors incurred in defending a civil or criminal action, suit or proceeding to be paid by the corporation as they are incurred and in advance of the final disposition of the action, suit or proceeding upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled to be indemnified by the corporation. No such person shall be indemnified against, or be reimbursed for, any expense or payments incurred in connection with any claim or liability established to have arisen out of his own willful misconduct or gross negligence. Any right of indemnification shall not be exclusive of any other right which such directors, officers or representatives may have or hereafter acquire and, which such directors, officers, or representatives may have or hereafter acquire and, without limiting the generality of such statement, they shall be entitled to their respective rights of indemnification under any bylaw, agreement, vote of shareholders, provision of law or otherwise, as well as their rights under this Article. The Board of Directors may cause the corporation to purchase and maintain insurance on behalf of any person who is or was a director or officer of the corporation, or is or was serving at the request of the corporation as a director or officer of another corporation, or as its representative in a partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred in any such capacity or arising out of such status, whether or not the corporation would have the power to indemnify such person. The Board of Directors may from time to time adopt further Bylaws with respect to indemnification and may amend these and such Bylaws to the full extent permitted by the Code.

![](ex100-030.jpg)

AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation ARTICLE XI MISCELLANEOUS Shareholders' Agreements . Notwithstanding anything contained in this Article X to the contrary, in the event the Corporation elects to become a close corporation, an agreement between two or more Shareholders thereof, if in writing and signed by the parties thereto, may provide that in exercising any voting rights, the shares held by them shall be voted as provided therein, and may otherwise modify the provisions contained in Article Iv, herein as to shareholders' meetings and actions. Effect of Shareholders' Agreements. Any Shareholders' Agreement authorized by the Code, shall only be effective to modify the terms of these Bylaws if the Corporation elects to become a close corporation with the appropriate filing of an amendment to its Articles of Incorporation as required by the Code and shall terminate when the Corporation ceases to be a close corporation. Such an agreement cannot waive or alter the Sections of the Code. Any other provisions of the Code or these Bylaws may be altered or waived thereby, but to the extent they are not so altered or waived, these Bylaws shall be applicable. Subsidiary Corporations. Shares of the Corporation owned by a subsidiary shall not be entitled to vote on any matter. For the purpose of this Section, a subsidiary of the Corporation as defined the Code is defined as another corporation of which shares thereof possessing more than 25% of the voting power are owned directly or indirectly through one or more other corporations of which the Corporation owns, directly or indirectly, more than 50% of the voting power.

![](ex100-031.jpg)

AMENDED & RESTATED BY-LAWS CS DIAGNOSTICS CORP. EXHIBIT "A" 3rd February 2003 Amended By-Laws (Secretary State Nevada, SEC SB-2)

![](ex100-032.jpg)

![](ex100-033.jpg)

![](ex100-034.jpg)

![](ex100-035.jpg)

![](ex100-036.jpg)

![](ex100-037.jpg)

![](ex100-038.jpg)

![](ex100-039.jpg)

![](ex100-040.jpg)

![](ex100-041.jpg)

![](ex100-042.jpg)

![](ex100-043.jpg)

![](ex100-044.jpg)

AMENDED & RESTATED BY-LAWS CS DIAGNOSTICS CORP. EXHIBIT "A" 3rd February 2003 Amended By-Laws (Secretary State Nevada, SEC SB-2)

![](ex100-045.jpg)

![](ex100-046.jpg)

![](ex100-047.jpg)

![](ex100-048.jpg)

![](ex100-049.jpg)

![](ex100-050.jpg)

![](ex100-051.jpg)

![](ex100-052.jpg)

![](ex100-053.jpg)

![](ex100-054.jpg)

![](ex100-055.jpg)

![](ex100-056.jpg)

![](ex100-057.jpg)

AMENDMENT TO THE ARTICLES OF INCORATION: ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES A PREFERRED STOCK of CS DIAGNOSTICS CORP. The undersigned, Thomas Graus, hereby certifies that: he is the duly elected and active President and Secretary of CS DIAGNOSTICS CORP., a Wyoming corporation (the "Corporation"). Pursuant to authority given by the Corporation's Articles of Incorporation in in accordance with the requirements of the Corporations Article of the Wyoming Revised Statutes the Board of Directors of the Corporation has duly Reinstated and Ratifies the previous Certificate of Designations for its Preferred Series A Shares. On 3rd February 3, 2003, the Corporation amended its Articles of Incorporation and filed the original Certificate of Designation for a Preferred Series "A" Stock. On May 4 2010, the Corporation amended its Articles of Incorporation and filed an Amended Certificate of Designation for its Preferred Series "A" Stock, Attached hereto as Exhibit "A". On March 24, 2024, the Board of Directors approved a Amendment to the Articles of Incorporation and this Restated and Amended Certificate of Designation of Series A Preferred Stock. This Restated and Amended Certificate of Designation of Series A Preferred Stock shall be applied retroactive to the Amended Certificate of Designation dated May 4 2010. SERIES A PREFERRED STOCK The Board does hereby Reinstate and Ratify the following: 1. DESIGNATION AND NUMBER OF SHARES. The Corporation's Board of Directors hereby designate Five Hundred Thousand (500,000) shares of preferred stock as "Series A Preferred Stock", par value $.00001, herein designated as the "Super Voting Stock" with voting and other powers, preferences and relative, participating, optional or other rights of the

![](ex100-058.jpg)

AMENDMENT TO THE ARTICLES OF INCORATION: ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES A PREFERRED STOCK of CS DIAGNOSTICS CORP. shares of such series and the qualifications, limitations and restrictions thereof as described below: 1. ISSUANCE: Shares of Series A Preferred Stock may only be issued in exchange for the partial or full retirement of debt held by management, employees or consultants, or as directed by a majority vote of the Board of Directors. The number of Shares of Series A Preferred Stock to be issued to each qualified person (member of Management, employee or consultant) holding a Note shall be determined by the following formula: For retirement of debt: ?=1 = number of shares of Series A Preferred Stock to be issued where X1 + X2 + X3 ? + ... Xn represent the discrete notes and other obligations owed the lender (holder), which are being retired. 2. VOTING RIGHTS. If at least one share of Series A Preferred Stock is issued and outstanding, then the total aggregate issued shares of Series A Preferred Stock at any given time, regardless of their number, shall have voting rights equal to four times the sum of: a) the total number of shares of Common Stock which are issued and outstanding at the time of voting, plus b) the total number of shares of any other series of preferred stock which are issued and outstanding at the time of voting. ii.) Each individual shares of Series A Preferred Stock shall have the voting rights equal to: [four times the sum of: { all shares of Common Stock issued and outstanding at time of voting + all shares of any other series of preferred stock which are issued and outstanding at time of voting}] divided by: [the number of shares of Series A Preferred Stock issued and outstanding at the time of voting.

![](ex100-059.jpg)

AMENDMENT TO THE ARTICLES OF INCORATION: ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES A PREFERRED STOCK of CS DIAGNOSTICS CORP. 3. LIQUIDATION RIGHTS. (a) Upon any liquidation, dissolution, or winding up of the Corporation, whether voluntary or involuntary, before any distribution or payment shall be made to the holders of any Common Stock, the holders of the Series A Preferred Stock shall be entitled to be paid out of the assets of the Corporation an amount (the "Liquidation Preference") equal to the product of (i) the original amount paid by the holder thereof (the "Original Issue Price") for each share of Series A Preferred Stock owned by such holder as of the effective date of such liquidation (the "Liquidation Date"), multiplied by (ii) the number of shares of Series A Preferred Stock owned of record by such holder as of the Liquidation Date. (as adjusted for any combinations, splits, recapitalization and the like with respect to such shares in the manner set forth herein). (b) After the payment of the full Liquidation Preference as set forth in Section 2(a) above, the remaining assets of the Corporation legally available for distribution, if any, shall be distributed among all holders of the Common Stock until such time as they have received, in the aggregate, an amount equal to the total amount of the Liquidation Preference distributed to the holders of the Series A Preferred Stock pursuant to Section 2(a) above, which amount shall be distributed to each holder of Common Stock on a pro rata basis in accordance with such Common Stock holder's percentage of ownership of the total number of shares of Common Stock issued by the Corporation and outstanding as of the Liquidation Date. (c) Upon completion of the distributions described in Sections 2(a) and 2(b) above, to the extent that there remains any further, undistributed assets of the Corporation, each of the holders of

![](ex100-060.jpg)

AMENDMENT TO THE ARTICLES OF INCORATION: ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES A PREFERRED STOCK of CS DIAGNOSTICS CORP. Common Stock and the Series A Preferred Stock shall receive, on a pro rata basis in accordance with such Common and Series A Preferred Stock holder's percentage of ownership of the total combined number of shares of Common Stock and Series A Preferred Stock outstanding as of the Liquidation Date, the remaining amount of undistributed assets of the Corporation available for distribution as of such Liquidation Date. (d) The following events shall be considered a "liquidation" under this Section: (i) Any consolidation or merger of the Corporation with or into any other corporation or other entity or person, or any other corporate reorganization, in which the stockholders of the Corporation sell or transfer to any other party or parties all or substantially all of the capital stock of the Corporation (an "Acquisition"); (ii) A sale, lease or other disposition of all or substantially all of the assets of the Corporation (an "Asset Transfer"). (e) If, upon any liquidation, distribution, or winding up, the assets of the Corporation shall be insufficient to make payment in full to all holders of Series A Preferred Stock of the Liquidation Preference set forth in Section 2(a) after payment in full of all other outstanding debts, judgments or other obligations of the Corporation as of the Liquidation Date, then such assets shall be distributed among the holders of the Series A Preferred Stock at the time outstanding, on a pro rata basis in proportion to the full amounts to which they would otherwise be respectively entitled if the entire amount due and payable pursuant to Section 2(a) above were available for distribution at such time.

![](ex100-061.jpg)

AMENDMENT TO THE ARTICLES OF INCORATION: ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES A PREFERRED STOCK of CS DIAGNOSTICS CORP. 4. CONVERSION RIGHTS. The holders of the Series A Preferred Stock shall no rights with respect to the conversion of the Series A Preferred Stock into an equivalent number of shares of Common Stock (the "Conversion Rights"), where the Series A Preferred Stock is defined as "Super Voting Stock". 5. NOTICES. Any notice required by the provisions of this Section 3 shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient; or, if not, then on the next successive business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices shall be addressed to each holder of record at the address of such holder appearing on the books of the Corporation as of the date of such notice. 6. OTHER RIGHTS. Except to the extent specifically set forth herein, the holders of the Series A Preferred Stock shall be entitled to all of the rights and benefits enjoyed by the holders of the Corporation's Common Stock under its Articles of Incorporation and Bylaws, as the same may be amended from time to time, and under applicable law. 7. ADJUSTMENT FOR STOCK SPLITS AND COMBINATIONS. If the Corporation shall at any time or from time to time after the date that the first share of Series A Preferred Stock is issued (the "Original Issue Date") effect a subdivision of the outstanding shares of Common Stock without providing for a corresponding subdivision of the number of shares of Series A

![](ex100-062.jpg)

AMENDMENT TO THE ARTICLES OF INCORATION: ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES A PREFERRED STOCK of CS DIAGNOSTICS CORP. Preferred Stock outstanding as of such date, then, the stock price in effect immediately before that subdivision shall be proportionately decreased. Conversely, if the Corporation shall at any time or from time to time after the Original Issue Date combine the outstanding shares of Common Stock into a smaller number of shares without providing for a corresponding combination of the outstanding Series A Preferred Stock, then the stock price in effect immediately before the combination shall be proportionately increased. Any adjustment under this Section 4 shall become effective at the close of business on the date the applicable subdivision or combination becomes effective. 8. NOTICES OF RECORD DATE. Upon (i) any taking by the Corporation of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any distribution, or (ii) any acquisition or other capital reorganization of the Corporation, any reclassification or recapitalization of the capital stock of the Corporation, any merger or consolidation of the Corporation with or into any other corporation, any asset transfer, or any voluntary or involuntary dissolution, liquidation or winding up of the Corporation, the Corporation shall mail to each holder of Series A Preferred Stock at least ten (10) days prior to the record date specified therein a notice specifying: (A) the date on which any such record is to be taken for the purpose of such distribution and a description of such distribution; (B) the date on which any such acquisition, reorganization, reclassification, transfer, consolidation, merger, asset transfer, dissolution, liquidation or winding up is expected to become effective; and (C) the date, if any, that is to be fixed as to when the holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common Stock (or other securities) for securities or other property deliverable upon such acquisition, reorganization, reclassification, transfer, consolidation, merger, asset transfer, dissolution, liquidation or winding up.

![](ex100-063.jpg)

AMENDMENT TO THE ARTICLES OF INCORATION: ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES A PREFERRED STOCK of CS DIAGNOSTICS CORP. IN WITNESS WHEREOF, the undersigned being a duly authorized officer of the Corporation, does file this Certificate of Designation, Rights and Preferences, hereby declaring and certifying that the facts stated herein are true and accordingly has hereunto set his had this 24th day of March, 2023 CS Diagnostics Corp. Thomas Graus, Secretary /s/Thomas Graus

![](ex100-064.jpg)

AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES A PREFERRED STOCK of CS DIAGNOSTICS CORP. EXHIBIT "" 3rd February 2003 1st July 2010 Original Certificate of Designation Series A Preferred Stock (Secretary State Nevada File Stamped and SEC Filing SB-2) Amended Certificate of Designation Series A Preferred Stock (Secretary State Wyoming, on re-domestication)

![](ex100-065.jpg)

![](ex100-066.jpg)

![](ex100-067.jpg)

![](ex100-068.jpg)

![](ex100-069.jpg)

![](ex100-070.jpg)

![](ex100-071.jpg)

![](ex100-072.jpg)

![](ex100-073.jpg)

![](ex100-074.jpg)

![](ex100-075.jpg)

![](ex100-076.jpg)

AMENDMENT TO THE ARTICLES OF INCORPORATION ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES B PREFERRED STOCK of CS DIAGNOSTICS CORP. The undersigned, Thomas Graus, hereby certifies that: he is the duly elected and active President and Secretary of CS DIAGNOSTICS CORP., a Wyoming corporation (the "Corporation"). Pursuant to authority given by the Corporation's Articles of Incorporation in in accordance with the requirements of the Corporations Article of the Wyoming Revised Statutes the Board of Directors of the Corporation has duly Reinstated and Ratifies the previous Certificate of Designations for its Preferred Series B Shares. On 18th October 2010, the Corporation amended its Articles of Incorporation and filed the original Certificate of Designation for a Preferred Series "B" Stock. March 31, 2015, the Corporation amended its Articles of Incorporation and filed an Amended Certificate of Designation for its Preferred Series "B" Stock. On March 24, 2024, the Board of Directors approved a Amendment to the Articles of Incorporation and this Restated and Amended Certificate of Designation of Series B Preferred Stock. This Amended and Restatement of the Certificate of Designation of Series B Preferred Stock shall be applied retroactive to the Amended Certificate of Designation dated March 31, 2015. SERIES B PREFERRED STOCK On the 18th of October 2010, the Board of Directors approved and filed a Certificate of Designation for Series B Preferred Shares and as amended on 31 March 2015. The Board does hereby Amend and Restate the Certificate of Designation for Series B Preferred Share the following: 1. DESIGNATION AND NUMBER OF SHARES. 20,000,000 shares of Series B Preferred Stock, par value $.00001 per share (the "Preferred B Stock"), are authorized pursuant to Article IV

![](ex100-077.jpg)

AMENDMENT TO THE ARTICLES OF INCORPORATION ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES A PREFERRED STOCK of CS DIAGNOSTICS CORP. of the Corporation's Amended Articles of Incorporation (the "Series B Preferred Stock" or "Series B Preferred Shares"). 2. DIVIDENDS. The holders of Preferred B Stock shall be entitled to receive dividends when, as if declared by the Board of Directors, in its sole discretion. 3. LIQUIDATION RIGHTS. Upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, before any distribution or payment shall be made to the holders of any stock ranking junir to the Preferred B Stock, the holders of the Preferred B Stock shall be entitled to be paid out of the assets of the Corporation an amount equal to $1.00 per share or, in the event of an aggregate subscription by any single subscriber for Preferred B Stock in excess of $100,000, $.997 per shares, (as adjusted for any stock dividents, combinations, splits, recapitalizations and the like with respect to such shares)(the "Preference Value"), plus all declared but unpaid dividends, for each share of Preferred B Stock held by them. After the payment of the full applicable Preference Value of each share of the Preferred B Stock as set forth herein, the remaining assets of the Corporation legally available for distribution, if any, shall be distributed ratably to the holders of the Corporation's Common Stock. 4. CONVERSION. The Conversion rate of one share Preferred Series B shall be 1 share of Preferred Series B shall be converted into 20,000 shares of common stock of the Corporation. The Corporation agrees upon the submission of a Notice of Conversion to authorize the Secretary of the Corporation to issue a Board Resolution authorizing the conversion and to notify the transfer agent to process the Conversion. The Preferred Series B shareholder is responsible for any legal or transfer agent fees for such conversion.

![](ex100-078.jpg)

AMENDMENT TO THE ARTICLES OF INCORPORATION ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES A PREFERRED STOCK of CS DIAGNOSTICS CORP. 5. VOTING. The Preferred Series B shareholders shall have the same voting rights as the Corporations Common Stock Shareholders, e.g. 1 vote for each share of Preferred Series B or Common Stock. 6. PRICE. The Board of Directors shall determine the price of issuance of any Preferred Series B Stock. 7. NOTICES OF RECORD DATE. Upon (i) any taking by the Corporation of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any distribution, or (ii) any acquisition or other capital reorganization of the Corporation, any reclassification or recapitalization of the capital stock of the Corporation, any merger or consolidation of the Corporation with or into any other corporation, any asset transfer, or any voluntary or involuntary dissolution, liquidation or winding up of the Corporation, the Corporation shall mail to each holder of Series A Preferred Stock at least ten (10) days prior to the record date specified therein a notice specifying: (A) the date on which any such record is to be taken for the purpose of such distribution and a description of such distribution; (B) the date on which any such acquisition, reorganization, reclassification, transfer, consolidation, merger, asset transfer, dissolution, liquidation or winding up is expected to become effective; and (C) the date, if any, that is to be fixed as to when the holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common Stock (or other securities) for securities or other property deliverable upon such acquisition, reorganization, reclassification, transfer, consolidation, merger, asset transfer, dissolution, liquidation or winding up. IN WITNESS WHEREOF, the undersigned being a duly authorized officer of the Corporation, does file this Certificate of Designation, Rights and Preferences, hereby declaring

![](ex100-079.jpg)

AMENDMENT TO THE ARTICLES OF INCORPORATION ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES A PREFERRED STOCK of CS DIAGNOSTICS CORP. and certifying that the facts stated herein are true and accordingly has hereunto set his had this 24th day of March, 2023 CS Diagnostics Corp. Thomas Graus, Secretary /s/Thomas Graus

![](ex100-080.jpg)

AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES B PREFERRED STOCK CS DIAGNOSTICS CORP. EXHIBIT "C" 18th October 2010 Original Certificate of Designation Series B Preferred Stock (Secretary State Wyoming, SEC 8k) 31 March 2015 Amended Certificate of Designation Series B Preferred Stock (Secretary State Wyoming)

![](ex100-081.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 ???????FORM 8-K??????? CURRENT REPORTPURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934 Date of Report: December 17, 2010(Date of earliest event reported) ???????THE CHILDREN'S INTERNET, INC.(Exact name of registrant as specified in charter)??????? NEVADA(State or other Jurisdiction of Incorporation or Organization) 000-29611 (Commission File Number) 20-1290331 (IRS Employer Identification No.) 2377 Gold Meadow Way,SUITE 100Gold River, CA 95670(Address of Principal Executive Offices and zip code) (916)631-1987(Registrant's telephone number, including area code) N/A(Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)¨Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

![](ex100-082.jpg)

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Information included in this Form 8-K may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Actof 1934, as amended (the "Exchange Act"). This information may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance orachievements of The Children's Internet, Inc. (the "Company") to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements.Forward-looking statements, which involve assumptions and describe future plans, strategies and expectations of the Companies, are generally identifiable by use of the words "may," "will,""should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-lookingstatements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass.The actual results of the Company could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, theCompany undertakes no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future. Item 5.03 Amendment to the Articles of Incorporation Pursuant to Article IV of the Company's Articles of Incorporation and Article VIII of the Company's Bylaws on October 18, 2010 the Company filed its Profit Corporation Articles ofAmendment (the "Amendment") with the Wyoming Secretary of State, increasing its authorized common shares from 500 million to 50 billion at par $0.00001 and designated its 25million Preferred B shares at a par value of $0.00001, inclusive in the 25 million Preferred Shares the Company designates a new series Preferred B stock which will have special rightsand privileges. A copy of the Amendment and exhibit are attached hereto as Exhibit A. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. The Children's Internet, Inc. Date: December 17, 2010By:/s/ R ICHARD J. L EWIS III Richard J. Lewis III,Chief Executive Officer

![](ex100-083.jpg)

![](ex100-084.jpg)

![](ex100-085.jpg)

![](ex100-086.jpg)

![](ex100-087.jpg)

![](ex100-088.jpg)

![](ex100-089.jpg)

![](ex100-090.jpg)

![](ex100-091.jpg)

![](ex100-092.jpg)

![](ex100-093.jpg)

## Exhibit 10.1

**Exhibit 10.1**

![](ex101-001.jpg)

CS DIAGNOSTICS CORP A Wyoming Corporation (the "Company") CERTIFICATE OF DESIGNATION SERIES C PREFERRED STOCK Of the twenty-five million (25,000,000) shares of Preferred Stock, par value $0.00001 per share, authorized pursuant to the Articles of Incorporation, as amended, four million (4,000,000) of such shares are hereby designated as "Series C Preferred Stock." The powers, designations, preferences, rights, privileges, qualifications, limitations and restrictions applicable to the Series C Preferred Stock are as follows: A. Designation. There is hereby designated a series of Preferred Stock denominated as Series C Preferred Stock, consisting of four million (4,000,000) shares, par value $0.00001 per share, having the powers, preferences, rights and limitations set forth below. B. Stated Value The stated value of the Series C Preferred Stock shall be One Thousand and 00/100 ($1,000/00) Dollars per share. (the "Stated Value"). C. Dividends. The holders of the Series C Preferred Stock shall be entitled to receive, out of funds legally available for the payment of dividends, cumulative dividends at the rate of 6.5% per annum of the stated value of each share of Preferred Stock (a "Dividend"). Such Dividends shall accrue daily and be payable semi-annually, in arrears, on each February 1st and August 1st, respectively, of each year (each, a "Dividend Payment Date"). Dividends shall be paid in cash to the extent funds are legally available for such payment. Any accrued but unpaid dividends shall compound annually at the rate of 6.5% per annum and remain payable prior to the payment of any dividends or other distributions on the Corporation's common stock or any other junior securities. D. Liquidation Rights. The holders of the Series C Preferred Stock shall have liquidation rights as follows (the "Liquidation Rights"): 1. Payments. In the event of any liquidation, dissolution or winding up of the Company, holders of shares of Series C Preferred Stock are entitled to receive, out of legally available assets, a liquidation preference Stated Value of the Series C Preferred Stock, plus accrued and unpaid interest and any other payments then due with respect to such shares before any payment or distribution is made to the holders of the of the Corporation's Series B Preferred Stock and it common stock (the "Common Stock"). But the holders of the Series C Preferred Stock will not be entitled to receive the liquidation preference of such shares until the liquidation preferences of any series or class

![](ex101-002.jpg)

2 of the Corporation's stock hereafter issued that ranks senior as to liquidation rights to the Special 2019 Series A Preferred Stock ("Senior Liquidation Stock") has been paid in full. The holders of the Series C Preferred Stock and all other series or classes of the Corporation's stock hereafter issued that rank on parity as to liquidation rights with the Series C Preferred Stock are entitled to share ratably, in accordance with the respective preferential amounts payable thereon. After payment in full of the liquidation preference of the shares of Series C Preferred Stock, the holders of such shares will not be entitled to any further participation in any distribution of assets by the Corporation. 2. Corporate Action. Neither a consolidation, merger or other business combination of the Company with or into another corporation or other entity, nor a sale or transfer of all or part of the Corporation's assets for cash, securities or other property will be considered a liquidation, dissolution or winding upon the Corporation. E. Conversion. The holders of the Series C Preferred Stock shall have the right to convert their shares into Common Stock at a price equal to 90% of the thirty (30)-day average ask price of the Common Stock as quoted on any national securities exchange where the Company's securities are listed or traded, calculated as of the date the conversion notice is delivered to the Company (the "Conversion Price"). Such conversion right may be exercised at any time during which the Series C Preferred Stock is outstanding. Any holder of Series C Preferred Stock desiring to convert its shares shall provide a written notice of conversion to the Company specifying the number of shares to be converted, accompanied by the certificate evidencing the Series C Preferred Stock to be converted, as well as a duly executed stock power with signature medallion guaranteed ("Conversion Notice"). In the event that, at the time of its receipt of the Conversion Notice, the Company does not have a sufficient number of authorized but unissued and unreserved shares of Common Stock to permit conversion of all outstanding shares of Series C Preferred Stock, it shall, within five (5) business days following its receipt of the Conversion Notice, provide written notice of its receipt of the Conversion Notice to all holders of Series C Preferred Stock (the "Company Notice"). Each holder of Series C Preferred Stock shall then have a period of five (5) business days from the date of the Company Notice in which to provide written notice to the Company of such holder's election to convert its Series C Preferred Stock into its pro-rata portion of the authorized but unissued and unreserved Common Stock upon conversion of the Series C Preferred Stock based upon the Conversion notice and responses to the Company Notice, if any. The first Conversion Notice received by the Company shall govern the issuance of Common Conversion Notice until the issuance of Common stock based upon the initial Conversion Notice has been completed. Future Conversion notices shall be governed by the process set forth in this paragraph. Notwithstanding the foregoing, at the option of the Company, all outstanding Series C Preferred Stock may be automatically converted into Common Stock at the then-

![](ex101-003.jpg)

3 applicable Conversion Price upon the occurrence of a change in control involving greater than fifty (50%) percent of the Company's voting securities. F. Voting rights. The Series C Preferred Stock does not carry any voting rights and the holders thereof shall not be entitled to participate in any of the Company's stockholder meetings. G. Preemptive Rights. Each holder will have a pre-emptive right to maintain its proportionate interest in the Series C Preferred Stock by way of subscription for the necessary percentage in any New Offering. For purposes herein, a "New Offering" shall mean any public offering and/or any privately negotiated debt, equity or equity-linked investment accepted by the Company, which shall include, but is not limited to, any placement executed in compliance with certain exemptions provided for under the Securities Act of 1933, as amended (a "non-Rule 144a transaction") or any registered direct transactions such as a primary shelf equity line or resale shelf equity line. In case one or more of the Stockholders reject such offer, the remaining Stockholders will have increased pre-emptive rights on a pro rata basis. Shares of Preferred Stock issued as a consequence of any employee incentive programs and/or execution of antidilution rights shall not trigger the pre-emptive rights. H. Company Redemption. On or after three (3) years following the issuance of shares of the Series C Preferred Stock, the Company may compel redemption of the shares, in whole or part, at its option, at the price per share equal to the Stated Value of such Preferred Stock at the time of such redemption, together with accrued but unpaid dividends and other payments then due with respect to such Preferred Stock (the "Company's Redemption Price"). The Company shall provide written notice of its intent to redeem to the Stockholder (the "Company's Redemption Notice") and no Dividend shall accrue on the Stockholder's Preferred Stock following receipt of Company's Redemption Notice. The Company's Redemption Price shall become due and payable on the next Dividend Payment Date. I. Stockholder Redemption. Upon either (a) the closing of a New Offering, the aggregate proceeds of which equal at least Five Hundred Million and 00/100 ($500,000,000/00) Dollars; or (b) the fifth anniversary of the issuance date a stockholder may compel redemption of the Series C Preferred Stock, in whole or part, at its option, at a price per share equal to the Stated Value of such shares at the time of such redemption, together with accrued but unpaid dividends and other payments then due with respect to such shares (the "Stockholders Redemption Price"). The stockholder shall provide written notice of its intent to redeem to the Company (the "Stockholder's Redemption Notice") and no Dividend shall accrue on the Series C Preferred Stock following receipt of Stockholder's Redemption Notice. The Stockholder's Redemption Price shall become due and payable on the next Dividend Payment Date. Notwithstanding the foregoing, the Company shall never be compelled to pay more than forty (40%) percent of its semi-annual net income as determined in accordance with Generally

![](ex101-004.jpg)

4 Accepted Accounting Principles towards Stockholder's Redemption Price. Accordingly, the Stockholder's Redemption Price shall be paid on a first come, first serve basis until paid in full. a. Failure of Redemption. Should the Company be unable or otherwise refuse to honor any Stockholder's Redemption Notice, the Company shall then cause the Stockholder's Redemption to be offered to the other Stockholders (the "Redemption Offer"). Should another Stockholder not accept the Redemption Offer within six (6) months thereafter, the Stockholder having made the Redemption Offer shall be granted a security interest in the assets of the Company in an amount equal to the Redemption Offer. The Redemption Offer shall not expire unless withdrawn by the Stockholder, at which time any security interest granted shall extinguish. Moreover, the Company's failure to honor any Stockholder's Redemption Notice shall not interfere with that Stockholder's right to receive Dividends. J. Protective Provisions. So long as shares of Series C Preferred Stock are outstanding, the Company shall not without first obtaining the approval (by voting or written consent, as provided by Wyoming law) of the holders of at least a majority of the then outstanding shares of Series C Preferred Stock; - Alter or change the rights, preferences or privileges of the shares of the Series C Preferred Stock so as to affect adversely the holders of the shares; or - Do any act or thing not authorized or contemplated by this Designation which would result in taxation of the holders of shares of the Series C Preferred Stock under Section 305 of the Internal Revenue Code of 1986, as amended (or any comparable provision of the Internal Revenue Code as hereafter from time to time amended). K. Preferences. Nothing contained herein shall be construed to prevent the Board of Directors of the Company from issuing one or more series of preferred stock with such preferences as may be determine by the Board of Directors, in its discretion. L. Amendments. Subject to the terms and conditions herein, the designation, number of, and voting powers, designations, preferences, limitations, restrictions and relative rights of the Series C Preferred Stock may be amended by the resolution of the Board of Directors. At any time that there are no shares of the Series C Preferred Stock outstanding, the Board of Directors may eliminate this class of securities by amendment to this Certificate of Designation.

![](ex101-005.jpg)

5 M. Adjustments. The outstanding shares of the Series C Preferred Stock shall be proportionally adjusted to reflect any forward split or reverse split of the Company's Common Stock occurring after the issuance of Series C Preferred Stock. Dated: January 17, 2025 CS DIAGNOTICS CORP Name: Thomas Fahrhoefer Title: President Name: Mohammad EsSayed Title: Chief Financial Officer/Director CS DIAGNOSTICS CORP c/o Wyoming Discount Registered Agent, Inc 36 Shadow Brook Ln Lander, WY 82520 USA

## Exhibit 10.2

**Exhibit 10.2**

![](ex102-001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP. CSDX QUARTERLY REPORT AND FINANCIALS FOR THE PERIOD ENDING MARCH 31, 2025

![](ex102-002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosure Statement Pursuant to the OTCQB Basic Disclosure Guidelines CS DIAGNOSTICS CORP, A Wyoming Corporation, Stresemannallee 4b Neuss, Germany 41460 Telephone +49 (0)2131-151 08 71 http://www.csdcorp.us info@csdcorp.us SIC CODE: 2834 QUARTER REPORT For the Period Ending March 31, 2025 Outstanding Shares The number of shares outstanding of our Common Stock was: 137,340,200 as of March 31, 2025 137,290,200 as of December 31, 2024

![](ex102-003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shell Status Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934): Yes: ? No: ? Indicate by check mark whether the company's shell status has changed since the previous reporting period: Yes: ? No: ? Change in Control Indicate by check mark whether a Change in Control1 of the company has occurred over this reporting period: Yes: ? No: ? 1) Name and address(es) of the issuer and its predecessors (if any) In answering this item, provide the current name of the Issuer any names used by predecessor entities, along with the dates of the name changes. The exact name of the issuer is CS Diagnostics Corp. On September 25, 1996, the issuer was incorporated in the State of Nevada as D.W.C. Installations, Inc.. On December 27, 2002, the issuer name was changed to Children's Internet, Inc.. On February 18, 2015, the issuer name was changed to FlashZero Corp. On May 31, 2022, the issuer name was changed to CS Diagnostics Corp.. On August 1, 2023, FINRA authorized the Corporation Action and the Articles were amended to change the name, CS Diagnostics Corp. Current State and Date of Incorporation or Registration: On October 15, 2010 the issuer was re- domiciled in the State of Wyoming. The issuer is in Good Standing in its domicile, Wyoming, and is designated status Active Business License. Standing in this jurisdiction: Active in Good Standing Prior Incorporation Information for the issuer and any predecessors during the past five years: NONE. Describe any trading suspension orders issued by the SEC concerning the Issuer or its predecessors since inception: NONE.

![](ex102-004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: On August 1, 2023, FINRA Notified the Issuer and its Transfer Agent that is has received the necessary documentation to process the below listed corporate action requested by FlashZero Corp (FZRO) and Transfer Online pursuant to FINRA Rule 6490. This Corporate Action included: ? 1 for 100,000 reverse split followed by a 200 for 1 forward split ? Name Change to: CS Diagnostics Corp. ? New CUSIP 33852L202 . On September 4, 2023, CS Diagnostics Group finalized the agreement whereas CS Diagnostics Group sold and transferred the tangible, intangible and patents for the CS Protect-Hydrogel, a hydrogel-based tissue spacer used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation to CS Diagnostics Corp. The CS Diagnostics Group have obtained a valuation for the CS Protect-Hydrogel in amount greater that 960,000,000 Euro based on its discounted present commercial value. The valuation is supported, as contained in the final valuation by the 2018 purchase of the similar product by Boston Scientific for $500,000,000 USD and further compensation based on the distribution revenues. CS Diagnostics Corp., based on this valuation, on September 27, 2023, the transfer agent, Transfer Online, issued 110,000,000 shares of the Issuer common stock to represent a payment of $500,000,000 USD for the rights, patents and intellectual property of the CS Protect-Hydrogel product to the CS Diagnostics Group, its successor or assigns. On July 29th 2024, FINRA processed a Form 211 relating to the initiation of priced quotations of CSDX, which means that the submitting broker-dealer has demonstrated to FINRA compliance with FINRA Rule 6432 and therefore has met the requirements under that rule to initiate a quotation for CSDX within four days of 07/29/2024. FINRA's processing of a Form 211 in no way constitutes FINRA's approval of the security, the issuer, or the issuer's business and relates solely to the submitting broker-dealer's obligation to comply with FINRA Rule 6432 and SEA Rule 15c2-11 when quoting a security. On August 9th 2024, a shareholder resolution has been issued for changes in CSDX board of directors as follows: Mr. Thomas Migotsch and Mr. Thomas Graus as well as the previous independent directors Mrs. Csilla Kanderka and Mrs. Delia-Alexandra Kreutner were replaced by Mr. Mohammad EsSayed is VP, Director and CFO, Mr. Thomas Migotsch remains a director and assigned as COO, Dr. Lauren Ugur and Mr. Mahmoud Ahmad Hashim AL-Sayed take on their role as independent directors, and Ms. Janel Luzana as an Officer and Company Secretary. It was agreed that Mr. Thomas Graus will receive compensation as Mr. Thomas Graus of $72,000 during 2025. The address(es) of the Issuer's principal place of business: Check box if principal executive office and principal place of business are the same address: ? Stresemann allée 4b Neuss 41460 Germany +49 (0)2131-151 08 71 Has the Issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years? Yes: ? No: ?

![](ex102-005.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below: NONE 1) Security Information Transfer Agent Name: Transfer Online, Inc. Phone: +1-503-227-2950 Email: info@transferonline.com Address: 512 SE Salmon St. Portland, OR 97214 Publicly Quoted or Traded Securities: Trading symbol: CSDX Exact title and class of securities outstanding: Common CUSIP: 33852L103 Par or stated value: 0.00001 FEIN 20-1290331 Total shares authorized 250,000,000 as of date March 31, 2025 Total Common shares outstanding: 137,340,200 as of date March 31, 2025 Number of shares in the Public Float2: 9,575,301 as of date March 31, 2025 Total number of shareholders of record: 314 as of date March 31, 2025 CUSIP NUMBER 33852L202 All additional class(es) of publicly traded securities (if any): N/A

![](ex102-006.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other classes of authorized or outstanding equity securities: The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities. Exact title and class of the security: Preferred Series A CUSIP (if applicable): N/A Par or stated value: $0.00001 Total shares authorized: 1,000,000 as of date March 31, 2025 Total shares outstanding (if applicable): 10 as of date March 31, 2025 Total number of shareholders of record 1 as of date March 31, 2025 Exact title and class of the security: Preferred Series B CUSIP (if applicable): N/A Par or stated value: $0.00001 Total shares authorized: 20,000,000 as of date March 31, 2025 Total shares outstanding (if applicable): 19,992,575 as of date March 31, 2025 Total number of shareholders of record 18 as of date March 31, 2025 Exact title and class of the security: Preferred Series C CUSIP (if applicable): N/A Par or stated value: $0.00001 Total shares authorized: 4,000,000 as of date March 31, 2025 Total shares outstanding (if applicable): 0 as of date March 31, 2025 Total number of shareholders of record 0 as of date March 31, 2025 2 "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

![](ex102-007.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Security Description: The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable: 1- For common equity, describe any dividend, voting and preemption rights. Currently there are no dividends. Dividends are subject to the Board of Directors discretion and approval. There are no preemption rights for Common Equity Shareholders. 2- For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions. Preferred Series A Currently there are no dividends. Dividends are subject to the Board of Directors discretion and approval. The Series A Preferred Stock has voting rights equal to four times the sum of: a) the total number of shares of Common Stock which are issued and outstanding at the time of voting, plus b) the total number of shares of any other series of preferred stock which are issued and outstanding at the time of voting. The holders of the Series A Preferred Stock shall no rights with respect to the conversion of the Series A Preferred Stock into an equivalent number of shares of Common Stock (the "Conversion Rights"), where the Series A Preferred Stock is defined as "Super Voting Stock". The Liquidation Rights are: Series A Preferred Stock shall be entitled to be paid out of the assets of the Corporation an amount (the "Liquidation Preference") equal to the product of (i) the original amount paid by the holder thereof (the "Original Issue Price") for each share of Series A Preferred Stock owned by such holder as of the effective date of such liquidation (the "Liquidation Date"), multiplied by (ii) the number of shares of Series A Preferred Stock owned of record by such holder as of the Liquidation Date. (as adjusted for any combinations, splits, recapitalization and the like with respect to such shares in the manner set forth herein). It does not have any sinking fund provisions. Preferred Series B Currently there are no dividends. Dividends are subject to the Board of Directors discretion and approval. The Series B Preferred Stock has same 1 vote for 1 shares as with the Common Share shareholders. The Series B Preferred Stock has conversion of 20,000 shares of common stock for each share of

![](ex102-008.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred Series B stock with a maximum conversion of up to 9.9% of the total outstanding common stock. It does not have any sinking fund provisions. The liquidation rights are Upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, before any distribution or payment shall be made to the holders of any stock ranking junir to the Preferred B Stock, the holders of the Preferred B Stock shall be entitled to be paid out of the assets of the Corporation an amount equal to $1.00 per share or, in the event of an aggregate subscription by any single subscriber for Preferred B Stock in excess of $100,000, $.997 per shares, (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares)(the "Preference Value"), plus all declared but unpaid dividends, for each share of Preferred B Stock held by them. After the payment of the full applicable Preference Value of each share of the Preferred B Stock as set forth herein, the remaining assets of the Corporation legally available for distribution, if any, shall be distributed ratably to the holders of the Corporation's Common Stock. 3- Describe any other material rights of common or preferred stockholders. None 4- Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report. On March 24, 2023, the issuer and the majority shareholder, holding 100% of the Series A and in excess of 90% of Preferred Series B and 110,000,000 shares of common stock, approved and ratified An Amendment and Restatement of the Certificate of Designation of the Preferred Series A and Preferred Series B and the By-Laws of the Issuer in order to clarity the previous amendments to the Certificate of Designations and Amendments to the Articles of Incorporation. These Amendments and Restatement of the Certificate of Designations were filed with the Secretary of State of Wyoming. 3- Issuance History The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period. Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

![](ex102-009.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. Changes to the Number of Outstanding Shares Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: No: ? Yes: X (If yes, you must complete the table below) Shares Outstanding as of Second Most Recent Fiscal Year End: Opening Balance Date January 1, 2023 Common: 135,287,214 Preferred A 10 Preferred B 9,989,000 \*Right-click the rows below and select "Insert" to add rows as needed. Date of Transaction Number of Class of Value of Were the Individual/ Reason for Restricted Exemption Transaction type (e.g. Shares Securities shares shares Entity Shares share issuance or or new Issued (or issued issued at were issued (e.g. for cash Unrestricted Registration issuance, cancelled) ($/per a to (entities or debt as of this Type. cancellation, share) discount must have conversion) filing. shares at to individual -OR- returned to Issuance market with voting / Nature of treasury) price at investment Services the time control Provided of disclosed). issuance? (Yes/No) 05-09-2022 Issuance 10,011,000 Preferred Series B 1,000 No PatientTrac Limited (See Note 1) Pursuant to the Securities Purchase Agreement for services rendered, e.g. acquisition costs, payments and organization reinstatements Restricted 4(a)(2) 08-01-2023 Corporate Action - 134,497,014 Common .00001 No Corporate Action all Same Restricted and 4(a)(2) Reverse shareholders Unrestricted split 1 to 100,000 and Forward Split 1 to 200

![](ex102-010.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;09/27/2023 Issuance 65,000,000 Common $4.54 No CS Diagnostics Pharma GmbH Note 2: Asset Purchase Agreement Restricted 4(a)(2) 09/27/2023 Issuance 20,000,000 Common $4.54 No CS Interpharm LLC Note 2: Asset Purchase Agreement Restricted 4(a)(2) Shares Outstanding on Date of This Report: Ending Balance Date March 31, 2025 Common: 137,340,200 Preferred A 10 Preferred B 19,992,575 Note 1: PatientTrac Limited is a United Kingdom company whose beneficial owner is H Wayne Hayes, Jr. of Bogota, Colombia and held these shares in trust. PatientTrac, pursuant to the Securities Purchase Agreement dated 30 March 2022 with CS Diagnostics Pharma GmbH, has agreed and on July 9, 2022 transferred the 10,011,000 to CS Diagnostics Pharma GmbH designees. Note 2: The Beneficial Owner Thomas Fahrhoefer, Dubai, UAE B. Promissory and Convertible Notes Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities. Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ? N/A Note: During the FINRA corporate action request, supra, On May 3, 2023, the Issuer Board of Directors and its Majority Shareholder pursuant to Wyoming Revised Statutes cancelled the remaining balance of the July 10, 2009 Promissory Note by and between the Issuer on David Lampel. A legal opinion has been issued and provided to the Issuer's PCAOB Auditors and the contingent liability, Promissory Note balance and interest, has been removed from the Issuer's financial statements.

![](ex102-011.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4- Issuer's Business, Products and Services The purpose of this section is to provide a clear description of the issuer's current operations. A. Summarize the Issuer's business operations (If the Issuer does not have current operations, state "no operations") The publicly traded company CS Diagnostics Corp. is the sole owner of the property CS Protect- Hydrogel. CS Protect-Hydrogel, a hydrogel-based tissue spacer used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation to CS Diagnostics Corp. The Issuer and its parent company, CS Diagnostics Pharma GmbH, and its affiliated company, CS Interpharm GT LLC, are actively engaged in proven operations in the Medical and Biotech industry. B. List any subsidiaries, parent company, or affiliated companies. Parent Company CS Diagnostics Pharma GmbH, Stresemannallee 4b Neuss, 41460 Germany Affiliated Company CS Interpharm General Trading LLC, 809-816 Bay Squair, Business Bay, Dubai, United Arab Emirates. C. Describe the Issuers' principal products or services. CS Diagnostics Group is a pharmaceutical international wholesaler and manufacturer of medical technology. For more than 10 years its current management has been supplying national and international specialists, practices, clinics as well as ministries of health. In addition, we offer international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, we develop our own products with the aim of maximizing patient benefit.

![](ex102-012.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5- Issuer's Facilities The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the Issuer and the extent in which the facilities are utilized. In responding to this item, please clearly describe the assets, properties or facilities of the Issuer, give the location of the principal plants and other property of the Issuer and describe the condition of the properties. If the Issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership. Headquarters: City of Neuss in Germany: City of Bruckmühl in Germany Dubai, United Arab Emirates Name of Officer/Director or Control Person Affiliation with Company (e.g. Officer/Director/Owner of more than 5%) Residential Address (City / State Only) Number of shares owned Share type/class Ownership Percentage of Class Outstanding Note Thomas Fahrhoefer President Dubai, United Arab Emirates 91,881,896 10 13,665,206 Common Preferred A Preferred B 67% 100% 68% Beneficial Ownership (No shares in personal name) Thomas J Migotsch Chief Operational Officer Rapperswil-Jona, Switzerland 480.000 N/A .004% Mohammad EsSayed Chief Financial Officer Dubai, UAE 0 N/A N/A Janel Luzana Company Secretary Dubai, UAE 0 N/A N/A CS Diagnostics Pharma GmbH More than 5% Neuss, Germany 74,855,800 10 7,924,180 Common Preferred A Preferred B 54.5% 100% 39.6% Thomas Fahrhoefer, Dubai, UAE CS Interpharm General Trading Co. LLC More than 5% Dubai, United Arab Emirates 17,026,096 5,731,026 Common Preferred B 12.3% 28.6% Thomas Fahrhoefer, Dubai, UAE Association Continental de Reassurance NV More than 5% Antwerpen Belgium 3,500,000 1,499,625 Common Preferred B 2.5% 7.5% Adriaan Vangelabbeek Antwerpen, Belgium Thomas Graus More than 5% Viganello Switzerland 3,700,000 1,273,737 Common Preferred B 2.7% 6.4% Thomas Graus Viganello, Switzerland Antonio Santoli More than 5% Breganzona Switzerland 3,800,000 1,273,737 Common Preferred B 2.7% 6.4% Antonio Santoli Breganzona, Switzerland

![](ex102-013.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6- Legal/Disciplinary History A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years: 1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations); NO 2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities; NO 3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated; NO 4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or NO 5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities. NO

![](ex102-014.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail. NO B. Describe briefly any material pending legal proceedings, other than ordinary B- routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities. NONE 7- Third Party Providers Please provide the name, address, telephone number and email address of each of the following outside providers: Securities Counsel Investor Relations/Marketing/Communications Mavacy, PLLC ROSEWOOD REPUTATION LIMITED 15169 N. Scottsdale Rd., 80 Coleman Street, ENG W1U 7LP Suite 205, London, United Kingdom Scottsdale, AZ 85254 Accounting/Auditing Firm LAO Professionals Suite 33, Hill Top Plaza, 13 Gwani Street, Zone 4, Wuse Abuja 00234, Nigeria

![](ex102-015.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provide the name of any other service provider(s) that that assisted, advised, prepared or provided information with respect to this disclosure statement. This includes counsel, advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period. NONE 8- Disclosure & Financial Information A. This Disclosure Statement was prepared by(name of individual): Name: Mohammad EsSayed Title: Chief Financial Officer Relationship to Issuer: VP, Director B. The following financial statements were prepared in accordance with: ? U.S. GAAP ? IFRS C. The financial statements for this reporting period were prepared by (name of individual)3: Name: Mohammad EsSayed Title: CFO Relationship to Issuer: VP, Director Describe the qualifications of the person or persons who prepared the financial statements: Accounting firm preparing financial reporting and certified US Tax. 3 The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

![](ex102-016.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9- Issuer Certification Principal Executive Officer: The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities). The certifications shall follow the format below: I, Thomas Fahrhoefer, certify that: 1. I have reviewed this Annual Report and Disclosure Statement for Period Ending March 31, 2025 of CS Diagnostic Corp. 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement. March 31, 2025 /s/ Thomas Fahrhoefer

![](ex102-017.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Principal Financial Officer: I, Mohammad EsSayed, certify that: 1. I have reviewed this Annual Report and Disclosure Statement for Period Ending March 31, 2025 of CS Diagnostic Corp. 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement. March 31, 2025 /s/ Mohammad EsSayed

![](ex102-018.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP FINANCIAL STATEMENTS FOR PERIOD ENDING March 31, 2025 BALANCE SHEET STATEMENT STATEMENT CASH FLOWS INCOME STATEMENT STATEMENT OF CHANGES IN SHAREHOLDERS EQUITY FINANCIAL NOTES

![](ex102-019.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP. OTCQB-CSDX INDEX TO FINANCIAL STATEMENTS Balance Sheets as of March 31, 2025, and December 31, 2024 Statements of Operations for the Three months period ended March 31, 2025, and March 31, 2024 Statements of Stockholders' Equity for Three months period ended March 31, 2025, and March 31, 2024 Statements of Cash Flows for the Three months period ended March 31, 2025, and March 31, 2024 Notes to the Financial Statements

![](ex102-020.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP. CSDX BALANCE SHEET FOR THE PERIOD ENDED March 31 2025 March 31, 2025 December 31, 2024 Un-Audited Audited Assets Current Assets Cash 51,386 501 Other Receivables 54,726 - Total Current Assets $106,112 $501 Intangible Assets 499,400,000 499,400,000 Total Assets $499,506,112 $499,400,501 Liabilities and Stockholders' Deficit Current Liabilities Account Payables 2,931 1,428 Non-current liabilities - Total Liabilities $74,931 $1,428 Shareholder's Deficit Common stock, $0.00001 par value; 250,000,000 shares authorized,137,340,200 shares issued and outstanding as of March 31, 2025 1,373 1,373 Preferred stock Series A, $0.00001 par value;5,000 shares authorized, 10 shares issued and outstanding as of March 31, 2025 - - Preferred stock Series B, $0.00001 par value; 20,000,000 shares authorized, 19,992,575 shares issued and outstanding as of March 31, 2025 2,000 2,000 Preferred stock Series C, $0.00001 par value; 4,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2025 40 - Additional paid-in capital 504,163,629 504,163,629 Accumulated deficit -4,735,861 -4,767,928 Total Stockholders' Deficit $499,431,181 $499,399,073 Total Liabilities and Stockholders' Deficit $499,506,112 $499,400,501 The accompanying notes are an integral part of these financial statements. This is an unaudited financial statement, can be subject to minor changes upon Auditor review

![](ex102-021.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP. STATEMENT OF OPERATIONS FOR THE PERIOD ENDED March 31, 2025 For the Three Months Ended March 31st 2025 2024 Revenue 70,420 53,258 Revenue $70,420 $53,258 Operating Expenses Professional Fee 16,519 44,555 General & Administrative Expenses 21,834 140 Total Operating expenses 38,353 8,564 Income/(loss) from Operations $32,067 $8,564 Other Income / (Expense) - - Debt Written off - - Net Income / (loss) $32,067 $0.00 Basic and diluted loss per share 0.00 0.00 basic and diluted loss weighted average shares 137,340,200 110,790,200 The accompanying notes are an integral part of these financial statements. This is an unaudited financial statement, can be subject to minor changes upon Auditor review

![](ex102-022.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP. STATEMENT OF STOCKHOLDERS (DEFICIT) FOR THE PERIOD ENDED March 31, 2025 Preferred Stock B Preferred Stock C Common Stock Additional Accumulated Shares Amount Shares Amount Shares Amount Paid-in Capital Deficit Total Balance, January 1, 2024 20,000,000 $2,000 $0 $0 110,790,200 $1,018 $504,173,122 -$4,798,689 $449,407,450 Reversed Stock Split - - - - - - - Shares Issued/Converted -1,325 $0 $0 $0 26,500,000 $355 -$9,493 - -$9,138 Net income (loss) for the year - - - - - $761 $761 Balance, December 31, 2024 19,998,675 $2,000 $0 $0 137,290,200 $1,373 $504,163,629 -$4,767,928 $449,399,073 Balance, January 1st, 2025 19,998,675 2,000 0 0 137,290,200 1,373 504,163,629 -4,767,928 449,399,073 Shares Issued/Converted -6,100 4,000,000 $40 50,000 Net income (loss) for the period ended March 31, 2025 $32,067 $32,067 Shares Issued in acquisition of Assets Balance, March 31, 2025 19,992,575 2,000 4,000,000 40 137,340,200 1,373 504,163,629 -4,735,861 449,431,181 The accompanying notes are an integral part of these financial statements. This is an unaudited financial statement, can be subject to minor changes upon Auditor review

![](ex102-023.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP. STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED March 31, 2025 For the Three Months Ended March 31st 2025 2024 Cash flows from operating activities Net profit/ (loss) 32,067 8,564 Adjustment to reconcile net loss to net cash used in operating activities Changes in assets and liabilities Other Receivables 21,750 - Account payables -2,931 -11,248 Net cash used in operating activities $50,886 $-2,684 Cash flows from investing activities Intangible Asset -499,444,401 - Net cash provided by Investing activities -$499,444,401 - Cash flows from financing activities Additional Capital Paid Up 499,444,401 - Loan forgiven - - Net cash provided by financing activities $499,444,401.00 - Net increase /(decrease) in cash 50,886 -2,684 Cash beginning of period 501 20,363 Cash end of period $51,386 $17,679 The accompanying notes are an integral part of these financial statements. This is an unaudited financial statement, can be subject to minor changes upon Auditor review

![](ex102-024.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C S DIAGNOSTICS CORP Notes to the Financial Statements March 31, 2025, and December 31, 2024 NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS CS Diagnostics Corp., (the "Company") a Wyoming Corporation in the United State, CS Diagnostics Corp., is an United States based Corporation, Its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit. We work hand in hand with universities, experts and experienced users as well as with our users, as well as with our own R&D team, in order to always offer the most innovative products in medical technology. On August 1, 2023, FINRA authorized the Corporate Action approved by the Board of Directors and majority shareholder for and amendment to the Articles of Incorporation from FlashZero Corp to CS Diagnostics Corp and a 1 for 100,000 reverse split followed by a 200 for 1 forward split and a change of the CUSIP to 33852L202. Pre-split shares: 135,287,214: Post Split share 790,200. On September 4, 2023, CS Diagnostics Corp purchased 100% of the tangible product CS Protect-Hydrogel, its intellectual property, distribution rights and patents from the CS Diagnostics Group, headquartered in Germany. The CS ProtectHydrogel is a hydrogel-based tissue spacer. It is used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation. Currently, hydrogel spacers are used exclusively in the treatment of prostate cancer. Here, the spacer pushes the rectum away from the prostate, thus reducing rectal damage from radiation therapy. The hydrogel spacer is injected once in liquid form through a thin needle into the space between cancer cells and healthy tissue and is broken down by the body after about six months. The CS Protect-Hydrogel is a "ready-to-use" product, which is sterile packed and can be applied directly. The hydrogel can be used in radiotherapy for prostate, cervical, esophageal, bladder and breast cancer. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates.

![](ex102-025.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company's cash is deposited with major financial institutions. At times, such deposits may be in excess of the Federal Deposit Insurance Corporation insurable amount. Cash and Cash Equivalents The Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less as cash and cash equivalents. The carrying amount of financial instruments included in cash and cash equivalents approximates fair value because of the short maturities for the instruments held. There were no cash equivalents for the period ended March 31, 2024, and 2023 Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC Topic No. 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels, as described below: Level 1: Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. Level 2 inputs include quoted prices for similar assets, quoted prices in markets that are not considered to be active, and observable inputs other than quoted prices such as interest rates. Level 3: Level 3 inputs are unobservable inputs. The following required disclosure of the estimated fair value of financial instruments has been determined by the Company using available market information and appropriate valuation methodologies. However, considerable judgment is required to interpret market data to develop the estimates of fair value. Accordingly, the use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. The methods and assumptions used to estimate the fair values of each class of financial instruments are as follows: Accounts Receivable, and Accounts Payable. The items are generally short-term in nature, and accordingly, the carrying amounts reported on the consolidated balance sheets are reasonable approximations of their fair values. The carrying amounts of Notes Payable approximate the fair value as the notes bear interest rates that are consistent with current market rates. Income Taxes We follow ASC 740-10-30, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income in the period that includes the enactment date.

![](ex102-026.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We adopted ASC 740-10-25 ("ASC 740-10-25") with regard to uncertainty income taxes. ASC 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10-25, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740-10-25 also provides guidance on derecognition, classification, interest and penalties on income taxes, and accounting in interim periods and requires increased disclosures. We had no material adjustments to our liabilities for unrecognized income tax benefits according to the provisions of ASC 740-10-25. Net income (loss) per common share Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented. For the period ended March 31, 2025 and 2024, the diluted loss per share is the same as the basic loss per shares as the inclusion of any potentially dilutive shares would result in anti- dilution due to the net loss incurred by the Company Recent Accounting Pronouncements The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. NOTE 3 - GOING CONCERN The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has accumulated deficit of $(4,760,125) at March 31, 2024. The continuation of the Company as a going concern through March 31, 2024, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due. The Company requires capital for its contemplated operational activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

![](ex102-027.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOTE 4 ? INCOME TAXES Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The U.S. federal income tax rate of 21% is being used. Net deferred tax assets consist of the following components as of: March 31, 2025 December 31, 2024 Federal income tax benefit attributable to: Current Operations $? $- Less: valuation allowance ? - Net provision for Federal income taxes $? $? The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from continuing operations for the fiscal years ending, due to the following: March 31, 2025 December 31, 2024 Deferred tax asset attributable to: Net operating loss carryover $? $? Less: valuation allowance ? ? Net deferred tax asset $? $? At March 31, 2025, the Company had net operating loss carry forwards of approximately $(4,735,861) that may be offset against future taxable income from the year 2022 to 2040. No tax benefit has been reported in the March 31 2025, financial statements since the potential tax benefit is offset by a valuation allowance of the same amount. Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for Federal Income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2015. NOTE 5 ? SUBSEQUENT EVENTS In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has identified the following events to disclose in these financial statements.

## Exhibit 10.3

**Exhibit 10.3**

![](ex103-001.jpg)

CS Diagnostics Corp.Amendment to Annual Report CSDX 2024 Annual Financial Report for 12/31/2024 originally published through the OTC Disclosure & News Ser-vice on 03/31/2025Explanatory Note:This is an amended annual report which includes the new PCAOB audit for the year ending 12/31/2024 by our newly engaged PCAOB auditors with Consent.\*\*This coversheet was automatically generated by OTC Markets Group based on the information provided by the Company. OTC Markets Group has not reviewed the contents of this amendment and disclaims all responsibility for the information contained herein.

![](ex103-002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP. CSDX ANNUAL REPORT AND FINANCIALS FOR THE PERIOD ENDING December 31, 2024

![](ex103-003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosure Statement Pursuant to the OTCQB Basic Disclosure Guidelines CS DIAGNOSTICS CORP, A Wyoming Corporation, Stresemannallee 4b Neuss, Germany 41460 Telephone +49 (0)2131-151 08 71 http://www.csdcorp.us info@csdcorp.us SIC CODE: 2834 ANNUAL REPORT For the Period Ending December 31, 2024 Outstanding Shares The number of shares outstanding of our Common Stock was: 137,290,200 as of December 31, 2024 110,790,200 as of December 31, 2023

![](ex103-004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shell Status Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934): Yes: ? No: ? Indicate by check mark whether the company's shell status has changed since the previous reporting period: Yes: ? No: ? Change in Control Indicate by check mark whether a Change in Control1 of the company has occurred over this reporting period: Yes: ? No: ? 1) Name and address(es) of the issuer and its predecessors (if any) In answering this item, provide the current name of the Issuer any names used by predecessor entities, along with the dates of the name changes. The exact name of the issuer is CS Diagnostics Corp. On September 25, 1996, the issuer was incorporated in the State of Nevada as D.W.C. Installations, Inc.. On December 27, 2002, the issuer name was changed to Children's Internet, Inc.. On February 18, 2015, the issuer name was changed to FlashZero Corp. On May 31, 2022, the issuer name was changed to CS Diagnostics Corp.. On August 1, 2023, FINRA authorized the Corporation Action and the Articles were amended to change the name, CS Diagnostics Corp. Current State and Date of Incorporation or Registration: On October 15, 2010 the issuer was re- domiciled in the State of Wyoming. The issuer is in Good Standing in its domicile, Wyoming, and is designated status Active Business License. Standing in this jurisdiction: Active in Good Standing Prior Incorporation Information for the issuer and any predecessors during the past five years: NONE. Describe any trading suspension orders issued by the SEC concerning the Issuer or its predecessors since inception: NONE.

![](ex103-005.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: On August 1, 2023, FINRA Notified the Issuer and its Transfer Agent that is has received the necessary documentation to process the below listed corporate action requested by FlashZero Corp (FZRO) and Transfer Online pursuant to FINRA Rule 6490. This Corporate Action included: ? 1 for 100,000 reverse split followed by a 200 for 1 forward split ? Name Change to: CS Diagnostics Corp. ? New CUSIP 33852L202 . On September 4, 2023, CS Diagnostics Group finalized the agreement whereas CS Diagnostics Group sold and transferred the tangible, intangible and patents for the CS Protect-Hydrogel, a hydrogel-based tissue spacer used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation to CS Diagnostics Corp. The CS Diagnostics Group have obtained a valuation for the CS Protect-Hydrogel in amount greater that 960,000,000 Euro based on its discounted present commercial value. The valuation is supported, as contained in the final valuation by the 2018 purchase of the similar product by Boston Scientific for $500,000,000 USD and further compensation based on the distribution revenues. CS Diagnostics Corp., based on this valuation, on September 27, 2023, the transfer agent, Transfer Online, issued 110,000,000 shares of the Issuer common stock to represent a payment of $500,000,000 USD for the rights, patents and intellectual property of the CS Protect-Hydrogel product to the CS Diagnostics Group, its successor or assigns. On July 29th 2024, FINRA processed a Form 211 relating to the initiation of priced quotations of CSDX, which means that the submitting broker-dealer has demonstrated to FINRA compliance with FINRA Rule 6432 and therefore has met the requirements under that rule to initiate a quotation for CSDX within four days of 07/29/2024. FINRA's processing of a Form 211 in no way constitutes FINRA's approval of the security, the issuer, or the issuer's business and relates solely to the submitting broker-dealer's obligation to comply with FINRA Rule 6432 and SEA Rule 15c2-11 when quoting a security. On August 9th 2024, a shareholder resolution has been issued for changes in CSDX board of directors as follows: Mr. Thomas Migotsch and Mr. Thomas Graus as well as the previous independent directors Mrs. Csilla Kanderka and Mrs. Delia-Alexandra Kreutner were replaced by Mr. Mohammad EsSayed is VP, Director and CFO, Mr. Thomas Migotsch remains a director and assigned as COO, Dr. Lauren Ugur and Mr. Mahmoud Ahmad Hashim AL-Sayed take on their role as independent directors, and Ms. Janel Luzana as an Officer and Company Secretary. It was agreed that Mr. Thomas Graus will receive compensation as Mr. Thomas Graus of $72,000 during 2025. The address(es) of the Issuer's principal place of business: Check box if principal executive office and principal place of business are the same address: ? Stresemann allée 4b Neuss 41460 Germany +49 (0)2131-151 08 71 Has the Issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years? Yes: ? No: ?

![](ex103-006.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below: NONE 1) Security Information Transfer Agent Name: Transfer Online, Inc. Phone: +1-503-227-2950 Email: info@transferonline.com Address: 512 SE Salmon St. Portland, OR 97214 Publicly Quoted or Traded Securities: Trading symbol: CSDX Exact title and class of securities outstanding: Common CUSIP: 33852L103 Par or stated value: 0.00001 FEIN 20-1290331 Total shares authorized 250,000,000 as of date December 31, 2024 Total Common shares outstanding: 137,290,200 as of date December 31, 2024 Number of shares in the Public Float2: 505,800 as of date December 31, 2024 Total number of shareholders of record: 312 as of date December 31, 2024 CUSIP NUMBER 33852L202 All additional class(es) of publicly traded securities (if any): N/A

![](ex103-007.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other classes of authorized or outstanding equity securities: The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities. Exact title and class of the security: Preferred Series A CUSIP (if applicable): N/A Par or stated value: $0.00001 Total shares authorized: 5,000,000 as of date December 31, 2024 Total shares outstanding (if applicable): 10 as of date December 31, 2024 Total number of shareholders of record 1 as of date December 31, 2024 Exact title and class of the security: Preferred Series B CUSIP (if applicable): N/A Par or stated value: $0.00001 Total shares authorized: 20,000,000 as of date December 31, 2024 Total shares outstanding (if applicable): 19,998,675 as of date December 31, 2024 Total number of shareholders of record 19 as of date December 31, 2024 2 "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons. Security Description: The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable: 1- For common equity, describe any dividend, voting and preemption rights. Currently there are no dividends. Dividends are subject to the Board of Directors discretion and approval. There are no preemption rights for Common Equity Shareholders. 2- For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions. Preferred Series A Currently there are no dividends. Dividends are subject to the Board of Directors discretion and approval.

![](ex103-008.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Series A Preferred Stock has voting rights equal to four times the sum of: a) the total number of shares of Common Stock which are issued and outstanding at the time of voting, plus b) the total number of shares of any other series of preferred stock which are issued and outstanding at the time of voting. The holders of the Series A Preferred Stock shall no rights with respect to the conversion of the Series A Preferred Stock into an equivalent number of shares of Common Stock (the "Conversion Rights"), where the Series A Preferred Stock is defined as "Super Voting Stock". The Liquidation Rights are: Series A Preferred Stock shall be entitled to be paid out of the assets of the Corporation an amount (the "Liquidation Preference") equal to the product of (i) the original amount paid by the holder thereof (the "Original Issue Price") for each share of Series A Preferred Stock owned by such holder as of the effective date of such liquidation (the "Liquidation Date"), multiplied by (ii) the number of shares of Series A Preferred Stock owned of record by such holder as of the Liquidation Date. (as adjusted for any combinations, splits, recapitalization and the like with respect to such shares in the manner set forth herein). It does not have any sinking fund provisions. Preferred Series B Currently there are no dividends. Dividends are subject to the Board of Directors discretion and approval. The Series B Preferred Stock has same 1 vote for 1 shares as with the Common Share shareholders. The Series B Preferred Stock has conversion of 20,000 shares of common stock for each share of Preferred Series B stock with a maximum conversion of up to 9.9% of the total outstanding common stock. It does not have any sinking fund provisions. The liquidation rights are Upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, before any distribution or payment shall be made to the holders of any stock ranking junir to the Preferred B Stock, the holders of the Preferred B Stock shall be entitled to be paid out of the assets of the Corporation an amount equal to $1.00 per share or, in the event of an aggregate subscription by any single subscriber for Preferred B Stock in excess of $100,000, $.997 per shares, (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares)(the "Preference Value"), plus all declared but unpaid dividends, for each share of Preferred B Stock held by them. After the payment of the full applicable Preference Value of each share of the Preferred B Stock as set forth herein, the remaining assets of the Corporation legally available for distribution, if any, shall be distributed ratably to the holders of the Corporation's Common Stock. 3- Describe any other material rights of common or preferred stockholders. None

![](ex103-009.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4- Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report. On March 24, 2023, the issuer and the majority shareholder, holding 100% of the Series A and in excess of 90% of Preferred Series B and 110,000,000 shares of common stock, approved and ratified An Amendment and Restatement of the Certificate of Designation of the Preferred Series A and Preferred Series B and the By-Laws of the Issuer in order to clarity the previous amendments to the Certificate of Designations and Amendments to the Articles of Incorporation. These Amendments and Restatement of the Certificate of Designations were filed with the Secretary of State of Wyoming. 3- Issuance History The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period. Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events. A. Changes to the Number of Outstanding Shares Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: No: ? Yes: X (If yes, you must complete the table below)

![](ex103-010.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Outstanding as of Second Most Recent Fiscal Year End: Opening Balance Date January 1, 2023 Common: 135,287,214 Preferred A 10 Preferred B 9,989,000 \*Right-click the rows below and select "Insert" to add rows as needed. Date of Transaction Number of Class of Value of Were the Individual/ Reason for Restricted Exemption Transaction type (e.g. Shares Securities shares shares Entity Shares share issuance or or new Issued (or issued issued at were issued (e.g. for cash Unrestricted Registration issuance, cancelled) ($/per a to (entities or debt as of this Type. cancellation, share) discount must have conversion) filing. shares at to individual -OR- returned to Issuance market with voting / Nature of treasury) price at investment Services the time control Provided of disclosed). issuance? (Yes/No) 05-09-2022 Issuance 10,011,000 Preferred Series B 1,000 No PatientTrac Limited (See Note 1) Pursuant to the Securities Purchase Agreement for services rendered, e.g. acquisition costs, payments and organization reinstatements Restricted 4(a)(2) 08-01-2023 Corporate Action - 134,497,014 Common .00001 No Corporate Action all Same Restricted and 4(a)(2) Reverse shareholders Unrestricted split 1 to 100,000 and Forward Split 1 to 200

![](ex103-011.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;09/27/2023 Issuance 65,000,000 Common $4.54 No CS Diagnostics Pharma GmbH Note 2: Asset Purchase Agreement Restricted 4(a)(2) 09/27/2023 Issuance 20,000,000 Common $4.54 No CS Interpharm LLC Note 2: Asset Purchase Agreement Restricted 4(a)(2) Shares Outstanding on Date of This Report: Ending Balance Date December 31, 2024 Common: 137,290,200 Preferred A 10 Preferred B 19,998,675 Note 1: PatientTrac Limited is a United Kingdom company whose beneficial owner is H Wayne Hayes, Jr. of Bogota, Colombia and held these shares in trust. PatientTrac, pursuant to the Securities Purchase Agreement dated 30 March 2022 with CS Diagnostics Pharma GmbH, has agreed and on July 9, 2022 transferred the 10,011,000 to CS Diagnostics Pharma GmbH designees. Note 2: The Beneficial Owner Thomas Fahrhoefer, Dubai, UAE B. Promissory and Convertible Notes Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities. Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ? N/A Note: During the FINRA corporate action request, supra, On May 3, 2023, the Issuer Board of Directors and its Majority Shareholder pursuant to Wyoming Revised Statutes cancelled the remaining balance of the July 10, 2009 Promissory Note by and between the Issuer on David Lampel. A legal opinion has been issued and provided to the Issuer's PCAOB Auditors and the contingent liability, Promissory Note balance and interest, has been removed from the Issuer's financial statements.

![](ex103-012.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4- Issuer's Business, Products and Services The purpose of this section is to provide a clear description of the issuer's current operations. A. Summarize the Issuer's business operations (If the Issuer does not have current operations, state "no operations") The publicly traded company CS Diagnostics Corp. is the sole owner of the property CS Protect- Hydrogel. CS Protect-Hydrogel, a hydrogel-based tissue spacer used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation to CS Diagnostics Corp. The Issuer and its parent company, CS Diagnostics Pharma GmbH, and its affiliated company, CS Interpharm GT LLC, are actively engaged in proven operations in the Medical and Biotech industry. B. List any subsidiaries, parent company, or affiliated companies. Parent Company CS Diagnostics Pharma GmbH, Stresemannallee 4b Neuss, 41460 Germany Affiliated Company CS Interpharm General Trading LLC, 809-816 Bay Squair, Business Bay, Dubai, United Arab Emirates. C. Describe the Issuers' principal products or services. CS Diagnostics Group is a pharmaceutical international wholesaler and manufacturer of medical technology. For more than 10 years its current management has been supplying national and international specialists, practices, clinics as well as ministries of health. In addition, we offer international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, we develop our own products with the aim of maximizing patient benefit.

![](ex103-013.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5- Issuer's Facilities The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the Issuer and the extent in which the facilities are utilized. In responding to this item, please clearly describe the assets, properties or facilities of the Issuer, give the location of the principal plants and other property of the Issuer and describe the condition of the properties. If the Issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership. Headquarters: City of Neuss in Germany: City of Bruckmühl in Germany Dubai, United Arab Emirates Name of Officer/Director or Control Person Affiliation with Company (e.g. Officer/Director/Owner of more than 5%) Residential Address (City / State Only) Number of shares owned Share type/class Ownership Percentage of Class Outstanding Note Thomas Fahrhoefer President Dubai, United Arab Emirates 93,881,896 10 13,655,206 Common Preferred A Preferred B % 100% 68% Beneficial Ownership (No shares in personal name) Thomas J Migotsch Chief Operational Officer Rapperswil-Jona, Switzerland 480.000 N/A .004% Mohammad EsSayed Chief Financial Officer Dubai, UAE 0 N/A N/A Janel Luzana Company Secretary Dubai, UAE 0 N/A N/A CS Diagnostics Pharma GmbH More than 5% Neuss, Germany 74,855,800 10 7,924,180 Common Preferred A Preferred B 54.5% 100% 39.6% Thomas Fahrhoefer, Dubai, UAE CS Interpharm General Trading Co. LLC More than 5% Dubai, United Arab Emirates 19,026,096 5,731,026 Common Preferred B 13.8% 26.6% Thomas Fahrhoefer, Dubai, UAE Association Continental de Reassurance NV More than 5% Antwerpen Belgium 3,500,000 1,499,625 Common Preferred B 2.5% 7.5% Adriaan Vangelabbeek Antwerpen, Belgium Thomas Graus More than 5% Viganello Switzerland 3,700,000 1,273,737 Common Preferred B 2.7% 6.4% Thomas Graus Viganello, Switzerland Antonio Santoli More than 5% Breganzona Switzerland 3,800,000 1,273,737 Common Preferred B 2.7% 6.4% Antonio Santoli Breganzona, Switzerland

![](ex103-014.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6- Legal/Disciplinary History A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years: 1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations); NO 2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities; NO 3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated; NO 4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or NO 5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities. NO

![](ex103-015.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail. NO B. Describe briefly any material pending legal proceedings, other than ordinary B- routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities. NONE 7- Third Party Providers Please provide the name, address, telephone number and email address of each of the following outside providers: Securities Counsel Investor Relations/Marketing/Communications Mavacy, PLLC ROSEWOOD REPUTATION LIMITED 15169 N. Scottsdale Rd., 80 Coleman Street, ENG W1U 7LP Suite 205, London, United Kingdom Scottsdale, AZ 85254 Accounting/Auditing Firm LAO Professionals Suite 33, Hill Top Plaza, 13 Gwani Street, Zone 4, Wuse Abuja 00234, Nigeria

![](ex103-016.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provide the name of any other service provider(s) that that assisted, advised, prepared or provided information with respect to this disclosure statement. This includes counsel, advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period. NONE 8- Disclosure & Financial Information A. This Disclosure Statement was prepared by(name of individual): Name: Mohammad EsSayed Title: Chief Financial Officer Relationship to Issuer: VP, Director B. The following financial statements were prepared in accordance with: ? U.S. GAAP ? IFRS C. The financial statements for this reporting period were prepared by (name of individual)3: Name: Mohammad EsSayed Title: CFO Relationship to Issuer: VP, Director Describe the qualifications of the person or persons who prepared the financial statements: Accounting firm preparing financial reporting and certified US Tax. 3 The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

![](ex103-017.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9- Issuer Certification Principal Executive Officer: The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities). The certifications shall follow the format below: I, Thomas Fahrhoefer, certify that: 1. I have reviewed this Annual Report and Disclosure Statement for Period Ending December 31, 2024 of CS Diagnostic Corp. 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement. December 31, 2024 /s/ Thomas Fahrhoefer

![](ex103-018.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Principal Financial Officer: I, Mohammad EsSayed, certify that: 1. I have reviewed this Annual Report and Disclosure Statement for Period Ending December 31, 2024 of CS Diagnostic Corp. 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement. December 31, 2024 /s/ Mohammad EsSayed

![](ex103-019.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP FINANCIAL STATEMENTS FOR PERIOD ENDING December 31, 2024 BALANCE SHEET STATEMENT STATEMENT CASH FLOWS INCOME STATEMENT STATEMENT OF CHANGES IN SHAREHOLDERS EQUITY FINANCIAL NOTES

![](ex103-020.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP. CSDX INDEX TO FINANCIAL STATEMENTS Balance Sheets as of December 31, 2024, and December 31, 2023 Statements of Operations for the twelve months period ended December 31, 2024, and December 31, 2023 Statements of Stockholders' Equity for twelve months period ended December 31, 2024, and December 31, 2023 Statements of Cash Flows for the twelve months period ended December 31, 2024, and December 31, 2023 Notes to the Financial Statements

![](ex103-021.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of CS Diagnostic Corp Opinion on the Financial Statements We have audited the accompanying balance sheets of CS Diagnostic Corp. (the ?Company') as of December 31, 2024, and the related statements of operations, changes in stockholders' equity and cash flows for the year ended December 31, 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3, the Company suffered an accumulated deficit of $(4,767,928). These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's plans with regards to these matters are also described in Note 3 to the financial statements. These financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matters Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. Communication of critical audit matters does not alter in any way our opinion on the financial statements taken as a whole and we are not, by communicating the critical audit matters, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate. /S/ Lateef Awojobi LAO PROFESSIONALS (PCAOB ID 7057) Lagos, Nigeria We have served as the Company's auditor since 2025. April 14, 2025

![](ex103-022.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP. CSDX BALANCE SHEET FOR THE PERIOD ENDED December 31 2024 December 31, 2024 December 31, 2023 Audited Audited Assets Current Assets Cash 501 20,363 Other Receivables - - Total Current Assets $501 $20,363 Intangible Assets 499,400,000 499,400,000 Total Assets $499,400,501 $499,420,363 Liabilities and Stockholders' Deficit Current Liabilities Account Payables 1,428 12,822 Non-current liabilities - Total Liabilities $1,428 $12,822 Shareholder's Deficit Common stock, $0.00001 par value; 250,000,000 shares authorized,137,290,200 shares issued and outstanding as of December 31, 2024 1,373 1,108 Preferred stock Series A, $0.001 par value;5,000 shares authorized, 10 shares issued and outstanding as of December 31, 2024 - - Preferred stock Series B, $0.001 par value; 19,998,675 shares authorized, 19,999,375 shares issued and outstanding as of December 31, 2024, 2,000 2,000 Additional paid-in capital 504,163,629 504,173,122 Accumulated deficit -4,767,928 -4,768,689 Total Stockholders' Deficit $499,399,073 $499,407,541 Total Liabilities and Stockholders' Deficit $499,400,501 $499,420,363 The accompanying notes are an integral part of these financial statements.

![](ex103-023.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP. STATEMENT OF OPERATIONS FOR THE PERIOD ENDED December 31, 2024 December 31, 2024 December 31, 2023 Revenue 110,911 126,038 Revenue $110,910.60 $126,038.00 Operating Expenses Professional Fee 109,755 54,026 General & Administrative Expenses 395 94,009 Total Operating expenses 110,150 148,035 Income/(loss) from Operations $761 $-21,997 Other Income / (Expense) - - Debt Written off - - Net Income / (loss) $761 $-21,997 Basic and diluted loss per share 0.00 0.00 basic and diluted loss weighted average shares 137,290,200 110,790,200 The accompanying notes are an integral part of these financial statements.

![](ex103-024.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP. STATEMENT OF STOCKHOLDERS (DEFICIT) FOR THE PERIOD ENDED December 31, 2024 Preferred Stock B Common Stock Additional Accumulated Shares Amount Shares Amount Paid-in Capital Deficit Total Balance, January 1, 2023 20,000,000 $2,000 135,287,214 $1,352 $4,712,037 -$4,746,692 -$31,303 Reversed Stock Split - - -134,497,014 -$1,344 - - -$1,344 Shares Issued in acquisition of Assets - - 110,000,000 $1,100 $499,461,085 - $499,462,185 Net income (loss) for the year - - - - - -$21,997 -$21,997 Balance, December 31, 2023 20,000,000 $2,000 110,790,200 $1,108 $504,173,122 -$4,768,689 $499,407,541 Balance, January 1, 2024 20,000,000 $2,000 110,790,200 $1,018 $504,173,122 -$4,798,689 $499,407,451 Shares Issued/Converted -1,325 $0 26,500,000 $355 $-9,493 $-9,138 Net income (loss) for the period ended September 30, 2024 $761 $761 Shares Issued in acquisition of Assets Balance, December 31, 2024 19,998,675 $2,000 137,290,200 $1,373 $504,163,629 -4,767,928 $499,339,073 The accompanying notes are an integral part of these financial statements.

![](ex103-025.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS DIAGNOSTICS CORP. STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED December 31, 2024 December 31, 2024 December 31, 2023 Cash flows from operating activities Net profit/ (loss) 761 -21,997 Adjustment to reconcile net loss to net cash used in operating activities Changes in assets and liabilities Other Receivables 8,842 - Account payables 1,428 31,285 Net cash used in operating activities $11,030 $9,288 Cash flows from investing activities Intangible Asset -499,444,401 -499,444,401 Net cash provided by Investing activities -$499,444,401 -$499,444,401 Cash flows from financing activities Additional Capital Paid Up 499,444,401 499,422,309 Loan forgiven - - Net cash provided by financing activities $499,444,401.00 $499,422,309.00 Net increase /(decrease) in cash 11,030 -12,804 Cash beginning of period 0 12,804 Cash end of period $11,030 $0 The accompanying notes are an integral part of these financial statements.

![](ex103-026.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C S DIAGNOSTICS CORP Notes to the Financial Statements December 31, 2024, and December 31, 2023 NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS CS Diagnostics Corp., (the "Company") a Wyoming Corporation in the United State, CS Diagnostics Corp., is an United States based Corporation, Its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit. We work hand in hand with universities, experts and experienced users as well as with our users, as well as with our own R&D team, in order to always offer the most innovative products in medical technology. On August 1, 2023, FINRA authorized the Corporate Action approved by the Board of Directors and majority shareholder for and amendment to the Articles of Incorporation from FlashZero Corp to CS Diagnostics Corp and a 1 for 100,000 reverse split followed by a 200 for 1 forward split and a change of the CUSIP to 33852L202. Pre-split shares: 135,287,214: Post Split share 790,200. On September 4, 2023, CS Diagnostics Corp purchased 100% of the tangible product CS Protect-Hydrogel, its intellectual property, distribution rights and patents from the CS Diagnostics Group, headquartered in Germany. The CS ProtectHydrogel is a hydrogel-based tissue spacer. It is used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation. Currently, hydrogel spacers are used exclusively in the treatment of prostate cancer. Here, the spacer pushes the rectum away from the prostate, thus reducing rectal damage from radiation therapy. The hydrogel spacer is injected once in liquid form through a thin needle into the space between cancer cells and healthy tissue and is broken down by the body after about six months. The CS Protect-Hydrogel is a "ready-to-use" product, which is sterile packed and can be applied directly. The hydrogel can be used in radiotherapy for prostate, cervical, esophageal, bladder and breast cancer. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates.

![](ex103-027.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company's cash is deposited with major financial institutions. At times, such deposits may be in excess of the Federal Deposit Insurance Corporation insurable amount. Cash and Cash Equivalents The Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less as cash and cash equivalents. The carrying amount of financial instruments included in cash and cash equivalents approximates fair value because of the short maturities for the instruments held. There were no cash equivalents for the period ended March 31, 2024, and 2023 Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC Topic No. 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels, as described below: Level 1: Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. Level 2 inputs include quoted prices for similar assets, quoted prices in markets that are not considered to be active, and observable inputs other than quoted prices such as interest rates. Level 3: Level 3 inputs are unobservable inputs. The following required disclosure of the estimated fair value of financial instruments has been determined by the Company using available market information and appropriate valuation methodologies. However, considerable judgment is required to interpret market data to develop the estimates of fair value. Accordingly, the use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. The methods and assumptions used to estimate the fair values of each class of financial instruments are as follows: Accounts Receivable, and Accounts Payable. The items are generally short-term in nature, and accordingly, the carrying amounts reported on the consolidated balance sheets are reasonable approximations of their fair values. The carrying amounts of Notes Payable approximate the fair value as the notes bear interest rates that are consistent with current market rates. Income Taxes We follow ASC 740-10-30, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income in the period that includes the enactment date.

![](ex103-028.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We adopted ASC 740-10-25 ("ASC 740-10-25") with regard to uncertainty income taxes. ASC 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10-25, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740-10-25 also provides guidance on derecognition, classification, interest and penalties on income taxes, and accounting in interim periods and requires increased disclosures. We had no material adjustments to our liabilities for unrecognized income tax benefits according to the provisions of ASC 740-10-25. Net income (loss) per common share Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented. For the period ended March 31, 2024 and 2023, the diluted loss per share is the same as the basic loss per shares as the inclusion of any potentially dilutive shares would result in anti- dilution due to the net loss incurred by the Company Recent Accounting Pronouncements The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. NOTE 3 - GOING CONCERN The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has accumulated deficit of $(4,767,928) at March 31, 2024. The continuation of the Company as a going concern through March 31, 2024, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due. The Company requires capital for its contemplated operational activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties. NOTE 4 ? INCOME TAXES Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The U.S. federal income tax rate of 21% is being used.

![](ex103-029.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net deferred tax assets consist of the following components as of: December 31, 2024 December 31, 2023 Federal income tax benefit attributable to: Current Operations $? $- Less: valuation allowance ? - Net provision for Federal income taxes $? $? The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from continuing operations for the fiscal years ending, due to the following: December 31, 2024 December 31, 2023 Deferred tax asset attributable to: Net operating loss carryover $? $? Less: valuation allowance ? ? Net deferred tax asset $? $? At September 30, 2024, the Company had net operating loss carry forwards of approximately $(4,759,589) that may be offset against future taxable income from the year 2022 to 2040. No tax benefit has been reported in the June 30, 2024, financial statements since the potential tax benefit is offset by a valuation allowance of the same amount. Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for Federal Income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2015. NOTE 5 ? SUBSEQUENT EVENTS In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has identified the following events to disclose in these financial statements.

## Exhibit 10.4

**Exhibit 10.4**

![](ex104-001.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 1 of 17 CS DIAGNOSTICS CORP ANNUAL REPORT AND FINANCIALS FOR THE PERIOD ENDING DECEMBER 31, 2023

![](ex104-002.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 2 of 17 Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines CS DIAGNOSTICS CORP, A Wyoming Corporation Stresemannallee 4c Neuss, Germany 41460 Telephone +49 (0)2131-151 08 http://www.cs-diaqnostics.de service@cs-diagnostics.de SIC CODE: 2834 ANNUAL REPORT For the Period Ending: December 31, 2023 Outstanding Shares The number of shares outstanding of our Common Stock was: 110,790,200 as of December 31, 2023 135,287,214 as of December 31, 2022

![](ex104-003.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 3 of 17 Shell Status Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934): Yes: ? No: ? Indicate by check mark whether the company's shell status has changed since the previous reporting period: Yes: ? No: ? Change in Control Indicate by check mark whether a Change in Control1 of the company has occurred over this reporting period: Yes: ? No: ? 1) Name and address(es) of the issuer and its predecessors (if any) In answering this item, provide the current name of the Issuer any names used by predecessor entities, along with the dates of the name changes. The exact name of the issuer is CS Diagnostics Corp. On September 25, 1996, the issuer was incorporated in the State of Nevada as D.W.C. Installations, Inc.. On December 27, 2002, the issuer name was changed to Children's Internet, Inc.. On February 18, 2015, the issuer name was changed to FlashZero Corp. On May 31, 2022, the issuer name was changed to CS Diagnostics Corp.. On August 1, 2023, FINRA authorized the Corporation Action and the Articles were amended to change the name, CS Diagnostics Corp. Current State and Date of Incorporation or Registration: On October 15, 2010 the issuer was re-domiciled in the State of Wyoming. The issuer is in Good Standing in its domicile, Wyoming, and is designated status Active Business License. Standing in this jurisdiction: Active in Good Standing Prior Incorporation Information for the issuer and any predecessors during the past five years: None Describe any trading suspension orders issued by the SEC concerning the Issuer or its predecessors since inception:

![](ex104-004.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 4 of 17 NONE List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: On August 1, 2023, FINRA Notified the Issuer and its Transfer Agent that is has received the necessary documentation to process the below listed corporate action requested by FlashZero Corp (FZRO) and Transfer Online pursuant to FINRA Rule 6490. This Corporate Action included ? 1 for 100,000 reverse split followed by a 200 for 1 forward split ? Name Change to: CS Diagnostics Corp. ? New CUSIP 33852L202 . On September 4, 2023, CS Diagnostics Group finalized the agreement whereas CS Diagnostics Group sold and transferred the tangible, intangible and patents for the CS Protect-Hydrogel, a hydrogel-based tissue spacer used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation, to CS Diagnostics Corp. The CS Diagnostics Group have obtained a valuation for the CS Protect-Hydrogel in amount greater that 960,000,000 Euro based on its discounted present commercial value. The valuation is supported, as contained in the final valuation by the 2018 purchase of the similar product by Boston Scientific for $500,000,000 USD and further compensation based on the distribution revenues. CS Diagnostics Corp., based on this valuation, on September 27, 2023, the transfer agent, Transfer Online, issued 110,000,000 shares of the Issuer common stock to represent a payment of $500,000,000 USD for the rights, patents and intellectual property of the CS Protect-Hydrogel product to the CS Diagnostics Group, its successor or assigns. The address(es) of the Issuer's principal place of business: Check box if principal executive office and principal place of business are the same address: ? Stresemannallee 4c Neuss 41460 Germany +49 (0)2131-151 08 Has the Issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years? Yes: ? No: ? If this Issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below: N.A NONE 2) Security Information Transfer Agent Name: Transfer Online, Inc. Phone: 503-227-2950 Email: info@transferonline.com Address: 512 SE Salmon St. Portland, OR 97214

![](ex104-005.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 5 of 17 Publicly Quoted or Traded Securities:?? Trading symbol: FZRO Exact title and class of securities outstanding: Common CUSIP: 33852L103 Par or stated value: 0.00001 FEIN 20-1290331 Total shares authorized 250,000,000 as of date December 31, 2023 Total Common shares outstanding: 110,790,200 as of date December 31, 2023 Number of shares in the Public Float2: 505,800 as of date December 31, 2023 Total number of shareholders of record: 293 as of date December 31, 2023 CUSIP NUMBER 33852L202 All additional class(es) of publicly traded securities (if any): N/A Other classes of authorized or outstanding equity securities:? The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.? Exact title and class of the security: Preferred Series A ? CUSIP (if applicable): N/A Par or stated value: $0.00001 Total shares authorized: 5,000,000 as of date December 31, 2023? Total shares outstanding (if applicable): 10 as of date December 31, 2023? Total number of shareholders of record 1 as of date December 31, 2023? Exact title and class of the security: Preferred Series B ? CUSIP (if applicable): N/A Par or stated value: $0.00001 Total shares authorized: 20,000,000 as of date December 31, 2023? Total shares outstanding (if applicable): 20,000,000 as of date December 31, 2023? Total number of shareholders of record 13 as of date December 31, 2023? Security Description: 2 "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

![](ex104-006.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 6 of 17 The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:? 1. For common equity, describe any dividend, voting and preemption rights.? Currently there are no dividends. Dividends are subject to the Board of Directors discretion and approval. There are no preemption rights for Common Equity Shareholders. 2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights?as well as redemption or sinking fund provisions.? Preferred Series A Currently there are no dividends. Dividends are subject to the Board of Directors discretion and approval. The Series A Preferred Stock has voting rights equal to four times the sum of: a) the total number of shares of Common Stock which are issued and outstanding at the time of voting, plus b) the total number of shares of any other series of preferred stock which are issued and outstanding at the time of voting. The holders of the Series A Preferred Stock shall no rights with respect to the conversion of the Series A Preferred Stock into an equivalent number of shares of Common Stock (the "Conversion Rights"), where the Series A Preferred Stock is defined as "Super Voting Stock". The Liquidation Rights are: Series A Preferred Stock shall be entitled to be paid out of the assets of the Corporation an amount (the "Liquidation Preference") equal to the product of (i) the original amount paid by the holder thereof (the "Original Issue Price") for each share of Series A Preferred Stock owned by such holder as of the effective date of such liquidation (the "Liquidation Date"), multiplied by (ii) the number of shares of Series A Preferred Stock owned of record by such holder as of the Liquidation Date. (as adjusted for any combinations, splits, recapitalization and the like with respect to such shares in the manner set forth herein). It does not have any sinking fund provisions. Preferred Series B Currently there are no dividends. Dividends are subject to the Board of Directors discretion and approval. The Series B Preferred Stock has same 1 vote for 1 shares as with the Common Share shareholders. The Series B Preferred Stock has conversion of 20,000 shares of common stock for each share of Preferred Series B stock with a maximum conversion of up to 9.9% of the total outstanding common stock. It does not have any sinking fund provisions. The liquidation rights are Upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, before any distribution or payment shall be made to the holders of any stock ranking junir to the Preferred B Stock, the holders of the Preferred B Stock shall be entitled to be paid out of the assets of the Corporation an amount equal to $1.00 per share or, in the event of an aggregate subscription by any single subscriber for Preferred B Stock in excess of $100,000, $.997 per shares, (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares)(the "Preference Value"), plus all declared but unpaid dividends, for each share of Preferred B Stock held by them. After the payment of the full applicable Preference Value of each share of the Preferred B Stock as set forth herein, the remaining assets of the Corporation legally available for distribution, if any, shall be distributed ratably to the holders of the Corporation's Common Stock.

![](ex104-007.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 7 of 17 3. Describe any other material rights of common or preferred stockholders.? None 4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.? On March 24, 2023, the issuer and the majority shareholder, holding 100% of the Series A and in excess of 90% of Preferred Series B and 110,000,000 shares of common stock, approved and ratified An Amendment and Restatement of the Certificate of Designation of the Preferred Series A and Preferred Series B and the By-Laws of the Issuer in order to clarity the previous amendments to the Certificate of Designations and Amendments to the Articles of Incorporation. These Amendments and Restatement of the Certificate of Designations were filed with the Secretary of State of Wyoming. On 3) Issuance History The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period. Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events. A. Changes to the Number of Outstanding Shares Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: No: ? Yes: X (If yes, you must complete the table below)

![](ex104-008.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 8 of 17 Shares Outstanding as of Second Most Recent Fiscal Year End: Opening Balance Date January 1, 2021 Common: 135,287,214 Preferred A 10 Preferred B 9,989,000 \*Right-click the rows below and select "Insert" to add rows as needed. Date of Transaction Transaction type (e.g. new issuance, cancellation, shares returned to treasury) Number of Shares Issued (or cancelled) Class of Securities Value of shares issued ($/per share) at Issuance Were the shares issued at a discount to market price at the time of issuance? (Yes/No) Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed). Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided Restricted or Unrestricted as of this filing. Exemption or Registration Type. 05-09-2022 Issuance 10,011,000 Preferred Series B 1,000 No PatientTrac Limited (See Note 1) Pursuant to the Securities Purchase Agreement for services rendered, e.g. acquisition costs, payments and organization reinstatements Restricted 4(a)(2) 08-01-2023 Corporate Action Reverse split 1 to 100,000 and Forward Split 1 to 200 -134,497,014 Common .00001 No Corporate Action all shareholders Same Restricted and Unrestricted 4(a)(2) 09/27/2023 Issuance 65,000,000 Common $4.54 No CS Diagnostics Pharma GmbH Note 2: Asset Purchase Agreement Restricted 4(a)(2) 09/27/2023 Issuance 20,000,000 Common $4.54 No CS Interpharm LLC Note 2: Asset Purchase Agreement Restricted 4(a)(2)

![](ex104-009.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 9 of 17 Note 1. PatientTrac Limited is a United Kingdom company whose beneficial owner is H Wayne Hayes, Jr. of Bogota, Colombia and held these shares in trust. PatientTrac, pursuant to the Securities Purchase Agreement dated 30 March 2022 with CS Diagnostics Pharma GmbH, has agreed and on July 9, 2022 transferred the 10,011,000 to CS Diagnostics Pharma GmbH designees. Note 2: The Beneficial Owner Thomas Fahrhoefer, Dubai, UAE B. Promissory and Convertible Notes Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities. Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ? N/A Note: During the FINRA corporate action request, supra, On May 3, 2023, the Issuer Board of Directors and its Majority Shareholder pursuant to Wyoming Revised Statutes cancelled the remaining balance of the July 10, 2009 Promissory Note by and between the Issuer on David Lampel. A legal opinion has been issued and provided to the Issuer's PCAOB Auditors and the contingent liability, Promissory Note balance and interest, has been removed from the Issuer's financial statements. 4) Issuer's Business, Products and Services The purpose of this section is to provide a clear description of the issuer's current operations. (Please ensure that these descriptions are updated on the Company's Profile on www.otcmarkets.com). A. Summarize the Issuer's business operations (If the Issuer does not have current operations, state "no operations") The publicly traded company CS Diagnostics Corp. is the sole owner of the property CS Protect-Hydrogel. CS Protect-Hydrogel, a hydrogel-based tissue spacer used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation, to CS Diagnostics Corp. The Issuer and its parent company, CS Diagnostics Pharma GmbH, are actively engaged in proven operations in the Medical and Biotech industry. B. List any subsidiaries, parent company, or affiliated companies. Parent Company 09/27/2023 Issuance 25,000,000 Common $4.54 No Euro Gus Group a.s. Note 2: Asset Purchase Agreement Restricted 4(a)(2) Shares Outstanding on Date of This Report: Ending Balance Date December 31, 2023 Common: 110,790,200 Preferred A 10 Preferred B 20,000,000

![](ex104-010.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 10 of 17 CS Diagnostics Pharma GmbH Stresemannallee 4c Neuss, 41460 Germany C. Describe the Issuers' principal products or services. CS Diagnostics is a pharmaceutical international wholesaler and manufacturer of medical technology. For more than 10 years its current management has been supplying national and international specialists, practices, clinics as well as ministries of health. In addition, we offer international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, we develop our own products with the aim of maximizing patient benefit. 5) Issuer's Facilities The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the Issuer and the extent in which the facilities are utilized. In responding to this item, please clearly describe the assets, properties or facilities of the Issuer, give the location of the principal plants and other property of the Issuer and describe the condition of the properties. If the Issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership. Headquarters: City of Neuss in Germany: 440 sqm (monthly rent 5.000 ?) City of Bruckmühl in Germany: 90 sqm (monthly rent 1.500 ?) Dubai, United Arab Emirates: 50 sqm (monthly rent 1.500 ?) 6) Company Insiders (Officers, Directors, and Control Persons) The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the Issuer, as well as the identity of any significant or beneficial shareholders. Name of Officer/Director or Control Person Affiliation with Company (e.g. Officer/Director/Owner of more than 5%) Residential Address (City / State Only) Number of shares owned Share type/class Ownership Percentage of Class Outstanding Note Thomas Fahrhoefer President Dubai, United Arab Emirates 110,000,000 10 7,935,940 Common Preferred A Preferred B 99% 100% 39.6% Beneficial Ownership (No shares in personal name) Thomas J Migotsch Chief Financial Officer Rapperswil-Jona, Switzerland 480.000 N/A .004% Thomas Graus Corporate Secretary Lugano, Switzerland 0 N/A N/A CS Diagnostics Pharma GmbH More than 5% Neuss, Germany 65,000,000 Common 58% Beneficial Owner Thomas Fahrhoefer, Dubai, UAE CS Interpharm General Trading Co. LLC More than 5% Dubai, United Arab Emirates 20,000,000 Common 18% Beneficial Owner Thomas Fahrhoefer, Dubai, UAE

![](ex104-011.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 11 of 17 Euro Gus Group A.S. More than 5% Praha, Czech Republic 25,000,000 7,578,500 Common Preferred B 23% 37.9% Beneficial Owner Thomas Fahrhoefer, Dubai, UAE

![](ex104-012.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 12 of 17 7) Legal/Disciplinary History A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years: 1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations); NO 2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities; NO 3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated; NO 4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or NO 5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities. NO 6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail. NO B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities. NONE

![](ex104-013.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 13 of 17 8) Third Party Providers Please provide the name, address, telephone number and email address of each of the following outside providers: Securities Counsel (must include Counsel preparing Attorney Letters). McMurdo Law Group, LLC Matthew McMurdo, Esq. 1185 Avenue of the Americas 3rd Floor New York, New York 10036 917-318-2865 matt@nannaronelaw.com Auditor Yinka Oyebola OLAYINKA OYEBOLA & CO 43, Churchgate Street Victoria Island, Lagos Nigeria +2348033338600 Olayinka_oyebola@hotmail.com Provide the name of any other service provider(s) that that assisted, advised, prepared or provided information with respect to this disclosure statement. This includes counsel, advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period. NONE 9) Disclosure & Financial Information A. This Disclosure Statement was prepared by (name of individual): Name: Thomas Graus Title: Corporate Secretary Relationship to Issuer: Corporate Secretary/Director B. The following financial statements were prepared in accordance with: ? U.S. GAAP ? IFRS C. The financial statements for this reporting period were prepared by (name of individual)3: Name: Peter Zompa Title: Accountant Relationship to Issuer: Contract Accounting Describe the qualifications of the person or persons who prepared the financial statements: Accounting firm preparing financial reporting and certified US Tax. 3 The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

![](ex104-014.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 14 of 17 10) Issuer Certification Principal Executive Officer: The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities). The certifications shall follow the format below: I, Thomas Fahrhoefer, certify that: 1. I have reviewed this Annual Report and Disclosure Statement for Period Ending December 31, 2023 of CS Diagnostic Corp..; 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement. March 12, 2024 /s/ Thomas Fahrhoefer Principal Financial Officer: I, Thomas J Migotsch, certify that: 1. I have reviewed this Annual Report and Disclosure Statement for Period Ending December 31, 2023 of CS Diagnostic Corp. 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the

![](ex104-015.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 15 of 17 financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement. March 12, 2024 /s/ Thomas J Migotsch

![](ex104-016.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 16 of 17 CS DIAGNOSTICS CORP FINANCIAL STATEMENTS WITH PCAOB AUDITORS CONSENT FOR PERIOD ENDING DECEMBER 31, 2023 AUDITOR LETTER BALANCE SHEET STATEMENT CASH FLOWS INCOME STATEMENT STATEMENT OF CHANGES IN SHAREHOLDERS EQUITY FINANCIAL NOTES

![](ex104-017.jpg)

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 17 of 17

![](ex104-018.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;C S DIAGNOSTICS CORP INDEX TO FINANCIAL STATEMENTS Balance Sheets as of December 31, 2023, and December 31, 2022 Statements of Operations for the year ended December 31, 2023, and December 31, 2022 Statements of Stockholders' Equity for the year ended December 31, 2023, and 2022 Statements of Cash Flows for the year ended December 31, 2023, and 2022 Notes to the Financial Statements

![](ex104-019.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Report of the Independent Registered Public Accounting Firm To the shareholders and the board of directors of CS DIAGNOSTICS CORP. Opinion on the Financial Statements We have audited the accompanying balance sheets of CS Diagnostics Corp. (the "Company") as of December 31, 2023, and 2022 and the related statements of operations, changes in shareholders' equity and cash flows, for each of the two years in the period ended December 31, 2023, and the related notes collectively referred to as the "financial statements. In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and 2022, and the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with U.S. generally accepted accounting principles. Going Concern The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has accumulated deficit of $(4,768,689) at December 31, 2023. The continuation of the Company as a going concern through December 31, 2023, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due. These factors raise substantial doubt about the company's ability to continue as a going concern. These financial statements do not include any adjustments that might result from the outcome of the uncertainty. Basis for Opinion These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. Critical Audit Matters Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole and we are not, by communicating the critical audit matters, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate. We have decided to communicate the matter below. Valuation of Intangible Assets As discussed in Note 1 to the financial statements, CS Diagnostics Corp purchased 100% of the tangible product CS Protect-Hydrogel, its intellectual property, distribution rights and patents from the CS Diagnostics Group, headquartered in Germany. The CS Protect Hydrogel is a hydrogel-based tissue spacer. We identified the Audit of valuation of intangible assets as a critical audit matter because of the significant estimates and management assumptions used. Performing audit procedures to evaluate the reasonableness of these estimates and assumptions required a high degree of auditor's judgement and an increase extent of effort.

![](ex104-020.jpg)

The primary procedures we performed include: 1. We reviewed and challenged the reasonableness of key management assumptions used for the estimate. 2. We reviewed the report of the independent valuation firm that performed the valuation of the intangible assets. 3. We assessed the suitability of the method used by the expert in valuation of the assets. 4. We evaluated the reasonableness of management significant assumptions used in developing discounted cashflow such as future projection of revenue growth and profitability and estimating the working capital needs by testing the data used by management in its analysis to compare to historical data. OLAYINKA OYEBOLA & CO. (Chartered Accountants) We have served as the Company's auditor since February 2022. March 11th, 2024. Lagos Nigeria

![](ex104-021.jpg)

C S DIAGNOSTICS CORP BALANCE SHEETS December 31, 2023 December 31, 2022 (Audited) Restated ASSETS Current Assets: Cash 20,363 12,804 Other receivables - - $20,363 $12,804 Total current asset Intangible assets 499,400,000 - Total Assets $499,420,363 $12,804 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: $$ Account Payables 12,822 4,107 Non-Current Liabilities $- $40,000 Total Liabilities 12,822 44,107 Stockholders' Deficit: Common stock, $0.00001 par value; 250,000,000 shares authorized, 110,790,200 shares issued and outstanding as of December 31, 2023, and 135,287,214 shares December 31, 2022 1,108 1,352 Preferred stock Series A, $0.001 par value;5,000 shares authorized, 10 shares issued and outstanding as of December 31, 2023, and 2022 - - Preferred stock Series B, $0.001 par value; 20,000,000 shares authorized, 20,000,000 shares issued and outstanding as of December 31, 2023, and 2022 2,000 2,000 Additional paid-in capital 504,173,122 4,712,037 Accumulated deficit (4,768,689) (4,746,692) Total Stockholders' Deficit 499,407,541 (31,303) Total Liabilities and Stockholders' Deficit $499,420,363 $12,804 The accompanying notes are an integral part of these financial statements.

![](ex104-022.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying notes are an integral part of these financial statements. CS DIAGNOSTICS CORP. STATEMENTS OF OPERATONS For the Years Ended December 31, 2023 2022 Revenue $126,038 $25,500 Operating Expenses: Professional fee $54,026 $6,040 General & administrative expenses $94,009 $14,255 Total operating expenses 148,035 20,292 Income /(loss) from operations (21,997) 5,205 Other Income / (Expense) - - Net Income / (loss) $(21,997) $5,205 Basic and diluted loss per share $(0.00) $(0.00) Basic and diluted weighted average shares 110,790,200 135,287,214

![](ex104-023.jpg)

The accompanying notes are an integral part of these financial statements. CS DIAGNOSTICS CORP. STATEMENT OF STOCKHOLDERS' (DEFICIT) FOR THE YEAR ENDED DECEMBER 31, 2023, AND 2022. Preferred Stock B Common Stock Additional Accumulated Shares Amount Shares Amount Paid-in Capital Deficit Total Balance, January 1, 2022 20,000,000 $2,000 135,287,214 $1,352 $4,712,037 $(4,751,897) $(36,508) Preferred stock issued - - - - - - - Net loss for the year - - - - - 5,205 5,205 Balance, December 31, 2022 20,000,000 2,000 135,287,214 1,352 4,712,037 (4,746,692) (31,303) Balance, January 1, 2023 20,000,000 $2,000 135,287,214 $1,352 $4,712,037 (4,746,692) $(31,303) Reverse stock split - - (134,497,015) (1,344) - - (1,344) Shares issued in acquisition of assets - - 110,000,000 1,100 499,461,085 - 499,462,185 Net income for the year - - - - - (21,997) (21,997) Balance, December 31, 2023 20,000,000 2,000 110,790,200 1,108 504,171,322 (4,768,689) 499,407,541

![](ex104-024.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying notes are an integral part of these financial statements. C S DIAGNOSTICS CORP STATEMENTS OF CASH FLOWS Year Ended December 31, 2023 2022 Cash flows from operating activities: Net profit / (loss) $(21,997) $17,901 Adjustments to reconcile net loss to net cash used in operating activities: Changes in assets and liabilities: Other receivables - Account payables 31,285 7,599 Net cash used in operating activities 9,288 25,500 Cash flows from investing activities: - Intangible Asset (499,444,401) (499,444,401) Cash flows from financing activities: Additional paid in capital 499,422,309 - Loan forgiven - Net cash provided by financing activities 499,422,309 - Net increase (decrease) in cash (12,804) 25,500 Cash, beginning of period 12,804 - Cash, end of period $- $25,500

![](ex104-025.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;C S DIAGNOSTICS CORP Notes to the Financial Statements December 31, 2023, and December 31, 2022 NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS CS Diagnostics Corp., (the "Company") a Wyoming Corporation in the United State, CS Diagnostics Corp., is an United States based Corporation, Its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit. We work hand in hand with universities, experts and experienced users as well as with our users, as well as with our own R&D team, in order to always offer the most innovative products in medical technology. On August 1, 2023, FINRA authorized the Corporate Action approved by the Board of Directors and majority shareholder for and amendment to the Articles of Incorporation from FlashZero Corp to CS Diagnostics Corp and a 1 for 100,000 reverse split followed by a 200 for 1 forward split and a change of the CUSIP to 33852L202. Pre-split shares: 135,287,214: Post Split share 790,200. On September 4, 2023, CS Diagnostics Corp purchased 100% of the tangible product CS Protect-Hydrogel, its intellectual property, distribution rights and patents from the CS Diagnostics Group, headquartered in Germany. The CS ProtectHydrogel is a hydrogel-based tissue spacer. It is used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation. Currently, hydrogel spacers are used exclusively in the treatment of prostate cancer. Here, the spacer pushes the rectum away from the prostate, thus reducing rectal damage from radiation therapy. The hydrogel spacer is injected once in liquid form through a thin needle into the space between cancer cells and healthy tissue and is broken down by the body after about six months. The CS Protect-Hydrogel is a "ready-to-use" product, which is sterile packed and can be applied directly. The hydrogel can be used in radiotherapy for prostate, cervical, esophageal, bladder and breast cancer. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates. Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company's cash is deposited with major financial institutions. At times, such deposits may be in excess of the Federal Deposit Insurance Corporation insurable amount. Cash and Cash Equivalents The Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less as cash and cash equivalents. The carrying amount of financial instruments included in cash and cash equivalents approximates fair value because of the short maturities for the instruments held. There were no cash equivalents for the period ended December 31, 2023, and December 31, 2022.

![](ex104-026.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC Topic No. 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels, as described below: Level 1: Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. Level 2 inputs include quoted prices for similar assets, quoted prices in markets that are not considered to be active, and observable inputs other than quoted prices such as interest rates. Level 3: Level 3 inputs are unobservable inputs. The following required disclosure of the estimated fair value of financial instruments has been determined by the Company using available market information and appropriate valuation methodologies. However, considerable judgment is required to interpret market data to develop the estimates of fair value. Accordingly, the use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. The methods and assumptions used to estimate the fair values of each class of financial instruments are as follows: Accounts Receivable, and Accounts Payable. The items are generally short-term in nature, and accordingly, the carrying amounts reported on the consolidated balance sheets are reasonable approximations of their fair values. The carrying amounts of Notes Payable approximate the fair value as the notes bear interest rates that are consistent with current market rates. Income Taxes We follow ASC 740-10-30, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income in the period that includes the enactment date. We adopted ASC 740-10-25 ("ASC 740-10-25") with regard to uncertainty income taxes. ASC 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10-25, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740-10-25 also provides guidance on derecognition, classification, interest and penalties on income taxes, and accounting in interim periods and requires increased disclosures. We had no material adjustments to our liabilities for unrecognized income tax benefits according to the provisions of ASC 740-10-25. Net income (loss) per common share Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented. For the year ended December 31, 2023 and December 31, 2022, the diluted loss per share is the same as the basic loss per shares as the inclusion of any potentially dilutive shares would result in anti- dilution due to the net loss incurred by the Company

![](ex104-027.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Recent Accounting Pronouncements The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. NOTE 3 - GOING CONCERN The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has accumulated deficit of $(4,792,727) at December 31, 2023. The continuation of the Company as a going concern through December 31, 2023, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due. The Company requires capital for its contemplated operational activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties. NOTE 4 ? INCOME TAXES Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The U.S. federal income tax rate of 21% is being used. Net deferred tax assets consist of the following components as of: December 31, 2023 December 31, 2022 Federal income tax benefit attributable to: Current Operations $? $- Less: valuation allowance ? - Net provision for Federal income taxes $? $? The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from continuing operations for the fiscal years ending, due to the following: December 31, 2023 December 31, 2022 Deferred tax asset attributable to: Net operating loss carryover $? $(3,333) Less: valuation allowance ? 3,333 Net deferred tax asset $? $? At December 31, 2023, the Company had net operating loss carry forwards of approximately $(4,792,727) that may be offset against future taxable income from the year 2022 to 2040. No tax benefit has been reported in the December 31, 2023, financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.

![](ex104-028.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for Federal Income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2015. NOTE 5 ? SUBSEQUENT EVENTS In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has identified the following events to disclose in these financial statements.

## Exhibit 10.5

**Exhibit 10.5**

![](ex105-001.jpg)

![](ex105-002.jpg)

![](ex105-003.jpg)

![](ex105-004.jpg)

![](ex105-005.jpg)

,SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT, dated as of April 4th , 2022 (this "Agreement") is entered into by and among PatientTrac Limited, an entity organized under the laws of United Kingdom, and its related group, (the "Shareholder"), and CS Diagnostics GmbH, an entity organized under the laws of Ge1many, its successor or assigns, (the "Purchaser"). The parties, intending to be legally bound, hereby agree as follows: WHEREAS. the Shareholder and Purchaser are executing and delivering this Agreement in reliance upon the exemption from secw·ities registration afforded by the rules and regulations promulgated by the United States Securities and Exchange Commission (The ''SEC") under the Securities Act of 1933, and amended (the "1933 Act"); WHEREAS, the Shareholder desires to issue and sell to Purchaser upon the terms and conditions set forth herein, and Purchaser, its successor or assigns, desires to purchase from Shareholder the following: Common Stock 110,352,000 Preferred Series A I 0 Preferred Series B 20,000,000 Unrestricted Shares 14,000,000 of FlashZero Corporation., a Wyoming corporation, (the ·'Sbares")(the "Transaction"); and NOW. THEREFORE, in consideration of the mutual promises herein made, a11d in consideration of the representations, wan-an ties and covenants herein contained, the Shareholder and Purchaser agree as follows: 1. Purchase of lhe Shares. On the Closing Date, subject to the terms and conditions of this Agreement, Shareholder hereby agrees to sell to Purchaser and Purchaser hereby agrees to purchase from Shareholder, the Shares. 2. Purcha.\'e Price. The Purchase Price for the Shares shall be One Hundred- Seventy Five Thousand and 00/100 ($175,000/00) Dollars (the "Purchase Price"'). The Purchase Price shal I be payable upon execution of this Agreement. 3. Closing: Closing Date. Subject to the satisfaction (or written waiver) of the conditions thereto set forth herein, the date and time of the Closing of the Transaction shall be on or before 12:00 noon, Eastern Standard Time, no more than ten (l 0) days following the execution of this agreement - April 14, 2022 (the ·'Closing Date"). The closing of the transactions contemplated by this Agreement (the ''Closing") shall occur on the Closing Date at such location as may be agreed to by the parties. At Closing, the Purchasor shall pay One Hundred Thousand USO, ($100,000), upon executed Securities Purchase Agreement and then the Purchasor shall pay the balance of $75.000 USO upon confirmation from Transfer OnLine, Inc., the transfer agent, of the fo llowing shares transfers in Book Entry at Transfer Online, Inc., (I) Transfer of On Hundred Ten Million Three Hundred Fifty-Two Thousand, (110.352,000), shares of Common Stock to CS Diagnostics GmbH, pursuant to the Distribution Chart (See Exhibit "A"), from Jose Salazar; (2) Transfer of Ten, (l 0), shares of Preferred Series A Stock to CS Diagnostics GmbH pursuant to 1 the Distribution Chart (See Exhibit .. A''), from Jose Salazar, (3) Transfer of Twenty Million, (20,000,000), shares to CS Diagnostics GmbH pursuant to the Disllibution Chart (See Exhibit ··A ..), from PatientTrac Limited and (4) Transfer of Fourteen Million, (14,000,000), Shares of Common Stock, unrestricted pursuant to Rule 144, Reg 4(a)(l), of the SEC Act to CS Diagnostics GmbH pursuant to the Distribution Chart (See Exhibit "A''). 4. Representations and Warranties ofShareholder. Shareholder hereby represents and warrants to Purchaser in the First Closing that the statements contained in the following paragraphs of this Section 4 are all ttue and correct as of the date of this Agreement and the Closing Date: a. Corporate Power. Shareholder has all requ1s1te legal and corporate power to enter into, execute, deliver and perform this Agreement of even date herewith between Shareholde1· and Purchaser. This Agreement has been duly executed by the Shareholder and constitute the legal, valid and binding obligations of Shareholder, enforceable in accordance with their terms, except as the same may be limited by (i) bankruptcy, insolvency, moratorium, and other laws of general application affecting the enforcement of creditors' rights and (ii) limitations on the enforceability of the indemnification provisions of the Registration Rights Agreement as limited by applicable securities laws. b. Authorization. 1. Corporate Action. All corporate and legal action on the part of Shareholder, its officers, directors and shareholders necessary for the execution and delivery of this Agreement, the Shares. and the performance of Shareholder's obligations hereunder have been taken. 11. Valid lm,ance. The Shares, when issued in compliance with the provisions of this Agreement, will be duly and validly issued. fully paid and nonassessable. free and clear of al I I iens and encumbrances~ provided. however, that the Note, and any securities into which it may be converted, may be subject to restrictions on transfer under state and/or federal securities laws as set forth herein, and as may be required by future changes in such laws. c. Governmenl Consent, Elc. No consent, approval, order or authorization of. or designation, registration, declaration or filing with. any federal, state, local or other governmental authority on the part of Shareholder is required in connection with the valid execution and delivery of this Agreement and Note other than, if required, fil ings or qualifications under the Wyoming Securities Act, as amended (the "Wyoming Law"), or other applicable blue sky laws, which filings or qual ifications, if required, will be timely filed or obtained by Shareholder. The execution, delivery and performance of the Agreement by the Shareholder and the consummation by the Shareholder of 2 the transactions contemplated thereby do not and will not conflict with, or constitute a default (or an event that with notice or lapse of time or both would becorne a default) under, or give to others any rights of te1minatio11, amendment, acceleration or cancellation (with or without notice, lapse of time or both) ot: any agreement. d. Private Placement. Assuming the accuracy of the Purchaser's representations and warranties set forth herein, no registration under the 1933 Act is required for the offer, issuance and sale of the Shares, by the Shareholder to Purchaser as contemplated hereby. 5. Representations and Warranties by Purchaser. Purchaser represents and watTants to Shareholder as of the Closing Date as follows: a. Investment Intent: Authority. This Agreement is made with Purchaser in reliance upon Purchaser's representation to Shareholder, evidenced by Purchaser's execution of this Agreement, that Purchaser is acquiring the Shares for investment for Purchaser's own account, not as nominee or agent, for investment and not with a view to, or for resale in connection with, any distribution or public offering thereof within the meaning of the 1933 Act; provided, however, that by making the representations herein, Pmchaser does not agree to hold any of the Shares for any minimwn or other specific term and reserves the right to dispose of the Shares at any time in accordance with 0r pursuant to a registration statement or an exemption under the 1933 Act. Purchaser has the requisite right, power, authority and capacity to enter into and perform this Agreement and tbe Agreement will constitute a valid and binding obligation upon Purchaser, except as the same may be limited by bankruptcy, insolvency, moratorium, and other laws of general application affecting the enforcement of creditors' rights. b. Knowledge and Experience. Purchaser (i) has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of Purchaser's prospective investment in the Shares (ii) has the ability to bear the economic risks of Purchaser's prospective investment; (iii) has had all questions which have been asked by Purchaser satisfactorily answered by Shareholder; and (iv) has not been offered the Shares by any form of adve11isement, article, notice or other communication published in any newspaper, magazine, or similar media or broadcast over television or radio, or any seminar or meeting whose attendees have been invited by any such media. Purchaser represents and warrants that it is an "accredited investor" within the meaning of Rule 50 I of Regulation D of the Securities Act. c. Tran.~fer Restrictions. Purchaser covenants that in no event will it sell, transf7r or otherwise dispose of any of the Shares other than in conjunction with an effective registration statement for the same under the Securities Act 3

![](ex105-006.jpg)

or pursuant to an exemption there from, or in compliance with Rule 144 promulgated under the Securities Act or to a person related to or an entity affiliated with said Purchaser and other than in compliance with the applicable securities regulation laws of any state. 6. legends. Shareholder may place the following legends on the Shares and any securities into which it may be conve11ed: THE SECURITIES REPRESENTED HEREBY HA VE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED ("ACT"), OR ANY APPLICABLE STATE SECURITIES LAWS ("BLUE SKY LAWS"). ANY TRANSFER OF SUCH SECURITIES WILL BE INVALID UNLESS A REGISTRATION STATEMENT UNDER THE ACT OR AS REQUIRED BY BLUE SKY LAWS IS TN EFFECT AS TO SUCH TRANSFER OR IN THE OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE SHAREHOLDER SUCH REGISTRATION lS UNNECESSARY IN ORDER FOR SUCH TRANSFER TO COMPLY WlTH THE ACT OR BLUE SKY LAWS. 7. lndemn[fication of Shareholder The Purchaser will indemnify and hold Shareholder and its directors. officers, shareholders, partners, employees and agents (each, a "Shareholder Party") harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys' fees and costs of investigation (collectively, "Losses") that a Shareholder Party may suffer or incur as a result of or relating to the failure of the representations and warranties of the Shareholder to be true and correct. 8. Miscellaneous. a. Waivers and Amendments. The provisions of this Agreement may only be amended or modified in a writing executed by each of Shareholder and Purchaser. A waiver shall not be effective unless in a writing by the party against whom such waiver is to be enforced. b. Governing law. This Agreement and all actions arising out of or in connection with this Agreement shall be governed by and construed in accordance with the laws of the United Kingdom, without regard to the conflicts oflaw provisions thereof. Any action arising out of this Agreement shall be heard in any cou1t of general jurisdiction in London, United Kingdom. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE. AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. 1 l c. Entire Agreement. This Agreement, the Registration Rights Agreement and the Warrants constilute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. d. Survival. The representations, wananties, covenants and agreements made herein shall survive the execution and delivery of Lhis Agreement. e. Notices. etc. Any notice. request or olher communication required or permitted hereunder shall be in writing and shall be deemed to have been duly given (i) upon receipt if personally deUvered, (ii) three (3) days after being mailed by registered or certified mail, postage prepaid, or (iii) one day after being sent by recognized overnight courier or by facsimile: If to Purchaser, Thomas Fahrhofer, CEO CS Diagnostics GmbH StresemannaUee 4c 41460 Neuss Ge1many +49 (0)2131-1510871 Thomas. fahrhoefor,ijcs-d iagnos li c~.de ff to Seller, H Wayne Hayes Jr _PatientTrac Limited 150-152 Fenchurcb Street 2nd Floor London, England EC3M 6BB ,vayncra•palienltrac.com f. Validity. lf any provision of this Agreement shall be judicially determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be aftected or impaired thereby. g. Counte,parts. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall be deemed to constitute one insnument. f; ' ,;!} h. Assignment. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the patties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 1. Remedies. The Purchaser shall have all rights and remedies set forth in the Transaction Documents and all rights and remedies which such holders have been granted at any time under any other agreement or contract and aJI of the rights which such holders have under any law. Any person having any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or other security), to _recover damages by reason of any breach of any provision of this Agreemen~ and to exercise all other rights granted by law. IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date and year first .written above. For the Shareholder: PatientTrac Limited -~ / President For the Purchaser C~ csGmbH '6~"'tr, By: Its: Stresemanna'fee 4c . ◄ 1,,,,, N -.UV 8<.IS.S • Gennany P +◄9 2131 1510871 f •◄9 2131 1510896 m service@cs-<1,agnostics de w v.ww C$-dJagnos1ics de

## Exhibit 10.6

**Exhibit 10.6**

![](ex106-001.jpg)

Page 1 of 4 _______________________________________________ CS DIAGNOSTICS CORP. Buyer And CS DIAGNOSTICS GROUP Seller ASSET PURCHASE AGREEMENT _______________________________________________________________________ This Asset Purchase Agreement is by and between CS Diagnostics Corp., a Wyoming Corp., CS Diagnostics Pharma GmbH, an German registered Company; CS Interpharm LLC, a Dubai, UAE limited liability partnership (collectively referred to "CS Diagnostics Corp"), is entered into with an effective date of 4th day of September 2023. On June 14, 2022, a binding agreement was executed with Lapharm GmbH1 and the issuer whereas La Pharm agreed to provide to CS an exclusive distributorship for a period of five years of Hydrogel. On September 4, 2023, CS Diagnostics Group agreed to sell and transfer the tangible, intangible and patents for the CS Protect-Hydrogel, a hydrogel-based tissue spacer used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation, to CS Diagnostics Corp. The CS Diagnostics Group have obtained a valuation for the CS Protect-Hydrogel in amount greater that 960,000,000 Euro based on its discounted present commercial value. The valuation is supported, as contained in the final valuation, see Exhibit A, by the October 16, 2018 purchase of the similar product by Boston Scientific for $500,000,000 USD and further compensation based on the distribution revenues, See Exhibit "B".CS Diagnostics Corp., based on this valuation, has agreed and has instructed its transfer agent, Transfer Online, to issue 110,000,000 shares of its common stock to represent a payment of Five Hundred Million USD ($500,000,000) for the rights, patents and intellectual property of the CS Protect-Hydrogel product to the CS Diagnostics Group, its successor or assigns. Seller has all requisite legal and corporate power to enter into, execute, deliver and perform this Agreement of even date herewith between Seller and Buyer. This Agreement has been duly executed by the Seller 1 Lapharm GmbH was subsequently merged into CS Diagnostics Pharma GmbH and the entity no longer exists.

![](ex106-002.jpg)

Page 2 of 4 and constitute the legal, valid and binding obligations of Seller, enforceable in accordance with their terms, except as the same may be limited by (i) bankruptcy, insolvency, moratorium, and other laws of general application affecting the enforcement of creditors' rights and (ii) limitations on the enforceability of the indemnification provisions of the Registration Rights Agreement as limited by applicable securities laws. All corporate and legal action on the part of Seller, its officers, directors and Sellers necessary for the execution and delivery of this Agreement, the Shares, and the performance of Seller's obligations hereunder have been taken. The Shares, when issued in compliance with the provisions of this Agreement, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens and encumbrances; provided, however, that the Note, and any securities into which it may be converted, may be subject to restrictions on transfer under state and/or federal securities laws as set forth herein, and as may be required by future changes in such laws. Government Consent, Etc. No consent, approval, order or authorization of, or designation, registration, declaration or filing with, any federal, state, local or other governmental authority on the part of Seller is required in connection with the valid execution and delivery of this Agreement. The execution, delivery and performance of the Agreement by the Seller and the consummation by the Seller of the transactions contemplated thereby do not and will not conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement of the Corporation. Private Placement. Assuming the accuracy of the Buyer's representations and warranties set forth herein, no registration under the 1933 Act is required for the offer, issuance and sale of the Shares, by the Seller to Buyer as contemplated hereby. Representations and Warranties by Buyer. Buyer represents and warrants to Seller as of the Closing Date as follows: Investment Intent: Authority. This Agreement is made with Buyer in reliance upon Buyer's representation to Seller, evidenced by Buyer's execution of this Agreement, that Buyer is acquiring the Shares for investment for Buyer's own account, not as nominee or agent, for investment and not with a view to, or for resale in connection with, any distribution or public offering thereof within the meaning of the 1933 Act; provided, however, that by making the representations herein, Buyer does not agree to hold any of the Shares for any minimum or other specific term and reserves the right to dispose of the Shares at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act. Buyer has the requisite right, power, authority and capacity to enter into and perform this Agreement and the Agreement will constitute a valid and binding obligation upon Buyer, except as the same may be limited by bankruptcy, insolvency, moratorium, and other laws of general application affecting the enforcement of creditors' rights.

![](ex106-003.jpg)

Page 3 of 4 Knowledge and Experience. Buyer (i) has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of Buyer's prospective investment in the Shares (ii) has the ability to bear the economic risks of Buyer's prospective investment; (iii) has had all questions which have been asked by Buyer satisfactorily answered by Seller; and (iv) has not been offered the Shares by any form of advertisement, article, notice or other communication published in any newspaper, magazine, or similar media or broadcast over television or radio, or any seminar or meeting whose attendees have been invited by any such media. Buyer represents and warrants that it is an "accredited investor" within the meaning of Rule 501 of Regulation D of the Securities Act. The provisions of this Agreement may only be amended or modified in a writing executed by each of Seller and Buyer. A waiver shall not be effective unless in a writing by the party against whom such waiver is to be enforced. This Agreement and all actions arising out of or in connection with this Agreement shall be governed by and construed in accordance with the laws of the United States without regard to the conflicts of law provisions thereof. Any action arising out of this Agreement shall be heard in any court of general jurisdiction in the State of Wyoming. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. This Agreement constitutes the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. The representations, warranties, covenants and agreements made herein shall survive the execution and delivery of this Agreement. If any provision of this Agreement shall be judicially determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall be deemed to constitute one instrument. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Buyer shall have all rights and remedies set forth in the Transaction Documents and all rights and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights which such holders have under any law. Any person having any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or

![](ex106-004.jpg)

Page 4 of 4 other security), to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law. IN WITNESS WHEREOF, the Parties hereto have executed this ASSET PURCHASE AGREEMENT EFFECTIVE 4 September 2023. CS Diagnostics Corp. CS Diagnostics Pharma GmbH _________________________ __________________________ Thomas Fahrhoefer Thomas Fahrhoefer CS Interpharm, LLC _________________________ Thomas Fahrhoefer

## Exhibit 10.7

**Exhibit 10.7**

![](ex107-001.jpg)

1 CONSULTING AGREEMENT BETWEEN LACHMAN CONSULTANT SERVICES, INC. AND CS DIAGNOSTICS CORP., ON BEHALF OF ITSELF AND ITS AFFILIATES This Consulting Services Agreement (Agreement) is effective as of March 5, 2025, by and between CS DIAGNOSTICS CORP., on behalf of itself and its affiliates, having an address at Stresemannallee 4b, Neuss 41460, Germany, (hereinafter referred to as CS DIAGNOSTICS) and LACHMAN CONSULTANT SERVICES, INC., having an address at 1600 Stewart Avenue, Suite 604, Westbury, NY 11590, USA, (hereinafter referred to as LACHMAN). CS DIAGNOSTICS wishes to engage LACHMAN and LACHMAN wishes to perform such consulting services as set forth in the Statement of Work(s) (SOWs) and/or proposals attached as Exhibit A to this Agreement, and any other SOW(s) and/or proposal(s) agreed to by the parties, or as otherwise mutually agreed by the parties, but nonetheless subject to the terms set forth under this Agreement. CS DIAGNOSTICS agrees that LACHMAN will serve as a consultant to CS DIAGNOSTICS on an hourly basis. Consulting services are based upon hourly rates charged for the Consulting Time of LACHMAN's consultants and management that work on matters for or on behalf of CS DIAGNOSTICS. "Consulting Time" is defined as services performed and any associated travel time. The current standard rates for LACHMAN consultants range between $325 and $425 per hour per consultant and the current standard rates for LACHMAN's management range between $450 and $550 per hour. Notwithstanding the above, special rates may apply for work performed by consultants with specialized subject matter skills and/or experience. A Management Review and Oversight Fee in the amount equal to 20% of project hours billed at the applicable management rate will be charged on a monthly basis based upon the actual consultant project hours incurred monthly, which covers management review and oversight and other associated project related charges. An initial advanced deposit of $12,500 will be invoiced to CS DIAGNOSTICS upon signing of this Agreement, with additional deposits required from time to time as agreed to by the parties in writing based upon applicable SOW(s) and/or proposal(s). Such deposit(s) will be applied directly to future consulting services. Invoices containing a detailed accounting of consulting time and all related expenses will be provided to CS DIAGNOSTICS. The current per diem allowance for meals and telephone expenses is $100 per consultant for travel within the U.S. and $120 per consultant for International travel. Payment terms for all invoices are net fifteen (15) days. Failure to object in writing to any invoice within fifteen (15) days from the date of mailing shall be deemed an acknowledgment of the amount owed. Any amounts not paid when due will accrue interest at the rate of 1% per month. In the event LACHMAN commences an action or proceeding to collect amounts due hereunder, CS DIAGNOSTICS shall pay LACHMAN its costs and expenses, including attorneys' fees, in connection therewith. CS DIAGNOSTICS and LACHMAN are parties to that certain Confidential Disclosure Agreement dated as of February 13, 2025 (the "CDA"), the terms of which are hereby incorporated herein by reference. The parties agree that the CDA shall govern the use and disclosure of Confidential Information (as defined in the CDA) in connection with this Agreement. The term of the CDA shall be deemed extended, as necessary, to be coterminous with this Agreement and the provisions thereof shall survive any expiration or termination of this Agreement for the period set forth in Section 7(e) thereof. This Agreement is for a maximum of two (2) years commencing on March 5, 2025. In order to maintain continuity and avoid delay to on-going projects, unless otherwise specified, services will not cease awaiting future renewal of this Agreement. The hourly rates provided for in this Agreement will be guaranteed for two (2) years from the date hereof, thereafter, such rates will be at the then-prevailing hourly rate. The terms of this Agreement will continue until a renewal of the Agreement is signed. Docusign Envelope ID: B1645654-6345-4E07-8A43-0784AD12B5C9

![](ex107-002.jpg)

2 CS DIAGNOSTICS agrees that during the term of this Agreement and for a period of two (2) years after the expiration of this Agreement, it will not, without the prior written consent of LACHMAN, solicit, hire, contract with nor engage the services of any consultant of LACHMAN. This Agreement supersedes all prior agreements, written or oral, between the parties relating to the subject matter of this Agreement. This Agreement may not be modified, amended or discharged, in whole or in part, except by an agreement in writing signed by the parties. If any provision in this Agreement shall be found or be held to be invalid or unenforceable in any jurisdiction in which this Agreement is being performed, then the meaning of said provision shall be construed, to the extent feasible, so as to render the provision enforceable, and if no feasible interpretation would save such provision, it shall be severed from the remainder of this Agreement which shall remain in full force and effect. LACHMAN makes no representations and/or warranties, express or implied, with respect to the services or the results thereof. This Agreement shall be construed and interpreted in accordance with the laws of the State of New York, United States, without regard to its conflicts of law principles. The parties further specifically agree that any action or proceeding arising out of or in connection with this Agreement will be commenced in the federal or state courts located in the County of New York in the State of New York, United States, which shall have exclusive jurisdiction thereof. Each party hereto irrevocably consents to the personal jurisdiction of such courts in the State of New York. The undersigned representative of each party represents and warrants that he/she has the authority to sign this Agreement on behalf of such party and such party's affiliates. Each party represents and warrants to the other that this Agreement has been authorized and is a valid and legal agreement binding on such party and its affiliates and is enforceable in accordance with its terms. Signatures sent by fax machine or electronic means shall be deemed original signatures of the parties, and this Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument. AGREED TO BY: LACHMAN CONSULTANT SERVICES, INC. CS DIAGNOSTICS CORP., on behalf of itself and its affiliates Signature:___________________________ ___________________________________ David B. Petshaft, Esq. Name: (print)_________________________ Chief Legal and Financial Officer Title:_______________________________ Agreement #: A 3/25-1 Mohammad EsSayedGroup Chief Financial OfficerDocusign Envelope ID: B1645654-6345-4E07-8A43-0784AD12B5C9

![](ex107-003.jpg)

3 EXHIBIT A Docusign Envelope ID: B1645654-6345-4E07-8A43-0784AD12B5C9

## Exhibit 99.1

**Exhibit 99.1**

![](cscorp_logosm.jpg)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10**

**GENERAL FORM FOR REGISTRATION OF SECURITIES**

**Pursuant to Section 12(g) of The Securities Exchange Act of 1934**

![](cscorp_logo.jpg)

CS DIAGNOSTICS CORP.

**State of Incorporation:** Wyoming<br> **I.R.S. Employer Identification No.:** 20-1290331<br> **Principal Executive Offices:**<br> Stresemannallee 4b, Neuss 41460, Germany +49 21311510871

www.csdcorp.us info@csdcorp.us

**Securities to be registered pursuant to Section 12(b):** None<br> **Securities to be registered pursuant to Section 12(g):** Common Stock, $0.00001 par value

1 www.csdcorp.us

![](cscorp_logosm.jpg)

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **FORWARD-LOOKING STATEMENTS** | **4** |
| **Business** | **4** |
| &nbsp;&nbsp;&nbsp;Overview | 4 |
| &nbsp;&nbsp;&nbsp;Corporate History | 4 |
| &nbsp;&nbsp;&nbsp;Flagship Product | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS Protect-Hydrogel | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MEDUSA (Long-Acting Disinfectant) | 6 |
| &nbsp;&nbsp;&nbsp;Leased Offices | 7 |
| **RISK FACTORS** | **7** |
| &nbsp;&nbsp;&nbsp;Risks Related to the Company | 7 |
| &nbsp;&nbsp;&nbsp;Risks Related to Business Operations | 8 |
| &nbsp;&nbsp;&nbsp;Risks Associated with the Pharmaceutical Industry | 12 |
| &nbsp;&nbsp;&nbsp;Risks Related to being a Publicly Traded Company | 14 |
| **SECURITY OWNERSHIP** | **17** |
| &nbsp;&nbsp;&nbsp;Principal Shareholders | 17 |
| &nbsp;&nbsp;&nbsp;Beneficial Owners and Management | 17 |
| **DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE** | **18** |
| &nbsp;&nbsp;&nbsp;Directors and Officers | 18 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thomas Fahrhoefer | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mohammad EsSayed | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sabrina Kummer Godehardt | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Janel Luzana | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mahmoud A. Al-Sayyed | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr. Ralf Herwig | 19 |
| &nbsp;&nbsp;&nbsp;Executive Compensation | 20 |
| &nbsp;&nbsp;&nbsp;Limitation of Liability and Indemnification | 20 |
| &nbsp;&nbsp;&nbsp;Stock and Stock Option Issuances in 2023 and 2024 | 21 |
| &nbsp;&nbsp;&nbsp;Related Party Transactions | 21 |
| **DESCRIPTION OF CAPITAL STOCK** | **22** |
| &nbsp;&nbsp;&nbsp;Common Stock | 22 |
| &nbsp;&nbsp;&nbsp;Preferred Stock | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series A Preferred Stock | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series B Preferred Stock | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series C Preferred Stock | 23 |
| &nbsp;&nbsp;&nbsp;Recent Issuances of Securities | 23 |
| **CAPITALIZATION** | **25** |
| **Management's Discussion and Analysis of Financial Condition and Results of Operation (MD&A)** | **26** |
| &nbsp;&nbsp;&nbsp;Overview and Business Summary | 26 |
| &nbsp;&nbsp;&nbsp;Results of Operations | 26 |

---

2 www.csdcorp.us

![](cscorp_logosm.jpg)

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fiscal Year 2024 Compared to 2023 | 26 |
| &nbsp;&nbsp;&nbsp;Quarter Ended March 31, 2025 Compared to March 31, 2024 | 27 |
| &nbsp;&nbsp;&nbsp;Liquidity and Capital Resources | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital Structure and Cash Position | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash Burn and Going Concern | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing Plans | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital Expenditures and Requirements | 28 |
| &nbsp;&nbsp;&nbsp;Critical Accounting Estimates and Judgments | 29 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other areas of significant accounting judgment include: | 29 |
| &nbsp;&nbsp;&nbsp;Known Trends, Events, and Uncertainties | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory Approval and Commercialization Timeline | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Launch and Manufacturing | 31 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market Adoption and Competition | 31 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial Potential vs. Risks | 31 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diversification and Other Products | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management and Organizational Changes | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Macroeconomic and Market Conditions | 32 |
| &nbsp;&nbsp;&nbsp;Conclusion | 32 |
| &nbsp;&nbsp;&nbsp;Going forward | 33 |
| **LEGAL PROCEEDINGS** | **33** |
| **SIGNATURES** | **33** |

---

3 www.csdcorp.us

![](cscorp_logosm.jpg)

**FORWARD-LOOKING STATEMENTS**

This Form 10 contains certain statements that discuss future expectations, contain projections of results of operations or financial condition or state other "forward-looking" information. The words "believe," "expect," "anticipate," "intend," "estimate," "may," "should," "could," "will," "plan," "future," "continue," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters identify forward-looking statements. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, the actual results could differ materially from these forward-looking statements.

**Business**

**Overview**

With CS PROTECT HYDROGEL, the CS Diagnostics Group has improved and further developed an existing product. HYDROGEL will quickly gain market share after receiving marketing approval, but market launch is associated with high costs for approval and marketing. At the end of 2021, the CS Diagnostics Group was faced with the decision to sell the intellectual property of CS PROTECT HYDROGEL or to organize product development, global distribution, cost-intensive product registrations/certifications and global marketing itself. For this reason at the beginning of 2022, CS Diagnostics decided to create an instrument to gain access to the capital market and after careful consideration of various options, the path of a takeover of a US OTC company whose shares are public traded and with favorable share structure was chosen. CS Diagnostic Corp. is currently listed on the US OTCQB Markets under the trading symbol "CSDX", (OTCQB- CSDX).

**Corporate History**

CS Diagnostics Corp., (the Company) was incorporated under the laws of the State of Nevada on September 25, 1996 under the name DWC Installations, Inc. Around 2002, the Company changed its name to The Children's Internet, Inc. On October 20, 2010, it relocated its domicile to Wyoming. Later on February 15, 2015, the Company adopted the name FlashZero Corp.

On April 4, 2022, after FlashZero Corp.'s shareholders and CS Diagnostics GmbH executed a securities purchase agreement, FlashZero Corp. ceased operations. CS Diagnostics GmbH continued the business under a new name, 'CS Diagnostics Corp.' and transformed its business model. FINRA approved the name change to 'CS Diagnostics Corp.' on August 3, 2023.

CS Diagnostics Corp. ("CS Diagnostics" or the "Company") is a medical technology and distribution company focused on improving patient care through innovative therapeutic and preventive solutions. The Company's mission centers on enhancing the effectiveness of treatments while reducing side effects, thereby improving patient outcomes and quality of life. CS Diagnostics Corp. is a member of the "CS Group," an international healthcare group with operations in Europe and Middle East, leveraging global partnerships with universities and medical partners to develop and distribute its products. The Company's current core products under development include CS PROTECT Hydrogel and MEDUSA (a long-acting disinfectant), described further below.

4 www.csdcorp.us

![](cscorp_logosm.jpg)

**Flagship Product**

**CS Protect-Hydrogel**

This product is a novel tissue spacer gel for use in radiation therapy, designed to separate healthy tissue from malignant tissue during treatment. CS Protect Hydrogel is an injectable "organ spacer" initially targeted for prostate cancer radiotherapy, where it increases the distance between the prostate tumor and the rectum to reduce radiation damage to healthy tissue. The CS Diagnostics Group was previously the European distributor for the leading first-generation spacer (SpaceOAR®) and has leveraged that experience to develop CS Protect Hydrogel as a second-generation spacer with significant improvements. Unlike the incumbent product (now marketed by Boston Scientific Corporation after its $500 million acquisition of Augmenix, Inc. in 2018), CS Protect Hydrogel is ready-to-use (pre-mixed in a sterile package) rather than requiring on-site mixing by clinicians. This improves hygiene and ease of use, eliminating a potential contamination step and simplifying application. Moreover, CS Protect Hydrogel's molecular structure and properties enable it to be used in multiple cancer types beyond prostate cancer – e.g. cervical, esophageal, bladder, and breast cancer – whereas the competitor's spacer gel is approved exclusively for prostate use. Management believes these unique advantages (broader applicability, improved safety and convenience) give CS Protect Hydrogel a strong unique selling proposition (USP) in the tissue space market. The Hydrogel remains under development in terms of regulatory approval: it has demonstrated promising results in trials and is expected to quickly gain market share once marketing authorization is obtained. However, the commercial launch will entail significant costs for clinical trials, regulatory approvals, and marketing efforts in each target jurisdiction. On March 2025 the company announced the appointment of an FDA agent to pursue an FDA approval for its CS Protect Hydrogel.

**<u>Unique Selling Proposition (USP) of CS Protect Hydrogel</u>**

The CS Protect-Hydrogel is a more advanced hydrogel both from the molecular structure, chemical physical properties and medical applications. Compared to the competitor product of Boston Scientific Corporation, CS Protect-Hydrogel has the following practical, hygienic, medical and economic advantages:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Easy application of the CS Protect-Hydrogel since it is a "ready-to-use" product - avoidance of a further work step immediate
application of the CS Protect- Hydrogel after removal from sterile packaging no risk of contamination due to preparation and assembly
of the product exclusion of another hygienic risk area within the treatment room.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. No risk of wrong mixture (especially wrong sequence) and therefore no potential patient's missed appointment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Extended application range; besides prostate cancer also for cervical, esophageal, bladder and breast cancer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Lower personnel costs during treatment due to the elimination of assistance for mixing the hydrogel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. Lower room utilization costs per patient as there is no longer a risk of patients having to be treated again due to incorrect mixtures
(higher number of patients per treatment room) lower cleaning costs due to the ready-to-use principle.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. Fewer lawsuits and/or insurance claims due to incorrectly mixed hydrogels requiring the patient to be treated again.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. Lower purchase price as for the competitor product.

**<u>Regulatory Matters and Compliance</u>**

The CS Protect-Hydrogel is a medical device and requires registration or approval by the respective governmental authorities, in particular the Food and Drug Administration (FDA) in the USA or the Federal Institute for Drugs and Medical Devices (BfArM) after CE testing and certification in Germany. Registration or approval is preceded by a testing procedure. The CS Diagnostics Group anticipates a period of 6 to 12 months for approval in the U.S. and 6 to 8 months for the testing procedure and registration of the CS Protect-Hydrogel in Germany.

5 www.csdcorp.us

![](cscorp_logosm.jpg)

**MEDUSA (Long-Acting Disinfectant)**

MEDUSA is a proprietary surface disinfectant product developed by CS Diagnostics with an emphasis on long-lasting efficacy and environmental/consumer safety. MEDUSA's formulation provides an extended duration of antimicrobial protection on surfaces – lasting up to 10 days after application, compared to mere hours for many competing disinfectants. The product includes color-changing test strips that allow users to verify the concentration of the active ingredient over time. Because of its long-acting effect, surfaces treated with MEDUSA can be periodically wiped with water between applications without fully removing its protective action. Notably, MEDUSA remains effective even in the presence of organic material (*e.g.* dirt or bodily fluids) on surfaces, an advantage over many existing disinfectants. MEDUSA has already been fully developed and has demonstrated its efficacy in studies (including showing >6-log reduction in viral load for an enveloped virus after 10 days on a treated surface). The Company indicates that obtaining regulatory approvals for MEDUSA as a disinfectant is expected to be straightforward, since the formulation and use-case align with existing regulations for surface disinfectants. CS Diagnostics has reported that it already has several distribution agreements or purchase commitments in place contingent on initial production, and that the primary barrier to commercialization is securing the funds to commence the first large-scale manufacturing lot. MEDUSA's go-to-market strategy will focus on healthcare and institutional markets seeking long-lasting infection control solutions.

**<u>Efficiency of MEDUSA</u>**

To assess the efficacy of MEDUSA, a surface disinfectant, after 10 days on a metal surface. To simulate an area treated with MEDUSA, sterilized test surfaces were sprayed perpendicularly from a distance of 20cm, one pump at a time. As a control, test areas were sprayed with PBS alone. All test areas were then stored under sterile conditions for 10 days at room temperature. After this period, 50μL of the test organisms were dropped onto the test areas and incubated at room temperature for 15 minutes. 1mL of neutralizing solution was then added to stop the action of MEDUSA. A disinfecting effect was determined based on the reduction in the colony forming units (CFU) for bacteria and fungi or the plaque forming units (PFU) for viruses compared to an untreated control sample. A positive effect was determined as a ≥ 5 log reduction for bacteria or ≥ 4 log reduction for viruses and yeasts/fungi.

After 10 days the test solutions of MEDUSA conferred a strong, limited virucidal effect to the surface, demonstrating a greater than 6-log reduction in PFU of Phi-6. A slight reduction in CFU for gram-positive bacteria, gram-negative bacteria and yeasts/fungi was noted. While the necessary log reductions to denote bactericidal/yeasticidal properties were not obtained, it is interesting to note that a mild reduction was observable, nonetheless.

After 10 days on the surface, MEDUSA retained strongly virucidal properties against an enveloped virus, Phi-6.

Medusa is fully Authorized in the European Markets and in the UAE, with manufacturing sites in UAE, Turkey and UK. In June 2025, the company-initiated discussions with an EPA agent to be appointed to pursue full marketing authorization within the US market.

6 www.csdcorp.us

![](cscorp_logosm.jpg)

**Leased Offices**

We are currently leasing our office spaces located in the following location:

&nbsp;&nbsp;&nbsp;&nbsp;· City of Neuss in Germany (headquarter)

&nbsp;&nbsp;&nbsp;&nbsp;· City of Bruckmühl in Germany

&nbsp;&nbsp;&nbsp;&nbsp;· Dubai, United Arab Emirates

You can find more information about our business on our website at: http://csdcorp.us/

**RISK FACTORS**

*Investing in our company's securities involves a high degree of risk. You should carefully consider and review the risks described below, together with all other information included or referred to in this report before purchasing our shares. There are numerous risks and uncertainties that are not known to us as of the time of this report and we might not consider its significance, which could adversely affect our business, financial condition, or results of operations. In such event, the trading price of our common stock could decline and you may lose all or part of your investment.*

**Risks Related to the Company**

*We expect to incur operating losses and experience negative cash flow and it is uncertain whether we will achieve future profitability.*

We anticipate incurring operating losses until we generate sufficient revenue from our operations. Achieving profitability depends on our ability to ensure our products function as intended, gain market acceptance, and successfully develop and launch additional products and, or services. We cannot guarantee that we will generate sales or reach profitability. As a result, we cannot predict the extent of future losses or how long it may take to achieve profitability, if at all.

*We may need to raise additional funds to finance our capital requirements, which is dilutive to your investment.*

Our cash requirements may vary materially from those now planned depending on numerous factors, including the status of our marketing efforts, our business development activities, the results of future research and development and competition. We may need to raise additional funds to finance our capital requirements through private or public financing before such point for a variety of reasons, including our inability to achieve more substantial revenue operations as we anticipated, and to achieve a profitable level of operations. Such financing could include equity financing, which may be dilutive to members, or debt financing, which would likely restrict our ability to make acquisitions and borrow from other sources. In addition, such securities may contain rights, preferences or privileges senior to those of the rights of our current shareholders. We do not currently have any commitments for additional financing. There can be no assurance that additional funds will be available on terms attractive to us or at all. If adequate funds are not available, we may be required to curtail our pre-production, sales and research and development activities and/or otherwise materially reduce our operations. Any inability to raise adequate funds could have a material adverse effect on our business, results of operation and financial condition.

*We may not be able to attain profitability without additional funding, which may be unavailable.*

We have limited capital resources. Unless we begin to generate sufficient revenues to finance operations as a going concern, the Company may experience liquidity and solvency problems. Such liquidity and solvency problems may force the Company to cease operations if additional financing is not available. No known alternative resources of funds are available in the event we do not generate sufficient funds from operations.

7 www.csdcorp.us

![](cscorp_logosm.jpg)

*Our lack of history makes evaluating our business difficult.*

We have a limited operating history and we may not sustain profitability in the future. In order to obtain and sustain profitability, we must:

- compete with larger, more established competitors;

- build, maintain, and enhance our portfolio of pharmaceutical products as well as our overall brand recognition; and

- adapt to meet changes in our markets and competitive developments.

We may not be successful in accomplishing these objectives. Further, our lack of operating history makes it difficult to evaluate our business and prospects. Our prospects must be considered in light of the risks, uncertainties, expenses and difficulties frequently encountered by companies in their early stages of development, particularly companies in highly competitive industries. The historical information in this report may not be indicative of our future financial condition and future performance.

*Our Articles of Incorporation and Bylaws limit the liability of, and provide indemnification for, our officers and directors.*

Our Articles of Incorporation, generally limits our officers' and directors' personal liability to the Company and its members for breach of fiduciary duty as an officer or director except for breach of the duty of loyalty or acts or omissions not made in good faith or which involve intentional misconduct or a knowing violation of law. Our Articles of Incorporation and Bylaws, provide indemnification for our officers and directors to the fullest extent authorized by the Wyoming Business Corporation Act against all expense, liability, and loss, including attorney's fees, judgments, fines excise taxes or penalties and amounts to be paid in settlement reasonably incurred or suffered by an officer or director in connection with any action, suit or proceeding, whether civil or criminal, administrative or investigative (hereinafter a "Proceeding") to which the officer or director is made a party or is threatened to be made a party, or in which the officer or director is involved by reason of the fact that he is or was an officer or director of the Company, or is or was serving at the request of the Company whether the basis of the Proceeding is an alleged action in an official capacity as an officer or director, or in any other capacity while serving as an officer or director. Thus, the Company may be prevented from recovering damages for certain alleged errors or omissions by the officers and directors for liabilities incurred in connection with their good faith acts for the Company. Such an indemnification payment might deplete the Company's assets. Members who have questions regarding the fiduciary obligations of the officers and directors of the Company should consult with independent legal counsel. It is the position of the Securities and Exchange Commission that exculpation from and indemnification for liabilities arising under the Securities Act of 1933, as amended, and the rules and regulations thereunder is against public policy and therefore unenforceable.

**Risks Related to Business Operations**

*Adverse economic or other conditions in the markets in which we do business could negatively affect our occupancy levels and rental rates and therefore our operating results.*

Our operating results are dependent upon our ability to commercialize our technology. If our technologies fail to generate revenues sufficient to meet our cash requirements, including operating and other expenses, debt service and capital expenditures, our net income, funds from operation (FFO), cash flow, financial condition, ability to make distributions to members and common unit trading price could be adversely affected. The following factors, among others, may adversely affect the operating performance of our properties:

- the national economic climate and the local or regional economic climate in the markets in which we operate, which may be adversely impacted by, among other factors, industry slowdowns, relocation of businesses and changing demographics;

8 www.csdcorp.us

![](cscorp_logosm.jpg)

- increased operating costs, including need for research and development, salaries and rent;

- changes in supply of or demand for similar or competing products;

- the impact of changes in regulation;

- earthquakes and other natural disasters, terrorist acts, civil disturbances or acts of war which may result in uninsured or underinsured losses; and

- changes in tax policy.

*Our future revenue and reputation may be affected by litigation or other liability claims.*

We have not procured a general liability insurance policy for our business. To the extent that we suffer a loss of a type which would normally be covered by general liability, we would incur significant expenses in defending any action against us and in paying any claims that result from a settlement or judgment against us. Adverse publicity could result in a loss of consumer confidence in our products.

*As we increase operations, our earnings may be sensitive to fluctuations in market prices and demand for our products and services.*

In addition, after we commence operations, the demand for our pharmaceutical products could decline, whether because of supply or for any other reason, including competing products considered to be superior by end users. A decrease in the selling price received for our products or a decline in demand for our products after we commence operations could have a material adverse effect on our business, results of operations and financial condition

*We have limited marketing capability.*

We have limited marketing capabilities and resources. In order to achieve market penetration, we will have to undertake significant efforts and expenditures to create awareness of, and demand for, our products and services. Our ability to penetrate the market and build our customer base will be substantially dependent on our marketing efforts. Our failure to successfully develop our marketing capabilities, both internally and through third-party alliances, would have a material adverse effect on our business, operating results and financial condition. Further, there can be no assurance that, if developed, such marketing capabilities will lead to sales of our products and services.

*Our investments in product research and development may not yield anticipated returns, which would harm our operating results and reduce the amount of funds available for distributions.*

A key component of our growth strategy is exploring new and innovative pharmaceutical products through strategic acquisition, licensing and joint ventures. To the extent that we engage in these development and redevelopment activities, they will be subject to the following risks normally associated with these projects:

- we may be unable to obtain financing for these projects on favorable terms or at all;

- we may not complete development projects on schedule or within budgeted amounts;

9 www.csdcorp.us

![](cscorp_logosm.jpg)

- we may encounter delays or refusals in obtaining all necessary regulatory approvals to distribute and sell our products to the public; and

- we may encounter competition from more established and better capitalized companies in our industry.

*We depend heavily on key personnel, and turnover of key senior management could harm our business.*

Our future business and results of operations depend in significant part upon the continued contributions of our Chief Executive Officer. If we lose his services or if he fails to perform in his current position, or if we are not able to attract and retain skilled employees as needed, our business could suffer. A significant turnover in our senior management could significantly deplete our institutional knowledge held by our existing senior management team. We depend on the skills and abilities of these key employees in managing the product development, marketing and sales aspects of our business, any part of which could be harmed by turnover in the future.

*Because we have a limited history of operations, we may not be able to successfully implement our business plan.*

As a development stage company, we have less than two years of operational history in our industry. Accordingly, our operations are subject to the risks inherent in the establishment of a new business enterprise, including access to capital, successful implementation of our business plan, and limited revenue from operations. We cannot assure you that our intended activities or plan of operation will be successful or result in revenue or profit to us and any failure to implement our business plan may have a material adverse effect on the business of the Company.

*If we fail to effectively manage our growth, our business, brand and reputation, results of operations and financial condition may be adversely affected.*

We may experience rapid growth in operations, which may place significant demands on our management team and our operational and financial infrastructure. As we continue to grow, we must effectively identify, integrate, develop and motivate new employees, and maintain the beneficial aspects of our corporate culture. To attract top talent, we believe we will have to offer attractive compensation packages. The risks of over-hiring or over-compensation and the challenges of integrating a rapidly growing employee base may impact profitability.

Additionally, if we do not effectively manage our growth, the quality of our product offerings could suffer, which could adversely affect our business, brand and reputation, results of operations and financial condition. If operational, research and development and staffing improvements are not implemented successfully, our ability to manage our growth will be impaired and we may have to make significant additional expenditures to address these issues. To effectively manage our growth, we will need to continue to improve our operational, financial and management controls and our reporting systems and procedures.

*We operate in both mature and developing markets, and there is uncertainty as to acceptance of our products and services in these markets.*

We researched the markets for our pharmaceutical products using our own personnel rather than third parties. We have conducted limited test marketing and thus have relatively little information on which to estimate our levels of sales, the amount of revenue our planned operations will generate and our operating and other expenses. There can be no assurance that we will be successful in our efforts to market our products or to develop our markets in the manner we contemplate.

Certain markets are developing and rapidly evolving and are characterized by an increasing number of market entrants who have developed or are developing a wide variety of products and technologies, a number of which offer certain of the features that our products offer. Because of these factors, demand and market acceptance for new products are subject to a high level of uncertainty. Thus, there can be no assurance that our products will become widely accepted. It is also difficult to predict with any assurance the future growth rate, if any, and size of these markets. If a substantial market fails to develop, develops more slowly than expected or becomes saturated with competitors or if our products do not achieve market acceptance, our business, operating results and financial condition will be materially and adversely affected.

10 www.csdcorp.us

![](cscorp_logosm.jpg)

*There is a significant amount of competition in our market.*

Our target market is extremely competitive. Competitive factors in the pharmaceutical industry inclusive innovation, cost and other factors. Our primary competitors are expected to include companies with substantially greater financial, technological, marketing, personnel and research and development resources than we currently have. There are direct competitors who have competitive product offerings for the markets we will seek to sell our products in. Further, there can be no assurance that new companies will not enter our markets in the future. Although we believe that our business model will be distinguishable from those of our competitors on the basis of our innovative research and development strategy, there can be no assurance that we will be able to penetrate any of our anticipated competitors'' portions of the market. There can be no assurance that we will be able to compete successfully against currently anticipated or future competitors or that competitive pressures will not have a material adverse effect on our business, operating results and financial condition.

*We are uncertain of our ability to protect our proprietary products.*

In addition to seeking patent protection, we rely on trade secrets, know-how and continuing technological advancement to achieve and thereafter maintain a competitive advantage. Although we have entered into or intend to enter into confidentiality and invention agreements with our employees, consultants, certain potential customers and advisors, no assurance can be given that such agreements will be honored or that we will be able to effectively protect our rights to our unpatented trade secrets and know-how. Moreover, no assurance can be given that others will not independently develop substantially equivalent proprietary information and development techniques or otherwise gain access to our trade secrets and know-how.

*We have not completed our trademark registrations.*

We have not filed for protection for any trademarks in connection with our proposed business and marketing activities. Although we intend to pursue the registration of our marks in the United States and other countries, there can be no assurance that prior registrations and/or uses of one or more of such marks, or a confusingly similar mark, does not exist in one or more of such countries, in which case we might be precluded from registering and/or using such mark in certain countries.

*There are economic and general risks relating to business.*

The success of our activities is subject to risks inherent in business generally, including demand for products and services; general economic conditions; changes in taxes and tax laws; and changes in governmental regulations and policies.

*We may be subject to regulatory inquiries, claims, suits and prosecutions which may impact on our profitability.*

Any failure or perceived failure by us to comply with applicable laws and regulations, in general, may subject us to regulatory inquiries, claims, suits and prosecutions. We can give no assurance that we will prevail in such regulatory inquiries, claims, suits and prosecutions on commercially reasonable terms or at all. Responding to, defending and/or settling regulatory inquiries, claims, suits and prosecutions may be time-consuming and divert management and financial resources or have other adverse effects on our business. A negative outcome in any of these proceedings may result in changes to or discontinuance of some of our services, potential liabilities or additional costs that could have a material adverse effect on our business, results of operations, financial condition and future prospects.

11 www.csdcorp.us

![](cscorp_logosm.jpg)

*The laws and regulations concerning data privacy and data security are continually evolving, and our actual or perceived failure to comply with these laws and regulations could harm our business.*

We are and will be subject to federal, state and foreign laws regarding privacy and the protection of the information that we collect regarding our users, which laws are currently in a state of flux and likely to remain so for the foreseeable future. If we fail to follow existing laws and regulations with respect to privacy-related matters or if consumers raise any concerns about our privacy practices, even if unfounded, it could damage our reputation and operating results.

In the area of information security and data protection, many states have passed laws requiring notification to users when there is a security breach for personal data or requiring the adoption of minimum information security standards that are often vaguely defined and difficult to implement. Costs to comply with these laws may increase as a result of changes in interpretation. Furthermore, any failure on our part to comply with these laws may subject us to significant liabilities. Security measures that we put in place to protect our data and the personal information of our employees, customers and partners could be breached due to cyber-attacks initiated by third party hackers, employee error or malfeasance, or otherwise. Because the techniques used to obtain unauthorized access, to disable or degrade service or to sabotage systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures. Any breach or unauthorized access could materially interfere with our operations or our ability to offer our services or result in significant legal and financial exposure, damage to our reputation and a loss of confidence in the security of our data, which could have an adverse effect on our business and operating results.

*We may be liable if third parties misappropriate our customers' personal information.*

If third parties are able to penetrate our network security or otherwise misappropriate our customers' personal information or credit card information, or if we give third parties improper access to our customers' personal information or credit card information, we could be subject to liability. This liability could include claims for unauthorized purchases with credit card information, impersonation or other similar fraud claims. This liability could also include claims for other misuses of personal information, including unauthorized marketing purposes.

These claims could result in litigation. Liability for misappropriation of this information could adversely affect our business. In addition, the Federal Trade Commission and state agencies have been investigating various Internet companies regarding their use of personal information. We could incur additional expenses if new regulations regarding the use of personal information are introduced or if government agencies investigate our privacy practices.

We rely on encryption and authentication technology licensed from third parties to provide the security and authentication necessary to effect secure transmission of confidential information such as customer credit card numbers. We cannot assure you that advances in computer capabilities, new discoveries in the field of cryptography or other events or developments will not result in a compromise or breach of the algorithms that we use to protect customer transaction data. If any such compromise of our security were to occur, it could harm our reputation, business, prospects, financial condition and results of operations. A party who is able to circumvent our security measures could misappropriate proprietary information or cause interruptions in our operations. We may be required to expend significant capital and other resources to protect against such security breaches or to alleviate problems caused by such breaches. We cannot assure you that our security measures will prevent security breaches or that failure to prevent such security breaches will not harm our business, prospects, financial condition and results of operations.

**Risks Associated with the Pharmaceutical Industry**

*Regulatory Approval and Compliance Risks*

The pharmaceutical industry is heavily regulated by government authorities, including the U.S. Food and Drug Administration (FDA) and similar agencies in other countries. The development, manufacturing, marketing, and sale of pharmaceutical products are subject to rigorous approval processes and ongoing regulatory compliance. Delays, denials, or the inability to obtain required regulatory approvals could materially and adversely affect the Company's operations and financial performance.

12 www.csdcorp.us

![](cscorp_logosm.jpg)

*Research and Development Risks*

The Company's success depends on its ability to develop and commercialize new pharmaceutical products. The process of research and development (R&D) is expensive, time-consuming, and subject to high levels of uncertainty. There is no guarantee that the Company's R&D efforts will result in successful products, or that these products will achieve market acceptance.

*Dependence on Key Products*

The Company may rely heavily on one or more key products for a substantial portion of its revenue. Any disruption in the production, approval, or market acceptance of these products could have a material adverse effect on the Company's financial performance.

*Competition and Market Risks*

The pharmaceutical industry is highly competitive, with many companies, including large multinational corporations, competing for market share. Competitors may develop and market products that are more effective, safer, or less expensive than the Company's products, which could adversely affect its ability to compete successfully.

*Patent Protection and Intellectual Property Risks*

The Company's success depends on its ability to protect its proprietary technology and products through patents and other intellectual property rights. There is no guarantee that the Company will obtain or maintain adequate intellectual property protection. Patent challenges, infringement claims, or the expiration of key patents could adversely affect the Company's competitive position and profitability.

*Manufacturing and Supply Chain Risks*

The pharmaceutical manufacturing process is complex and subject to strict regulatory oversight. The Company may face risks related to supply chain disruptions, manufacturing delays, quality control issues, or reliance on third-party suppliers and contract manufacturers. Any such disruptions could harm the Company's operations and reputation.

*Liability and Litigation Risks*

Pharmaceutical companies are frequently subject to product liability claims and litigation. The Company may face lawsuits related to its products, alleging adverse side effects, improper marketing, or other claims. Such litigation could result in significant legal costs, settlements, or judgments, as well as reputational damage.

*Pricing and Reimbursement Risks*

The pricing of pharmaceutical products is subject to government regulations, healthcare policies, and negotiations with payers, including insurance companies and government programs. Changes in pricing regulations, reimbursement policies, or pricing pressure from payers could negatively impact the Company's revenue and profitability.

*Market Acceptance and Commercialization Risks*

Even if the Company successfully develops and obtains regulatory approval for its products, there is no assurance that these products will achieve market acceptance. Factors such as competition, pricing, marketing strategies, and healthcare provider preferences may impact the commercial success of the Company's products.

13 www.csdcorp.us

![](cscorp_logosm.jpg)

*Dependence on Key Personnel*

The Company's success depends on its ability to attract, retain, and motivate highly skilled executives, scientists, and other key personnel. The loss of key employees or the inability to recruit additional qualified personnel could adversely affect the Company's operations and development efforts.

*Risks Related to Changes in Laws and Regulations*

The pharmaceutical industry is subject to frequent changes in laws, regulations, and policies. Changes in healthcare reform, drug approval processes, or other regulatory requirements could increase costs, delay product development, or otherwise negatively impact the Company's business.

*Global Market and Economic Risks*

The Company may operate in or sell products to international markets, exposing it to risks such as currency fluctuations, geopolitical instability, trade restrictions, and economic conditions in foreign countries. These factors could affect the Company's ability to conduct business globally.

*Risks Related to COVID-19 or Other Pandemics*

The pharmaceutical industry may be directly impacted by public health emergencies, including pandemics such as COVID-19. Such events could disrupt the Company's supply chain, R&D efforts, regulatory approval processes, or market demand for its products.

**Risks Related to being a Publicly Traded Company**

*Market Volatility*

The Company's common stock is publicly traded, and the market price of the stock may experience significant volatility due to various factors, including financial results, changes in the Company's business or industry, general market conditions, and economic trends. Such volatility may impact on the valuation of the Company and, indirectly, the value of the Shares.

*Potential Dilution* 

As a publicly traded company, the Company may issue additional shares of common or preferred stock in the future, which could dilute the interests of existing shareholders, including investors in the offered securities. Such dilution may result from financing activities, employee compensation plans, or strategic transactions.

*Dependence on Market Perception* 

The performance and valuation of the Company's publicly traded common stock may depend significantly on market perception and investor sentiment. Negative news, adverse developments, or unfavorable market conditions could harm the Company's reputation and adversely impact its financial condition and operations.

*Compliance with Public Company Reporting Obligations* 

As a publicly traded company, the Company is subject to periodic reporting and other disclosure requirements under applicable securities laws. Compliance with these obligations involves significant costs, and any failure to timely or accurately meet these requirements could result in regulatory penalties, reputational harm, and adverse impacts on the Company's financial performance.

14 www.csdcorp.us

![](cscorp_logosm.jpg)

*Insider Ownership and Control*

The Company's officers, directors, and significant shareholders may hold a substantial portion of the Company's publicly traded common stock, which could give them significant control over matters requiring shareholder approval, including corporate transactions. This control could conflict with the interests of other investors.

*Risks of Delisting or Trading Suspension* 

The Company's common stock is listed on OTC Markets. If the Company fails to meet applicable listing or trading requirements, its stock could be delisted or suspended from trading, which could significantly impair its liquidity and value, as well as the Company's ability to raise capital.

*Litigation and Regulatory Risks* 

Publicly traded companies often face heightened risks of shareholder litigation, regulatory scrutiny, and enforcement actions. Such risks could result in significant legal costs, settlements, or damages and may adversely impact the Company's financial condition.

*Impact of Securities Laws on Resale of Shares* 

The Company's status as a publicly traded company may subject investors to certain legal and regulatory restrictions on the resale of the offered securities, particularly if the resale involves significant ownership stakes or affiliates of the Company.

*Disclosure of Material Non-Public Information* 

As a publicly traded company, the Company must carefully manage its disclosure obligations. Purchasers of the offered securities should be aware that they may, at times, have access to material non-public information that could restrict their ability to trade in the Company's publicly traded securities under applicable insider trading laws.

*Risks Related to the Shares*

Our Officers and Directors owns a significant percentage of our outstanding voting securities which could reduce the ability of minority securities holders to effect certain corporate actions. Their ownership and control may also have the effect of delaying or preventing a future change in control, impeding a merger, consolidation, takeover or other business combination or discourage a potential acquirer from making a tender offer.

*There may not be funds available for net income because our Officers and Directors maintain significant control and can determine their own salary and perquisites.*

Our Officers and Directors own a majority of our outstanding voting securities. As a result, there may not be funds available for net income because he maintains significant control and can determine his own salary and perquisites.

*We may, in the future, issue additional Shares which would reduce investors' percentage of ownership and may dilute our common membership unit value.*

Our Articles of Incorporation authorize the issuance of 4,000,000 shares of the Series C Preferred Stock. The issuance of Preferred Stock for future services or acquisitions or other corporate actions may have the effect of diluting the value of the units held by our investors and might have an adverse effect on any trading market for our common units.

15 www.csdcorp.us

![](cscorp_logosm.jpg)

*We are subject to compliance with securities law, which exposes us to potential liabilities, including potential rescission rights.*

We may offer to sell our securities to investors pursuant to certain exemptions from the registration requirements of the Securities Act of 1933, as well as those of various state securities laws. The basis for relying on such exemptions is factual; that is, the applicability of such exemptions depends upon our conduct and that of those persons contacting prospective investors and making the offering. We may not seek any legal opinion to the effect that any such offering would be exempt from registration under any federal or state law. Instead, we may elect to relay upon the operative facts as the basis for such exemption, including information provided by investor themselves. If any such offering did not qualify for such exemption, an investor would have the right to rescind its purchase of the securities if it so desired. It is possible that if an investor should seek rescission, such investor would succeed. A similar situation prevails under state law in those states where the securities may be offered without registration in reliance on the partial preemption from the registration or qualification provisions of such state statutes under the National Securities Markets Improvement Act of 1996. If investors were successful in seeking rescission, we would face severe financial demands that could adversely affect our business and operations. Additionally, if we did not in fact qualify for the exemptions upon which it has relied, we may become subject to significant fines and penalties imposed by the SEC and state securities agencies.

*There is no current established trading market for our Shares and if a trading market does not develop, purchasers of our securities may have difficulty selling their Shares.*

There is currently no established public trading market for our Shares and an active trading market in our Shares may not develop or, if developed, may not be sustained. No market makers have committed to becoming market makers for our Shares and none may do so in the future.

*Because we do not intend to pay any cash dividends on our Shares our members will not be able to receive a return on their Shares unless they sell them.*

We intend to retain any future earnings to finance the development and expansion of our business. We do not anticipate paying any cash dividends on our Shares in the foreseeable future. Unless we pay dividends, our members will not be able to receive a return on their Shares unless they sell them. There is no assurance that members will be able to sell Shares when desired.

*Following on next page*

16 www.csdcorp.us

![](cscorp_logosm.jpg)

**SECURITY OWNERSHIP**

**Principal Shareholders**

The following table sets forth information, as of the date of this Memorandum, with respect to the number of Shares of common stock of the Company beneficially owned by (i) individual directors, by all directors and officers of the Company as a group; (ii) persons known by the Company to own more than five percent (5%) of the Company's common stock; and (iii) consultants.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name of <br> Officer/Director or <br> Control Person** | **Affiliation with Company**<br> **(Officer/Director/Owner of<br> more than 5%)** | **Number of shares <br> owned** | **Share <br> type/class** | **Ownership<br> Percentage of**<br> **Class<br> Outstanding** |
| Thomas Fahrhoefer | President | 91881896 | Common | 67% |
| Thomas Fahrhoefer | President | 10 | Preferred A | 100% |
| Thomas Fahrhoefer | President | 13665206 | Preferred B | 68% |
| Thomas J Migotsch | Chief Operational Officer | 480.000 | N/A | .004% |
| CS Diagnostics Pharma GmbH | More than 5% | 74855800 | Common | 54.5% |
| CS Diagnostics Pharma GmbH | More than 5% | 10 | Preferred A | 100% |
| CS Diagnostics Pharma GmbH | More than 5% | 7924180 | Preferred B | 39.6% |
| CS Interpharm General Trading Co.<br> LLC | More than 5% | 17026096 | Common | 12.3% |
| CS Interpharm General Trading Co.<br> LLC | More than 5% | 5731026 | Preferred B | 28.6% |
| Association Continental de Reassurance NV | More than 5% | 3500000 | Common | 2.5% |
| Association Continental de Reassurance NV | More than 5% | 1499625 | Preferred B | 7.5% |
| Thomas Graus | More than 5% | 3700000 | Common | 2.7% |
| Thomas Graus | More than 5% | 1273737 | Preferred B | 6.4% |
| Antonio Santoli | More than 5% | 3800000 | Common | 2.7% |
|  |  | 1273737 | Preferred B | 6.4% |

---

**Beneficial Owners and Management**

The following table sets forth information with respect to the beneficial information of our Common Stock as of March 31, 2025, for:

&nbsp;&nbsp;&nbsp;&nbsp;· Each person who we know beneficially owns more than 5% of our Common Stock,

&nbsp;&nbsp;&nbsp;&nbsp;· Each person who we know beneficially owns more than 5% of our Preferred A Stock,

&nbsp;&nbsp;&nbsp;&nbsp;· Each person who we know beneficially owns more than 5% of our Preferred B Stock,

&nbsp;&nbsp;&nbsp;&nbsp;· Each of our directors, and

&nbsp;&nbsp;&nbsp;&nbsp;· Each of our executive officers.

*Following on next page*

 

17 www.csdcorp.us

 

 

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name of <br> Officer/Director or <br> Control Person** | **Affiliation with Company**<br> **(Officer/Director/Owner of<br> more than 5%)** | **Number of shares <br> owned** | **Share <br> type/class** | **Ownership<br> Percentage of**<br> **Class<br> Outstanding** |
| Thomas Fahrhoefer | President | 91881896 | Common | 67% |
| Thomas Fahrhoefer | President | 10 | Preferred A | 100% |
| Thomas Fahrhoefer | President | 13665206 | Preferred B | 68% |
| Thomas J Migotsch | Chief Operational Officer | 480.000 | N/A | .004% |
| Mohammad EsSayed | Chief Financial Officer | 0 | N/A | N/A |
| Janel Luzana | Company Secretary | 0 | N/A | N/A |
| CS Diagnostics Pharma GmbH | More than 5% | 74855800 | Common | 54.5% |
| CS Diagnostics Pharma GmbH | More than 5% | 10 | Preferred A | 100% |
| CS Diagnostics Pharma GmbH | More than 5% | 7924180 | Preferred B | 39.6% |
| CS Interpharm General Trading Co.<br> LLC | More than 5% | 17026096 | Common | 12.3% |
| CS Interpharm General Trading Co.<br> LLC | More than 5% | 5731026 | Preferred B | 28.6% |
| Association Continental de Reassurance NV | More than 5% | 3500000 | Common | 2.5% |
| Association Continental de Reassurance NV | More than 5% | 1499625 | Preferred B | 7.5% |
| Thomas Graus | More than 5% | 3700000 | Common | 2.7% |
| Thomas Graus | More than 5% | 1273737 | Preferred B | 6.4% |
| Antonio Santoli | More than 5% | 3800000 | Common | 2.7% |
|  |  | 1273737 | Preferred B | 6.4% |

---

**DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE<br> GOVERNANCE**

**Directors and Officers**

The following table sets forth the names, positions and ages of our directors and/or executive officers. Our directors were elected by the majority written consent of our stockholders in lieu of a shareholder's disclosure. Our directors are elected at each annual meeting and serve for one year and until their successors are elected and qualified. Officers are elected by our board of directors and their office terms are at the discretion of our board.

---

| | |
|:---|:---|
| Name | Position |
| Thomas Fahrhoefer | President, Chief Executive Officer, & Chairman of the Board of Directors |
| Mohammad EsSayed | Vice President, Chief Financial Officer, & Director |
| Sabrina Kummer Godehardt | Business Development, & Director |
| Janel Luzana | Corporate Secretary |
| Mahmoud A. Al-Sayyed | Independent Director |
| Dr. Ralf Herwig | Independent Director |

---

18 www.csdcorp.us

![](cscorp_logosm.jpg)

**Thomas Fahrhoefer**

Mr. Fahrhoefer, born in 1970, is the founder of the CS Diagnostics Group and an expert in pharmaceutical distribution and healthcare business developmentfile-7ishfdm411rdeduxkgarhj. After studies in medicine and pharmacy, he built a career in pharmaceutical sales and management, including roles at Pfizer Germany (2001–2003) and Sanochemia AG (in the diagnostics business unit). In 2009, Mr. Fahrhoefer founded CS Diagnostics in Germany, growing it into the current CS Diagnostics Group comprising CS Diagnostics Pharma GmbH, CS Interpharm LLC, and CS Diagnostics Corp.file-7ishfdm411rdeduxkgarhj. Under his leadership, the Company is pursuing innovative solutions like the CS Protect Hydrogel. Mr. Fahrhoefer has been the President and a Director of the Company since the April 2022 change-in-control, and he also serves as the Chairman of the Board.

**Mohammad EsSayed**

Born in 1978, has over 22 years of professional experience in finance, banking, and executive management. He holds multiple finance degrees and certifications, including an MBA in International Corporate Banking and the CFA (Chartered Financial Analyst) designation. Prior to joining CS Diagnostics, Mr. EsSayed served as CFO and Managing Director for other companies, and he has a strong background in financial planning, corporate finance, and governance. CS Diagnostics benefits from his extensive financial management experience. He was appointed as CFO and Vice President of the Company in 2022. In this capacity, Mr. EsSayed manages the Company's financial strategy, accounting and reporting, and investor relations functions.

**Sabrina Kummer Godehardt**

Sabrina Godehardt, born on March 16, 1980 in Bad Langensalza, Germany is a certified office communication clerk with over 15 years of experience in medical administration and practice management. She worked as practice manager in a radiology and nuclear medicine clinic from 2015 to 2024, with additional responsibility for IT systems. Since June 2024, she serves as Head of Sales Coordination at CS Diagnostics Pharma GmbH. She holds IHK certifications in practice and marketing management and is proficient in MS Office, Lexware, PACS/RIS systems, and various administrative tools.

**Janel Luzana**

Ms. Luzana serves as the Company's Corporate Secretary, responsible for corporate records, compliance with corporate governance requirements, and assisting the executive team on legal/administrative matters. She joined the Board as part of the 2022 reorganization. Ms. Luzana's professional biography is not elaborated in the available disclosure, but she is identified as the Corporate Secretary in official filings.

**Mahmoud A. Al-Sayyed**

Mahmoud A. Al-Sayyed is a senior executive nearly three decades of experience in investment advisory, corporate strategy, and governance. His background includes expertise in IPOs, mergers and acquisitions, business valuation, and financial modeling. He has held various leadership and board positions, bringing a wealth of management and oversight experience. Mr. Al-Sayyed's career highlights include developing corporate strategies, executing performance management programs, and serving on supervisory boards and board committees in an advisory capacity. He joined CS Diagnostics Corp. as an independent Board member to provide guidance on corporate finance, strategy, and compliance.

**Dr. Ralf Herwig**

Dr. Ralf Herwig is a board-certified physician since 1995 with a doctorate in medicine (magna cum laude) and habilitation in urology. He holds professorial titles and serves as President of both the Austrian Andrological Society and the International Autism Association (2025). His expertise spans urology, andrology, minimally invasive surgery, molecular biology, and sexual medicine, supported by extensive scientific training and over a dozen memberships in international medical societies. He is Editor-in-Chief of multiple scientific journals and has received several prestigious awards for his research.

19 www.csdcorp.us

![](cscorp_logosm.jpg)

**Executive Compensation**

On July 18<sup>th</sup> 2025, a shareholder resolution has been issued for changes in CSDX board of directors as follows:

Mr. Thomas Migotsch as well as the previous independent director Dr. Lauren Kate Ugur were replaced by Ms. Sabrina K. Godehardt as Director of Business Development, and Dr. Ralf Herwig as independent director.

On August 9<sup>th</sup> 2024, a shareholder resolution has been issued for changes in CSDX board of directors as follows: Mr. Thomas Migotsch and Mr. Thomas Graus as well as the previous independent directors Mrs. Csilla Kanderka and Mrs. Delia-Alexandra Kreutner were replaced by Mr. Mohammad EsSayed as VP, Director and CFO, Mr. Thomas Migotsch remains a director and assigned as COO, Dr. Lauren Ugur and Mr. Mahmoud Ahmad Hashim AL-Sayed take on their role as independent directors, and Ms. Janel Luzana as an Officer and Company Secretary.

It was agreed that Mr. Thomas Graus will receive compensation of $72,000. The rest of the officers & Directors receive compensation through their ownership and focus on building the Company's value. As the Company grows and potentially uplists in the future, it may adopt market-based executive compensation and establish employment contracts. For now, the management team aligns its interests closely with shareholders, given their significant stock holdings.

**Limitation of Liability and Indemnification**

The Wyoming Business Corporation Act (the "Act"), under which the Company is organized, permits the inclusion in the Articles of Incorporation of a provision limiting or eliminating the potential monetary liability of directors to a corporation or its stockholders by reason of their conduct as directors. The provision would not permit any limitation on or the elimination of liability of a director for disloyalty to his corporation or its stockholders, failing to act in good faith, engaging in intentional misconduct or a knowing violation of the law, obtaining an improper personal benefit or paying a dividend or approving a stock repurchase that was illegal under the Act. Accordingly, the provisions limiting or eliminating the potential monetary liability of directors permitted by the Act apply only to the "duty of care" of directors, i.e., to unintentional errors in their deliberations or judgments and not to any form of "bad faith" conduct.

The Articles of Incorporation of the Company contain a provision which eliminates the personal monetary liability of directors to the extent allowed under Wyoming law. Accordingly, a stockholder is able to prosecute an action against a director for monetary damages only if he can show a breach of the duty of loyalty, a failure to act in good faith, intentional misconduct, a knowing violation of law, an improper personal benefit or an illegal dividend or stock repurchase, as referred to in the amendment, and not "negligence" or "gross negligence" in satisfying his duty of care. The Act applies only to claims against a director arising out of his role as a director and not, if he is also an officer, his role as an officer or in any other capacity or to his responsibilities under any other law, such as the federal securities laws.

In addition, the Company's Articles of Incorporation provides that the Company will indemnify our directors, officers, employees and other agents to the fullest extent permitted by Wyoming law. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

20 www.csdcorp.us

![](cscorp_logosm.jpg)

No pending litigation or proceeding involving a director, officer, employee or other agent of the Company as to which indemnification is being sought exists, and the Company is not aware of any pending or threatened material litigation that may result in claims for indemnification by any director, officer, employee or other agent.

**Stock and Stock Option Issuances in 2023 and 2024**

The following table details all stock and stock option issuances made to Company officers and directors during fiscal years 2023 and 2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **<u>Date</u>** | **<u>Securities</u>** | **<u>Class of <br> Securities</u>** | **<u>Amount <br> Per Share</u>** | **<u>Issued To</u>** | **<u>Purpose</u>** | **<u>Exemption</u>** |
| 08/01/23 | (134974014) | Common | $0.0001 | All Shareholders | Reverse Split: 1 for 100,000 and forward split 1 to 200 | 4(a)(2) |
| 09/27/23 | 65000000 | Common | $4.54 | CS Diagnostics Pharma GmbH (1) | Asset Purchase Agreement | 4(a)(2) |
| 09/27/23 | 20000000 | Common | $4.54 | CS Interpharm LLC (2) | Asset Purchase Agreement | 4(a)(2) |

---

<u>Notes:</u>

1. The beneficial owner is the Company's Chief Executive Officer, President and Director Thomas Fahrhoefer

2. The beneficial owner is the Company's Chief Executive Officer, President and Director Thomas Fahrhoefer

**Related Party Transactions**

During fiscal year 2023 the Company entered into two asset purchase agreements with entities controlled by our Chief Executive Officer Thomas Fahrhoefer relating to the Company's acquisition of certain intellectual property controlled by Mr. Fahrhoefer. See Recent Issuances of Securities.

*Following on next page*

21 www.csdcorp.us

![](cscorp_logosm.jpg)

**DESCRIPTION OF CAPITAL STOCK**

**Common Stock**

The Company is authorized to issue up to 250,000,000 Shares of Common Stock, $0.00001 par value per share, of which 137,340,200 are issued and outstanding. Holders of our common stock are entitled to one vote for each share in the election of directors and on all matters submitted to a vote of stockholders. There is no cumulative voting in the election of directors.

The holders of the common stock are entitled to receive dividends, when and as declared, from time to time, by our board of directors, in its discretion, out of any assets of the Company legally available therefore.

Upon the liquidation, dissolution or winding up of the Company, the remaining assets of the Company available for distribution to stockholders will be distributed among the holders of Common Stock, pro rata based on the number of Shares of common stock held by each.

Holders of common stock generally have no preemptive, subscription, redemption or conversion rights. The outstanding Notes of common stock are, when issued, fully paid and nonassessable.

As of June 30, 2025, we have 317 shareholders of record, and our outstanding common shares is 137,340,200.

**Preferred Stock**

The Company is authorized to issue up to 25,000,000 shares of Preferred Stock, par value $0.0001 per share, of which 19,992,585 shares are issued and outstanding. The Company has created three (3) classes of preferred stock with distinct rights and privileges.

**Series A Preferred Stock**

The Company is authorized to issue up to 1,000,000 shares of Series A Preferred Stock, of which 10 shares are issued and outstanding. The holder of the Series A Preferred Stock are entitled to vote pari passu with holders of the Company's common stock on the following basis: four times the sum of (a) the total number of shares of common stock which are issued and outstanding together with; (b) the total number of shares of any other series of preferred stock which are issued and outstanding.

The holders of the Series A Preferred Stock are entitled to receive dividends, when and as declared, from time to time, by our board of directors, in its discretion, out of any assets of the Company legally available therefore.

The holder of the Series A Preferred Stock holds a dividend preference over the Series B Preferred Stock and common stock of the Company.

Upon liquidation, the holders of the Series A Preferred Stock are entitled to receive an amount equal to the sum of (a) the original issue price of the Series A Preferred Stock multiplied by; (b) the number of shares of Series A Preferred Stock owned by such holder upon liquidation, as adjusted for any for any recapitalizations. This right is senior to any other class of securities of the Company.

**Series B Preferred Stock**

The Company is authorized to issue up to 20,000,000 shares of Series B Preferred Stock, of which 19,992,575 shares are issued and outstanding. Holders of the Series B Preferred Stock are entitled to convert each share of stock into 20,000 shares of the Company's common stock, with the limitation of no greater than 9.9% of the total issued and outstanding common stock of the Company.

22 www.csdcorp.us

![](cscorp_logosm.jpg)

The holder of the Series B Preferred Stock are entitled to vote pari passu with holders of the Company's common stock on a one-to-one basis.

The holders of the Series B Preferred Stock are entitled to receive dividends, when and as declared, from time to time, by our board of directors, in its discretion, out of any assets of the Company legally available therefore. The holder of the Series B Preferred Stock holds a hold a dividend preference junior in right to that of the Series A Preferred Stock and Series C Preferred Stock but senior in right to the common stock of the Company.

Upon an event of liquidation, the holders of the Series B Preferred Stock are entitled to receive, to the extent available, an amount equal to $1.00 per share, as adjusted for any stock dividends, splits, combinations and capitalization, plus all declared but unpaid dividends.

**Series C Preferred Stock**

The Company is authorized to issue up to 4,000,000 shares of Series C Preferred Stock – the shares being offered by this Memorandum, of which zero (0) shares are issued and outstanding. The Series C Preferred Stock does not carry any voting rights.

Holders of the Series C Preferred stock are entitled to receive an annual dividend in the amount of 6.5% of the stated value of $1,000 per share, payable in arrears. All unpaid dividends shall accrue. The Series C Preferred Stock carries a dividend preference over all other classes of securities of the Company.

Upon an event of liquidation, the holders of the Series C Preferred Stock are entitled to receive, to the extent available, an amount equal to the stated value together with any accrued but unpaid dividends. The Series C Preferred stock carries a liquidation preference over the common stock of the Company.

**Recent Issuances of Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Date of Transaction | Transaction Type (*e.g.* new issuance, cancellation, shares returned to treasury) | Number of Shares Issued (or cancelled) | Class of Securities | Value of Shares Issued ($/per share) at Issuance | Were the shares issued at a discount to market price at the time of issuance (Yes/No) | Reason for share issuance (*e.g.* for cash or debt conversion) - OR- Nature of Services Provided | Restricted or Unrestricted as of this filing. | Exemption or Registration Type |
| 05-09-2022 | Issuance | 10011000 | Preferred Series B | 1000 | No Patientrac Limited<sup>1</sup> | Pursuant to the Securities<br> Purchase<br> Agreement for services<br> rendered, *e.g.*<br> acquisition costs,<br> payments and organization reinstatements | Restricted | 4(a)(2) |

---

23 www.csdcorp.us

![](cscorp_logosm.jpg)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| 08-01-2023 | Corporate Action Reverse split 1 to 100,000 and Forward Split 1 to 200 | -134497014 | Common | 0.00001 | No | Same | Restricted and Unrestricted | 4(a)(2) |
| 09-27-2023 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Issuance<br>| 65000000 | Common | $4.54 | No CS Diagnostics Pharma GmbH<sup>2</sup> | Asset Purchase Agreement | Restricted | 4(a)(2) |
| 09-27-2023 | Issuance<br>| 20000000 | Common | $4.54 | No CS Interpharm LLC<sup>2</sup> | Asset Purchase Agreement | Restricted | 4(a)(2) |

---

<u>Note</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. PatientTrac Limited is a United Kingdom company whose beneficial owner is H Wayne Hayes, Jr. of Bogota, Colombia and held these shares
in trust. PatientTrac, pursuant to the Securities Purchase Agreement dated 30 March 2022 with CS Diagnostics Pharma GmbH, has agreed and
on July 9, 2022 transferred the 10,011,000 to CS Diagnostics Pharma GmbH designees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The beneficial owner of both CS Diagnostics Pharma GmbH and CS Interpharm LLC is Thomas Fahrhoefer, Dubai, UAE.

*Following on next page*

24 www.csdcorp.us

![](cscorp_logosm.jpg)

**CAPITALIZATION**

CS DIAGNOSTICS CORP. (CSDX) <br> BALANCE SHEET <br> FOR THE PERIOD ENDED MARCH 31, 2025

---

| | | |
|:---|:---|:---|
|  | Mar. 31, 2025 | Dec. 31, 2024 |
|  | *Un-Audited* | *Audited* |
| *Assets* |  |  |
| **Current Assets** |  |  |
| Cash | 51386 | 501 |
| Other Receivables | 54726 |  |
| **Total Current Assets** | $**106112** | $**501** |
| Intangible Assets | 499400000 | 499400000 |
| **Total Assets** | $**499506112** | $**499400501** |
| *Liabilities and Stockholders' Deficit* |  |  |
| **Current Liabilities** |  |  |
| Account Payables | 2931 | 1428 |
| Non-current liabilities | 0 | 0 |
| **Total Liabilities** | **74931** | **1428** |
| **Shareholder's Deficit** |  |  |
| Common stock, $0.00001 par value; 250,000,000 shares authorized 137,340,200 shares issued and outstanding as of March 31, 2025 | 1373 | 1373 |
| Preferred stock Series A, $0.00001 par value;5,000 shares authorized, 10 shares issued and outstanding as of March 31, 2025 |  |  |
| Preferred stock Series B, $0.00001 par value; 20,000,000 shares authorized, 19,992,575 shares issued and outstanding as of March 31, 2025 | 2000 | 2000 |
| Preferred stock Series C, $0.00001 par value; 4,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2025 | 40 |  |
| Additional paid-in capital | 504163629 | 504163629 |
| Accumulated deficit | -4735861 | -4767928 |
| **Total Stockholders' Deficit** | $**499431181** | $**499399073** |
| **Total Liabilities and Stockholders' Deficit** | $**499506112** | $**499400501** |

---

NOTE: *This is an unaudited financial statement, that can be subject to minor changes upon Auditor review*

25 www.csdcorp.us

![](cscorp_logosm.jpg)

**Management's Discussion and Analysis of Financial Condition and Results of Operation (MD&A)**

**Overview and Business Summary**

CS Diagnostics Corp. ("CSDX" or "the Company") is a medical technology company focused on improving therapy outcomes in cancer treatment and reducing side effects for patients. The Company provides medical industry partners with access to international markets and regulatory approval services in Europe and the Middle East/North Africa (MENA) region, while also developing its own innovative products. In August 2023, CSDX underwent a corporate reorganization – changing its name from FlashZero Corp. to CS Diagnostics Corp. – and repositioned itself in the healthcare sector. A pivotal event was the acquisition of the CS Protect-Hydrogel technology in September 2023, when CSDX purchased 100% of the rights, intellectual property, and patents for this product from its parent group. CS Protect-Hydrogel is a hydrogel-based tissue spacer used in radiation therapy to increase the distance between malignant tumors and healthy tissue, thereby protecting healthy tissue from high-dose radiation damage. This spacer is injected in liquid form into the space between cancerous and healthy tissues (e.g. between the prostate and rectum in prostate cancer), and it biodegrades after about six months. Importantly, CS Protect-Hydrogel is a sterile, "ready-to-use" product that can be applied directly without on-site preparation, and it is intended for use not only in prostate cancer radiotherapy but also in other cancer types such as cervical, esophageal, bladder, and breast cancers.

As of the end of 2024 and through the first quarter of 2025, the Company's primary focus has been advancing the CS Protect-Hydrogel toward commercialization and regulatory approval, alongside managing its financial position as a newly reorganized entity. The Company trades on the OTCQB market under the ticker CSDX, providing U.S. investors an opportunity to invest in its growth plans. In addition to the hydrogel product, CSDX has begun to diversify its portfolio; notably, in January 2025 the Company launched a next-generation disinfectant product called MEDUSA in the U.S. market. MEDUSA, an advanced long-acting surface disinfectant, has already been approved in the EU and UAE and is pending U.S. regulatory approval. While MEDUSA's commercialization is at an early stage, the Company has articulated ambitious growth targets for this product (seeking to capture a significant share of an $8+ billion global disinfectant market). The inclusion of MEDUSA in the product lineup reflects management's strategy to leverage its expertise in regulatory approvals and distribution to build multiple revenue streams. However, CS Protect-Hydrogel remains the cornerstone of CSDX's business strategy and value proposition, given its breakthrough potential in cancer therapy.

**Results of Operations**

**Fiscal Year 2024 Compared to 2023**

For the fiscal year ended December 31, 2024, the Company generated modest revenues of $110,911, compared to $126,038 in the prior year 2023. This slight decline in revenue year-over-year reflects the Company's early-stage operations and a continued focus on product development and regulatory preparation. We note that these revenues likely stem from CSDX's legacy service business (assisting with medical product distribution/approvals) or initial product sales, as full commercial sales of CS Protect-Hydrogel had not commenced by 2024. Despite the small decrease in top-line, the Company's bottom-line improved year-over-year. CSDX reported a net profit of $761 for 2024, a turnaround from a net loss of $21,997 in 2023. This swing to roughly break-even results was achieved primarily through expense management.

26 www.csdcorp.us

![](cscorp_logosm.jpg)

Operating expenses in 2024 totaled $110,150, down 25% from $148,035 in 2023. Notably, general and administrative (G&A) expenses were sharply lower in 2024 (only $395, versus $94,009 in 2023), indicating significant cost-cutting or the absence of prior-year one-time costs. By contrast, professional fees (which can include legal, consulting, and accounting costs) increased to $109,755 in 2024 from $54,026 in 2023. The higher professional fees in 2024 are attributable to corporate activities such as auditing, regulatory compliance, and the transactions surrounding the hydrogel asset acquisition and public listing process. These professional costs were largely offset by the drastic reduction in G&A overhead, resulting in near break-even operating income of $761 for 2024 (versus a $21,997 operating loss in 2023). The improvement reflects management's efforts to streamline operations and focus expenditures on essential corporate and development activities. Basic and diluted earnings per share were $0.00 for both years, given the negligible net income and the Company's expanded share count after the 2023 equity issuance for the hydrogel acquisition. Weighted average shares outstanding increased from about 110.8 million in 2023 to 137.3 million in 2024, reflecting new shares issued as part of the asset purchase and any other equity issuances during 2024.

**Quarter Ended March 31, 2025 Compared to March 31, 2024**

For the first quarter of 2025, CSDX reported revenue of $70,420, representing growth compared to approximately $53,258 in the first quarter of 2024. This year-over-year quarterly increase (~32%) suggests early traction in the Company's business activities, potentially from higher service revenue or initial sales of its products (including possibly the first contributions from MEDUSA's rollout or increased demand for the Company's regulatory consulting services). First quarter revenues outpaced operating expenses, leading to positive operating income. Operating expenses for Q1 2025 were $38,353, higher than the unusually low $8,564 reported in Q1 2024. The increase in expenses is largely due to a normalization of G&A costs and continued professional services as the Company scales its operations. In Q1 2024, CSDX's G&A expense was virtually nil (only $140), reflecting minimal staffed operations at that time, whereas in Q1 2025 G&A was $21,834 as the Company began incurring costs for business development, regulatory filings, and product launch activities. Conversely, professional fees in Q1 2025 ($16,519) were lower than the $44,555 spent in Q1 2024, when significant legal/accounting work related to the corporate reorganization and asset acquisition was underway.

Overall, CSDX achieved a net profit of $32,067 in the first quarter of 2025, a substantial improvement from essentially break-even results in the same quarter of the prior year (net income was reported as $0 in Q1 2024). The positive first quarter earnings in 2025 were driven by the revenue growth combined with controlled operating expenses. It is worth noting that a portion of Q1 2025 revenue was not yet collected by quarter-end (accounts receivable increased during the quarter), indicating that some sales were on credit terms. As a result, cash flow from operations in the quarter was likely lower than net income, an aspect discussed in the Liquidity section below. Nevertheless, the Q1 2025 profitability underscores management's focus on reaching a sustainable cost-revenue balance even at this early stage. Given CSDX's developmental status, quarterly results may fluctuate and may not yet reflect the full revenue potential of its flagship products. The Company expects future periods to be significantly influenced by the commercial rollout of CS Protect-Hydrogel (pending regulatory approval) and the ramp-up of MEDUSA sales, which were only just beginning in Q1 2025.

**Liquidity and Capital Resources**

**Capital Structure and Cash Position**

CSDX's financial condition at year-end 2024 reflects a company that has acquired a major intangible asset but has very limited liquidity. As of December 31, 2024, the Company's balance sheet shows total assets of approximately $499.4 million, almost entirely consisting of the CS Protect-Hydrogel intangible asset valued at $499.4 million, with only $501 in cash on hand. By March 31, 2025, cash had increased to $51,386 (unaudited) as the Company received some funds from operations or small financing activities during Q1. Current assets at March 31, 2025 were $106,112, including cash and new accounts receivable of about $54,726, while current liabilities were $74,931 (primarily accounts payable and accruals). The working capital position remains strained – current liabilities slightly exceeded current assets at Q1's end, and the cash on hand is minimal relative to the Company's needs for product development and launch. CSDX has essentially no long-term debt as of Q1 2025, and total liabilities are very low (only ~$75K). However, stockholders' equity is dominated by the large intangible asset value offset by a corresponding amount recorded in additional paid-in capital. The Company's shareholders' deficit was about $499.4 million at year-end 2024, reflecting the recognition of the hydrogel asset and the equity issued for its purchase. The accumulated deficit stood at $(4.77) million at December 31, 2024, only slightly improved to $(4.74) million by March 31, 2025 due to the small profits earned in late 2024 and Q1 2025. This deficit is the result of prior years' losses, as the Company is only now moving toward profitability on a very small scale.

27 www.csdcorp.us

![](cscorp_logosm.jpg)

**Cash Burn and Going Concern**

The Company's historical operations have been funded by equity infusions from its shareholders/parent group rather than by sustainable cash flows. Net cash used in operating activities has likely continued in early 2025 given ongoing expenses and the need to build inventory and infrastructure for product launches. The going concern note in the 2024 financial statements emphasizes that the Company's ability to continue as a going concern is dependent on improving profitability and obtaining financial support from shareholders or other external financing. Management acknowledges that additional capital will be required for the planned operational activities and that there is uncertainty regarding the ability to raise such capital. These conditions raise substantial doubt about CSDX's ability to continue as a going concern absent new funding. The Company's strategy to address this includes seeking external financing and leveraging the value of its assets to secure investment.

**Financing Plans**

In fact, subsequent to Q1 2025, CSDX took steps to bolster its capital resources. In June 2025, the Company announced plans for a Regulation D Offering for $10,000,000 utilizing its newly created Series C Preferred Stock. This funding arrangement is aimed at supporting the production and commercialization of CSDX's key assets, particularly CS-Protect Hydrogel and the MEDUSA disinfectant, in global markets. The $5 million infusion, if finalized, would be a significant boost to liquidity, far exceeding the Company's current cash balance. According to the disclosure, the parties are conducting final due diligence and negotiating definitive agreements, with a target to close the financing in the coming weeks. Management intends to allocate these funds toward scaling up manufacturing (especially U.S. production for the hydrogel), further R&D, operational expansion, and obtaining any remaining regulatory approvals (for example, U.S. EPA approval for MEDUSA). This planned financing is a critical component of CSDX's liquidity strategy and demonstrates the Company's ability to attract investment based on its asset potential. It should be noted, however, that until the transaction is closed, the Company remains reliant on interim support from its major shareholders for meeting obligations. There can be no guarantee that the $10 million financing will close on the anticipated timeline or that it will be sufficient to fund all operational needs.

**Capital Expenditures and Requirements**

CSDX currently has no significant capital expenditures disclosed for 2024, as it does not yet have large-scale manufacturing facilities of its own (the hydrogel production for initial markets may be handled through partners or existing capacity of the CS Diagnostics Group). However, in preparation for commercial launch, the Company will likely need to invest in production tooling, inventory build-up, and distribution capabilities, particularly as it approaches the U.S. market entry by 2026. The Company's ability to raise additional capital through equity is evidenced by its prior issuances: in late 2023, it issued 110 million shares (valued at $500 million) to acquire the hydrogel IP, and it has the option to issue more shares if needed (authorized common stock is 250 million shares). Potential future equity issuances could, however, result in dilution to existing shareholders. Besides equity financing, management may also explore strategic partnerships or licensing arrangements to share the costs of commercialization. At this time, the Company has no off-balance sheet arrangements or significant contractual obligations aside from standard accounts payable and the pending financing agreement.

28 www.csdcorp.us

![](cscorp_logosm.jpg)

In summary, CSDX's liquidity position is presently very tight, but management has taken steps to secure needed capital. Successful consummation of the planned $5 million financing (or similar funding) is essential for the Company to fund its operations over the next 12-18 months, including completing regulatory approval processes and initiating product sales at scale. If such financing were to be delayed or fail to close, the Company would need to rely on further shareholder loans or curtail its activities. Management believes that the value of its core technology and the size of the market opportunities will ultimately enable the Company to obtain sufficient capital to execute its plans, but it recognizes the need to demonstrate progress (such as obtaining FDA approval and initial revenues) to maintain investor support. The Company will continue to monitor its cash flow closely and will update its capital plan as needed to ensure it can meet its short-term liabilities and invest in growth initiatives.

**Critical Accounting Estimates and Judgments**

The preparation of CSDX's financial statements in accordance with U.S. GAAP requires management to make certain estimates and judgments that have a significant impact on reported results and financial position. The Company's most critical accounting estimate at this stage revolves around the valuation and potential amortization or impairment of the CS Protect-Hydrogel intangible asset. This intangible asset is carried at approximately $499.4 million on the balance sheet, reflecting the value assigned to the acquired product technology and intellectual property. Management recorded this asset based on the fair value of consideration given – 110,000,000 shares of common stock issued in September 2023 – which was determined by reference to a third-party valuation of the hydrogel's discounted future commercial potential (over €960 million) and a benchmark transaction (Boston Scientific's 2018 purchase of a similar spacer product for $500 million). This valuation approach embodies significant judgments about the hydrogel's future revenue, market adoption, and cash flow generation. No amortization expense has been recorded on the hydrogel intangible through 2024, suggesting that management may consider this asset to have an indefinite life at present (or that amortization will commence once the product is fully commercialized). This treatment is a critical judgment; if the hydrogel is deemed to have a finite life (for example, tied to patent expirations or a product lifecycle), the Company would need to amortize the $499 million asset over its useful life, which would greatly increase annual expenses and could quickly eliminate any accounting profits. Management will need to continually evaluate the appropriate useful life and amortization method for this asset as commercialization progresses.

Impairment considerations: Given the Company's lack of substantial revenue to date and the early stage of product approval, there is inherent uncertainty as to whether the hydrogel asset will ultimately generate cash flows to support its carrying value. Management performs impairment analyses as part of its critical accounting judgments. If facts and circumstances (such as a significant delay in FDA approval, lower-than-expected market demand, or inability to secure commercialization funding) indicate that the hydrogel asset's carrying amount may not be recoverable, the Company would conduct an interim impairment test. Any impairment charge could be material, as the $499.4 million intangible constitutes virtually the entire asset base of CSDX. Investors should understand that a write-down of this asset, if required, would severely impact the Company's reported equity and could reclassify the Company as a development stage entity with negative net worth. Management believes the recorded value is supported by external data (e.g., the precedent acquisition by Boston Scientific) and the broad potential applications of the CS Protect-Hydrogel technology, but it acknowledges that this is a key area of estimation uncertainty.

**Other areas of significant accounting judgment include:**

&nbsp;&nbsp;&nbsp;&nbsp;· Going Concern Assessment: As discussed in the Liquidity section, management must evaluate whether the Company can continue as a going
concern for the next 12 months. This involves judgment about future financing and revenue. While the 2024 financials were prepared on
a going concern basis, substantial doubt was disclosed, and management's plans to alleviate that doubt (through financing and improving
profitability) were outlined. This assessment is revisited in each reporting period.

29 www.csdcorp.us

![](cscorp_logosm.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;· Deferred Tax Assets: The Company has accumulated losses (approximately $4.7 million deficit) that could give rise to deferred tax
assets. However, given the Company's short operating history in its new line of business and uncertainty about future taxable income,
management has likely determined that a full valuation allowance is necessary. This means no deferred tax asset is recognized on the balance
sheet for net operating loss carryforwards, since it is not "more likely than not" that such **assets would be realized.** This judgment affects the tax expense and will be revisited if the Company begins generating substantial taxable profits.

&nbsp;&nbsp;&nbsp;&nbsp;· Revenue Recognition: While current revenues are small, management must ensure proper cut-off and recognition of any service or product
revenues. For example, any distribution or consulting service revenue is recognized when earned, and any product sales will be recognized
upon delivery of product to customers (assuming no further performance obligations). Given that some Q1 2025 sales were on credit, the
Company also evaluates collectability. To date, revenue recognition has not involved complex arrangements, but as product sales grow (especially
with MEDUSA and potentially hydrogel in multiple markets), management will need to consider any licensing deals, consignment arrangements,
or usage-based pricing which could introduce more complexity.

&nbsp;&nbsp;&nbsp;&nbsp;· Stock-Based Transactions: The Company's issuance of shares for asset acquisition and any future equity financing (such as the
Series C Preferred proposed issuance) are accounted for at fair value. Management relies on valuation techniques to determine fair value
of shares, especially since the stock is thinly traded. Any discrepancy in these estimates would affect additional paid-in capital and
could have tax implications for the parties involved.

Management believes that the above critical accounting estimates are based on reasonable assumptions and consistently applied. However, actual results could differ from these estimates, and changes in assumptions or market conditions could require adjustments to carrying values or recognition of additional expenses in future periods. The Company's audit for 2024 resulted in an unqualified opinion with no critical audit matters identified beyond the going concern emphasis, indicating that the external auditors concurred with management's accounting treatments and estimates as of that time.

**Known Trends, Events, and Uncertainties**

As CSDX moves beyond its restructuring phase and into active commercialization, several key trends, events, and uncertainties are likely to influence its financial condition and operations:

**Regulatory Approval and Commercialization Timeline**

The foremost near-term event for the Company is obtaining U.S. FDA approval for CS Protect-Hydrogel. Management has been fast-tracking this process by engaging experienced FDA regulatory consultants (Lachman Consultants) and, as of March 12, 2025, anticipated FDA clearance of the hydrogel within 3–4 months from that date. If this timeline holds, the Company could receive approval by mid-2025, which would be a catalyst for initiating sales in the U.S. market. Any delay or unexpected requirement from the FDA would be a significant uncertainty – regulatory processes can be unpredictable, and the Company may need to conduct additional clinical studies or provide more data, which could postpone commercialization. In parallel with U.S. efforts, the product will also require regulatory registration in other jurisdictions. The Company's background in navigating European and MENA regulatory environments should be advantageous in obtaining approvals in those markets; however, timelines for CE marking under Europe's MDR or other local approvals are not explicitly disclosed and remain an uncertainty.

30 www.csdcorp.us

![](cscorp_logosm.jpg)

**Product Launch and Manufacturing**

CSDX is preparing for the scale-up of production for CS Protect-Hydrogel. The Company projects that U.S. production will commence by the first quarter of 2026, aligning with expected market approval and the need to ramp manufacturing capacity. This suggests that 2025 will be focused on setting up manufacturing processes (potentially tech-transfer to a U.S. manufacturing site or contract manufacturer) and securing supply chain logistics. There is a known trend in the medtech industry of supply chain challenges and costs inflation, so the Company will need to manage raw material sourcing for the hydrogel and sterile packaging in a cost-effective manner. The ability to meet production timelines by Q1 2026 is crucial; any operational hurdles or delays in facility readiness could impact the product launch schedule. Management's decision to pursue an equity funding (the $5M loan agreement) in 2025 is directly tied to financing these manufacturing and launch activities. Investors should monitor the progress of production preparations in late 2025, as this will indicate whether the Company is on track to fulfill its projected timeline.

**Market Adoption and Competition**

Upon entering the market, CS Protect-Hydrogel will face competition from at least one well-established product. Boston Scientific's SpaceOAR hydrogel (acquired from Augmenix) is currently the leading tissue spacer for prostate cancer radiotherapy and has an installed base of users. While CS Protect-Hydrogel is positioned as a next-generation spacer with broader applications, it may initially compete directly with SpaceOAR in the prostate cancer segment. Boston Scientific's resources and relationships with hospitals could pose a competitive challenge. CSDX's strategy is to differentiate CS Protect-Hydrogel through its enhanced features – notably, its versatility to be used in multiple cancer types (beyond just prostate) and its ready-to-use formulation that requires no mixing or prep work in the operating room. These competitive advantages, such as eliminating contamination risk and preventing potential errors in preparation, will be key selling points to drive adoption by radiation oncologists and urologists. Market acceptance is a potential uncertainty; the medical community will need to be educated on the hydrogel's benefits, and CSDX may need to sponsor additional clinical studies or publish data demonstrating improved outcomes (e.g. reduced side effects or the ability to safely escalate radiation doses). The broader trend in oncology toward hypofractionation (fewer, higher-dose treatments) could work in the Company's favor – a spacer that reliably protects healthy tissue can enable such treatment protocols. If CS Protect-Hydrogel can facilitate safer hypo fractionated radiotherapy, it could accelerate adoption in modern cancer care settings**.**

**Commercial Potential vs. Risks**

The market potential for CS Protect-Hydrogel is significant, as indicated by the valuation references: management often notes that a predecessor product was bought for $500 million, underscoring the high value placed on effective spacer technologies in radiation oncology. Moreover, by expanding the indications to other cancers (e.g. gynecological or gastrointestinal cancers where organ spacing can prevent collateral damage), CSDX aims to tap into multiple therapy markets. If successful, the hydrogel could generate substantial revenue streams across different oncology subfields. However, this potential comes with execution risks. The Company is still small and will need to form distribution partnerships or build a salesforce to reach hospitals and clinics globally. Establishing relationships with key opinion leaders in radiation oncology is crucial for driving adoption. There is also the risk of new entrants or technologies: for instance, other biotech companies might develop alternative spacer materials or completely different solutions (such as protective pharmaceuticals or advanced radiation techniques that mitigate the need for spacers). CSDX must continuously innovate and protect its intellectual property; fortunately, the Company acquired all patents and distribution rights for CS Protect-Hydrogel from the former parent group, which should provide some moat against direct product copycats in the near term. Another risk to the commercial potential is reimbursement – insurance coverage in the U.S. and elsewhere will influence how readily hospitals adopt the hydrogel. SpaceOAR, for example, obtained specific reimbursement codes; CSDX will need to ensure similar coverage, otherwise the out-of-pocket cost to patients could limit usage.

31 www.csdcorp.us

![](cscorp_logosm.jpg)

**Diversification and Other Products**

A notable development through Q1 2025 is the launch of the MEDUSA disinfectant product. This indicates a trend of diversification within CSDX's business model – addressing not just therapeutic devices but also infection control. MEDUSA's initial reception and sales will be something to watch in 2025. The Company announced very optimistic targets for MEDUSA (projecting $80 million in revenue in 2025 and $460 million within three years), which, if even partially realized, would drastically change the scale of CSDX's operations. While these projections are forward-looking statements and not guaranteed, they demonstrate management's growth ambitions. The pursuit of a high-profile sponsorship (negotiations with a major European football club for MEDUSA branding) exemplifies the creative marketing approaches the Company is willing to take. The success of MEDUSA is uncertain – it depends on competitive factors in the disinfectant market and execution of a B2B/B2C sales strategy – but it represents an upside opportunity that could provide additional liquidity and cash flow to support the Company's core medical device endeavors. Investors should note that while MEDUSA's potential is large, it also introduces a different regulatory path (EPA approval in the U.S., which the Company is seeking with part of the new funding) and a different competitive landscape (with many established chemical manufacturers). Balancing the focus between hydrogel (a medical device requiring FDA clearance and specialist marketing) and MEDUSA (a chemistry-based product with broad market reach) is a management challenge and a trend to monitor.

**Management and Organizational Changes**

Another development in late 2024 was changes to the Company's board and executive team. In August 2024, new directors and officers were appointed, including a Vice President/CFO and additional independent directors, while some prior directors stepped down. These changes brought in individuals with specific expertise (the presence of a COO with medtech experience, and presumably the new board members with industry connections). Such changes can impact the Company's strategic direction and operational execution. Early 2025 actions, such as the financing LOI and product launches, suggest the new management is proactive. However, the Company's ability to grow will also depend on hiring qualified staff (for R&D, regulatory affairs, sales etc.), and competition for talent in the biotech and medtech field is a known challenge. CSDX will likely need to expand its team as it enters commercialization, which could increase expenses in the short term.

**Macroeconomic and Market Conditions**

CSDX operates in the healthcare sector, which is generally less cyclical than other industries, but it is not immune to broader economic conditions. Inflationary pressures could increase the cost of raw materials for the hydrogel or components for packaging. Currency fluctuations may also affect the Company since part of its operations (and potentially manufacturing or parent company support) is in Europe – the valuation of the hydrogel was initially done in euros and then translated to USD. If the dollar/euro rate changes significantly, it could impact cost structures or the perceived value of overseas funding. Additionally, capital market conditions in 2025 will determine how easily the Company can raise further equity. Micro-cap public companies can face volatile trading and difficult financing environments if investor sentiment turns negative. The OTCQB listing provides a platform, but ultimately CSDX may seek an uplist to a national exchange to access a broader pool of investors – such ambitions would depend on meeting certain financial and governance criteria, which remain a longer-term consideration.

**Conclusion**

the path forward for CS Diagnostics Corp. involves significant opportunities accompanied by equally significant uncertainties. On one hand, the Company is at the cusp of introducing a novel medical device with life-saving potential and entering a large addressable market with both that device and a new disinfection product. On the other hand, it faces the classic challenges of an emerging growth company: obtaining regulatory approvals, scaling up manufacturing and sales, securing adequate financing, and outmaneuvering established competitors – all under the scrutiny of maintaining transparent and compliant operations as it transitions into an SEC-reporting entity. Management has issued forward-looking statements projecting a favorable outcome on many of these fronts (e.g., expected FDA approval in 2025, U.S. production by 2026, multi-million dollar revenues in the near future). These statements are grounded in the Company's current plans and the positive indicators it has observed, such as the prior success of similar products and early interest from customers. However, investors and readers should carefully consider the risk factors and uncertainties discussed above. Many of these external and internal factors – such as regulatory timing, market competition, and the ability to execute on commercialization – could cause actual results to differ materially from CSDX's optimistic projections. The Company has acknowledged these risks in its communications, noting that general economic conditions, technical/regulatory hurdles, and unexpected events can all impact the outcome.

32 www.csdcorp.us

![](cscorp_logosm.jpg)

**Going forward**

CS Diagnostics Corp. intends to continuously update stakeholders on its progress. The Company's management remains confident that by focusing on its core strengths – innovative product development, regulatory expertise, and strategic partnerships – it can navigate the upcoming challenges and build a sustainable, high-growth business that delivers long-term shareholder value. The remainder of 2025 will be a crucial period for executing on its milestones (FDA approval, financing closure, initial market launches), and the Company's financial health and operational results will hinge on the successful realization of these plans. All forward-looking statements in this MD&A are made as of the current date and are subject to the safe harbor provisions; actual outcomes will be reported in future filings, and management undertakes to update its guidance as appropriate in light of new information or changes in circumstances.

**LEGAL PROCEEDINGS**

From time to time, we may become involved in various legal or administrative claims and proceedings arising in the ordinary course of business. The Company is actively involved in a legal proceeding and will provide further information as the matter enters the stage of discovery. Litigation or any other legal or administrative proceeding, regardless of the outcome, is likely to result in substantial cost and diversion of our resources, including our management's time and attention.

Currently a lawsuit is undergoing number Case No: 3:25-cv-01158-N and in due time the company will announce the outcome of the proceedings.

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: July 18, 2025 | **CS Diagnostics Corp.** | **CS Diagnostics Corp.** |
|  | By: | /s/Mohammad EsSayed |
|  |  | Mohammad EsSayed |
|  |  | Group CFO, VP |

---

33 www.csdcorp.us